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Sponsor: 
GlaxoSmithKline Biologicals 
Rue de l’Institut 89, 1330 Rixensart, 
Belgium 
Study vaccine 
number 
257049 (GlaxoSmithKline Biologicals’ candidate Plasmodium 
falciparum malaria vaccine RTS,S/AS01E). 
Study vaccines Cell Culture Rabies Vaccine from two manufacturers:  
HDC or Purified Vero cell Rabies Vaccine (Sanofi Pasteur); PCEC 
Rabies Vaccine (Rabipur or equivalent, Novartis). 
DTPwHepB/Hib vaccine: Tritanrix HepB™/Hib (GSK) 
Oral Polio Vaccine: Polio Sabin™ (GSK). 
Meningococcal C Conjugate Vaccine from three manufacturers: 
Meningitec (Wyeth); NeisVac-C (Baxter); Menjugate (Novartis). 
Amended 24 October 2008 
eTrack study number 
and abbreviated title 
110021 (Malaria-055 PRI) 
Date of protocol Final 10 March 2008 
Date of amendments Amendment 1, 19 August 2008 
Amendment 2, 24 October 2008 
Amendment 3, 26 November 2009 
Amendment 4, 01 December 2010 
Amendment 5, 23 January 2012 
Amendment 6, 08 August 2012 
Title Efficacy of GSK Biologicals’ candidate malaria vaccine (257049) against 
malaria disease caused by P. falciparum infection in infants and children 
in Africa. 
Detailed Title A phase III, double blind (observer-blind), randomized, controlled multi-
center study to evaluate, in infants and children, the efficacy of the 
RTS,S/AS01E candidate vaccine against malaria disease caused by 
P. falciparum infection, across diverse malaria transmission settings in 
Africa. 
GlaxoSmithKline Biologicals 
Co-ordinating author PII - blinded, Scientific Writer. 
Contributing authors  PII - blinded, Central Study Coordinator. 
 PII - blinded, Vice President–Global Clinical R&D. 
 PII - blinded, Clinical Data Management. 
 PII - blinded, Vice President–Vaccines for Emerging Diseases.  
 PII - blinded, Clinical Immunology Read Outs. 
 PII - blinded, Project Manager. 
 PII - blinded, Clinical Development Manager. 
 PII - blinded, Statistician. 
 PII - blinded, Clinical Development Manager. 
 PII - blinded, Central Study Coordinator. 
 PII - blinded, Scientific Writer. 
 PII - blinded, Central Study Coordinator. 
 PII - blinded, Central Study Coordinator. 
 PII - blinded, Quality Assurance. 
 PII - blinded, Safety Physician. 
 PII - blinded, Regulatory Affairs. 
 PII - blinded, US Regulatory Affairs. 
 PII - blinded, Safety Physician. 
 PII - blinded, Clinical Regulatory Affairs. 
 PII - blinded, Clinical Development Manager. 
 PII - blinded, Clinical Planning Manager. 
GSK Biologicals’ Protocol DS V 12.4 
Copyright 2008-2012 the GlaxoSmithKline group of companies. 
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eTrack study number 
and abbreviated title 
110021 (Malaria-055 PRI) 
Date of protocol Final 10 March 2008 
Date of amendments Amendment 1, 19 August 2008 
Amendment 2, 24 October 2008 
Amendment 3, 26 November 2009 
Amendment 4, 01 December 2010 
Amendment 5, 23 January 2012 
Amendment 6, 08 August 2012 
Program for Appropriate Technology in Health (PATH) Malaria Vaccine Initiative 
(MVI) Contributing Authors 
Contributing authors  PII - blinded, Technical Coordinator. 
 PII - blinded, Senior Program Officer. 
 PII - blinded, Program Officer. 
 PII - blinded, Technical Coordinator.  
 PII - blinded, Director, Portfolio Management. 
GlaxoSmithKline Biologicals will act as regulatory sponsor for this trial 
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Protocol Amendment 6 Sponsor Signatory Approval 
eTrack study number 
and abbreviated title 
110021 (Malaria-055 PRI). 
Date of protocol 
amendment 
Amendment 6 Final: 08 August 2012 
Detailed title A phase III, double blind (observer-blind), randomized, 
controlled multi-center study to evaluate, in infants and 
children, the efficacy of the RTS,S/AS01E candidate vaccine 
against malaria disease caused by P. falciparum infection, 
across diverse malaria transmission settings in Africa. 
Sponsor signatory PII - blinded, 
Director, Clinical Development Manager 
Signature ---------------------------------------------------------------------- 
Date ---------------------------------------------------------------------- 
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Protocol Amendment 6 Rationale 
Amendment number: Amendment 6 
Rationale/background for changes: 
At the European Medicines Agency’s (EMA) request, GSK Biologicals has updated its 
procedure for emergency unblinding during the conduct of a clinical study. 
According to the revised procedure, the responsibility and the decision to break the 
treatment code in emergency situations resides solely with the investigator and 
consequently, the investigator will have full authority to break the treatment code. 
The text in section 6.5 “Method of blinding and breaking the study blind” has been 
modified accordingly. 
In addition, the timings for the intervals between study visits during the extension were 
not consistent within the document and have been corrected or more specified to 
increase clarity. 
Amended text has been included in bold italics, deletions by strikethrough. 
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Protocol Amendment 6 Investigator Agreement 
I agree: 
 To assume responsibility for the proper conduct of the study at this site. 
 To conduct the study in compliance with this protocol, any mutually agreed future 
protocol amendments, and with any other study conduct procedures provided by 
GlaxoSmithKline Biologicals (GSK Biologicals). 
 To ensure that all persons assisting me with the study are adequately informed about 
the GSK Biologicals investigational product(s) and other study-related duties and 
functions as described in the protocol. 
 Not to implement any changes to the protocol without agreement from the sponsor 
and prior review and written approval from the Institutional Review Board (IRB) or 
Independent Ethics Committee (IEC), except where necessary to eliminate an 
immediate hazard to the subjects, or where permitted by all applicable regulatory 
requirements (for example, for administrative aspects of the study). 
 That I am thoroughly familiar with the appropriate use of the vaccine(s), as described 
in this protocol, and any other information provided by the sponsor, including, but not 
limited to, the following: the current Investigator’s Brochure (IB) or equivalent 
document, IB supplement (if applicable), prescribing information (in the case of a 
marketed vaccine). 
 That I am aware of, and will comply with, “Good Clinical Practice” (GCP) and all 
applicable regulatory requirements. 
 That I have been informed that certain regulatory authorities require the sponsor to 
obtain and supply, as necessary, details about the investigator’s ownership interest in 
the sponsor or the investigational product, and more generally about his/her financial 
ties with the sponsor. GSK Biologicals will use and disclose the information solely 
for the purpose of complying with regulatory requirements. 
Hence I: 
 Agree to supply GSK Biologicals with any necessary information regarding 
ownership interest and financial ties (including those of my spouse and dependent 
children). 
 Agree to promptly update this information if any relevant changes occur during the 
course of the study and for 1 year following completion of the study.  
 Agree that GSK Biologicals may disclose any information it has about such 
ownership interests and financial ties to regulatory authorities. 
 Agree to provide GSK Biologicals with an updated Curriculum Vitae and other FDA 
required documents. 
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eTrack study number 
and abbreviated title 
110021 (Malaria-055 PRI). 
Date of protocol 
amendment 
Amendment 6 Final: 08 August 2012 
Detailed title A phase III, double blind (observer-blind), randomized, 
controlled multi-center study to evaluate, in infants and 
children, the efficacy of the RTS,S/AS01E candidate vaccine 
against malaria disease caused by P. falciparum infection, 
across diverse malaria transmission settings in Africa. 
Investigator signatory  
Name ---------------------------------------------------------------------- 
Signature ---------------------------------------------------------------------- 
Date ---------------------------------------------------------------------- 
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Synopsis 
Synopsis Amended 19 August 2008 
Synopsis Amended 24 October 2008 
Synopsis Amended 26 November 2009 
Synopsis Amended 01 December 2010 
Synopsis Amended 23 January 2012 
Detailed Title A phase III, double blind (observer-blind), randomized, controlled 
multi-center study to evaluate, in infants and children, the efficacy 
of the RTS,S/AS01E candidate vaccine against malaria disease 
caused by P. falciparum infection, across diverse malaria 
transmission settings in Africa. 
Study population Male and female infants and children aged 6-12 weeks and 5-17 
months of age at first vaccination if eligible according to 
inclusion and exclusion criteria. 
Study population 
of the extension 
Male and female infants and children enrolled in Malaria-055 PRI 
and having received at least one dose of study or control vaccine 
during the primary trial phase. 
Rationale for the 
study 
This Phase III study of GSK Biologicals candidate malaria 
vaccine RTS,S/AS01E has been designed to address the key 
safety and efficacy information required for vaccine licensure. In 
addition, other disease endpoints that allow the evaluation of the 
full public health impact and cost effectiveness of vaccine 
implementation are included. Co-primary objectives will 
investigate the efficacy against clinical disease in children from 5-
17 months of age at first dose and the efficacy in infants 6-12 
weeks of age who receive the vaccine in co-administration with 
EPI antigens (i.e. DTPw Hep B/Hib). 
 All participating centers will use standardized case definitions for 
efficacy endpoints and a structured approach to case-assessment. 
Cases of clinical disease will be pooled across participating 
centers to determine the primary endpoint of efficacy against 
clinical disease in each age category. Secondary objectives will 
assess the efficacy of the vaccine on severe malaria disease, 
severe anemia and malaria hospitalization. Analysis by site will 
allow the evaluation of efficacy under different conditions of 
malaria transmission and randomization to a booster dose will 
allow the evaluation of the duration of efficacy of a primary 
course and the requirement for boosting. Additional objectives 
include determination of efficacy of the vaccine against all 
medical hospitalization, non-malaria serious illness, fatal malaria 
and all-cause mortality. In addition immunological correlates of 
protection will be investigated. 
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Analyses are planned at the following timepoints during the trial: 
  A primary analysis to investigate efficacy against clinical 
malaria disease after approximately 6000 children 5-17 
months of age at first dose (4000 RTS,S/AS01E recipients) 
have completed 14 months of follow up post dose 1. 
  A primary analysis to investigate efficacy against clinical 
malaria disease after approximately 6000 infants 6 to 12 
weeks of age at first dose (4000 RTS,S/AS01E recipients) 
have completed 14 months of follow up post dose 1. 
  A secondary analysis for evaluation of efficacy against severe 
disease when there are 250 accumulated cases, or at study 
end, whichever occurs earlier. 
  A secondary analysis for evaluation of efficacy, safety and 
immunogenicity when all children have completed 18 month 
follow-up post Dose 3 (Visit 22). 
  A secondary analysis for evaluation of the antibody responses 
to polio serotypes 1, 2 and 3 in the 6-12 weeks age category 
one month post boost (Visit 23). 
  A final analysis will be carried out at the end of the trial and 
will include further investigations of vaccine efficacy against 
a range of manifestations of malaria disease and evaluate the 
booster dose. 
  An additional analysis will be conducted at the end of the 
extension including an evaluation of safety and efficacy 
against clinical malaria, severe malaria and prevalent 
parasitemia. 
Rationale for the 
extension 
The strategy underlying the development of the RTS,S/AS01E 
malaria vaccine is that it would target the most vulnerable age 
group: infants and young children. It would provide protection 
from the most severe forms of the disease whilst allowing natural 
blood stage immunity to develop due to continued exposure to 
infections. However, there is a theoretical concern that the 
protection conferred by a malaria vaccine in young children may 
impair their ability to acquire natural immunity to the blood stage 
form of P. falciparum and that, if the vaccine efficacy decreases 
over time, these children would become vulnerable to malaria. 
This could result in a higher susceptibility to severe malaria 
and/or a higher frequency of clinical malaria disease in vaccinated 
children compared to children of the same age that were not 
vaccinated. This long term follow-up probably represents the last 
opportunity to evaluate the duration of vaccine efficacy and the 
long term safety of RTS,S/AS01E relative to a control group in a 
large multi-country study. 
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Mean follow-up time: The last study visit of the extension (Visit 
38) is scheduled in December 2013 (interval: Nov 2013-Jan 
2014). This means a variable number of months after vaccination 
by individual children. Based on the actual enrolment, the mean 
follow-up time will be: 
- 5-17 months: 49 months post Dose 1 (range: 41-55) 
- 6-12 weeks: 41 months post Dose 1 (range: 32-48) 
Objectives Primary 
 
Efficacy coprimary objectives: Efficacy against clinical malaria 
disease when primary immunization starts at 6-12 weeks, or 5-17 
months of age 
  To evaluate the protective efficacy of RTS,S/AS01E against 
clinical malaria disease caused by Plasmodium falciparum in 
African children whose age at first dose will be from 6-12 
weeks and will receive vaccine in co-administration with 
DTPwHepB/Hib antigens (Tritanrix HepB/Hib) and OPV. 
Duration of follow up will be for a minimum of 12 months 
and a maximum of 18 months after completion of the primary 
course (Primary Analysis).  
  To evaluate the protective efficacy of RTS,S/AS01E against 
clinical malaria disease caused by Plasmodium falciparum in 
African children whose age at first dose will be from 5-17 
months. Duration of follow up will be for a minimum of 12 
months and a maximum of 18 months after completion of the 
primary course (Primary Analysis).  
Objectives Secondary 
 Efficacy against severe malaria disease 
  To evaluate the protective efficacy of RTS,S/AS01E on a 
primary schedule with and without booster dose against 
severe malaria disease. Duration of follow up will extend to 
30 months after completion of primary course.  
 Efficacy against incident severe anemia and malaria 
hospitalization 
  To evaluate the protective efficacy of RTS,S/AS01E on a 
primary schedule with and without booster dose against 
incident severe anemia and malaria hospitalization. Duration 
of follow up will extend to 30 months after completion of 
primary course. 
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 Efficacy; duration of efficacy of a primary course 
  To evaluate the duration of protective efficacy of a primary 
schedule of RTS,S/AS01E with no booster dose against 
clinical malaria disease. Duration of follow up will extend to 
30 months after completion of primary course.  
 Efficacy; the role of a booster 
  To evaluate the protective efficacy of RTS,S/AS01E against 
clinical malaria disease with and without a booster dose given 
18 months after completion of a primary schedule. Duration 
of follow up will be for 12 months after a booster dose.  
 Efficacy under different transmission settings 
  To evaluate the protective efficacy of RTS,S/AS01E on a 
primary schedule with and without booster dose against 
clinical malaria disease under different conditions of malaria 
transmission. Field site will be used as a proxy for 
transmission setting. Duration of follow up will extend to 30 
months after completion of primary course.  
 Efficacy against secondary case definitions of clinical malaria 
disease 
  To evaluate the protective efficacy of RTS,S/AS01E on a 
primary schedule with and without booster dose against 
secondary case definitions of clinical malaria disease. 
Duration of follow up will extend to 30 months after 
completion of primary course.  
 Efficacy against prevalence of parasitemia 
  To evaluate the protective efficacy of RTS,S/AS01E against 
prevalence of parasitemia 18 and 30 months after a primary 
schedule and 12 months after a booster dose.  
 Efficacy against prevalence of moderate and severe anemia 
  To evaluate the protective efficacy of RTS,S/AS01E against 
prevalence of moderate and severe anemia 18 and 30 months 
after a primary schedule and 12 months after a booster dose.  
 Safety of a primary course 
  For each age category, to evaluate the safety of a primary 
schedule of RTS,S/AS01E in African children. Duration of 
follow up will be for 14 months after receipt of the first dose 
(Primary Analysis).  
  For each age category, to evaluate the safety of a primary 
schedule of RTS,S/AS01E without a boost. Duration of 
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follow up will be for 32 months after receipt of first dose. 
 Safety of a booster dose 
  For each age category, to evaluate the safety of a booster dose 
of RTS,S/AS01E administered 18 months after completion of 
primary course. Duration of follow up will be for 12 months 
after receipt of boost.  
 Immunogenicity of a primary course 
  For children aged 5-17 months at first vaccination, to 
evaluate the anti-CS and anti-HBs immunogenicity of a 
primary schedule of RTS,S/AS01E without a boost. Duration 
of follow up will be for 32 months after receipt of first dose.  
  For children aged 6-12 weeks at first vaccination, to evaluate 
the anti-CS and anti-HBs immunogenicity of a primary 
schedule of RTS,S/AS01E without a boost when 
coadministered with DTPwHepB/Hib (Tritanrix HepB/Hib). 
Duration of follow up will be for 32 months after receipt of 
first dose. 
 Immunogenicity of a booster dose 
  For children aged 5-17 months at first vaccination, to 
evaluate the anti-CS and anti-HBs immunogenicity of a 
booster dose of RTS,S/AS01E administered 18 months after 
completion of primary course. Duration of follow up will be 
for 12 months after receipt of boost. 
  For children aged 6-12 weeks at first vaccination, to evaluate 
the anti-CS and anti-HBs immunogenicity of a booster dose 
of RTS,S/AS01E administered 18 months after completion of 
primary course of RTS,S/AS01E coadministered with 
DTPwHepB/Hib (Tritanrix HepB/Hib). Duration of follow up 
will be for 12 months after receipt of boost. 
 Immunogenicity of polio serotypes 1, 2 and 3 
  To describe antibody responses to polio serotypes 1, 2 and 3 
when OPV is given on a primary schedule co-administered 
with DTPwHepB/Hib (Tritanrix HepB/Hib) with or without 
RTS,S/AS01E at one month post dose 3. 
  To describe antibody responses to polio serotypes 1, 2 and 3 
when OPV is given on a primary schedule (co-administered 
with DTPwHepB/Hib with or without RTS,S/AS01E) and a 
booster dose at 18 months post primary (with or without 
RTS,S/AS01E) at one month post boost. 
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 Efficacy against other serious illness 
  To evaluate the protective efficacy of RTS,S/AS01E against 
other serious illness when given on a primary schedule with 
or without boost. Other serious illness is all-cause 
hospitalization, sepsis and pneumonia. Duration of follow-up 
will extend to 30 months after completion of primary course.  
 Efficacy against fatal malaria and all-cause mortality 
  To evaluate the protective efficacy of RTS,S/AS01E against 
fatal malaria and all-cause mortality when given on a primary 
schedule with or without boost. Duration of follow up will 
extend to 30 months after completion of primary course.  
 Effect on growth 
  To evaluate the effect of RTS,S/AS01E when given on a 
primary schedule with and without a booster dose on growth. 
 Gender-specific efficacy 
  To evaluate the vaccine efficacy of RTS,S/AS01E in male 
and female children when given on a primary schedule with 
and without a boost. 
 Immunological correlates of protection 
  To evaluate the association between CS-antibody response 
and protection against malaria disease.  
 Safety and immunogenicity in ‘special’ subgroups 
  To evaluate safety and immunogenicity of a primary course 
or a booster dose of RTS,S/AS01E in low weight for age (i.e. 
z-score  -2) and very low weight for age (i.e. z-score  -3) 
children.  
  To evaluate safety and immunogenicity of a primary course 
or a booster dose of RTS,S/AS01E in HIV-infected children. 
- Note: HIV testing is not a trial procedure. This analysis 
will include all children known to be HIV-infected at 
enrollment or subsequently diagnosed. 
Objectives of the 
extension 
Secondary 
Efficacy 
In children from 6 weeks to 17 months of age at primary 
immunisation for the period 14 days post Dose 3 to the end of 
extension: 
 For each of the RTS,S/AS01E immunisation regimens 
primary alone or primary plus boost, to evaluate the 
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protective efficacy against clinical malaria disease caused by 
Plasmodium falciparum in each of at least 3 transmission 
settings. 
 For each of the RTS,S/AS01E immunisation regimens 
primary alone or primary plus boost, to evaluate the total 
cases of clinical malaria disease caused by Plasmodium 
falciparum averted in each of at least 3 transmission settings. 
 To evaluate the protective efficacy of RTS,S/AS01E (pooled 
immunisation regimens) against severe malaria disease. 
 To evaluate the total cases of severe malaria disease averted 
by RTS,S/AS01E (pooled immunisation regimens). 
 To evaluate the protective efficacy of RTS,S/AS01E (pooled 
immunisation regimens) against malaria hospitalization. 
 To evaluate the total cases of malaria hospitalization averted 
by RTS,S/AS01E (pooled immunisation regimens). 
In children from 6 weeks to 17 months of age at primary 
immunisation, at annual timepoints during the extension: 
 To evaluate the protective efficacy of RTS,S/AS01E against 
prevalence of parasitemia. 
 To evaluate the protective efficacy of RTS,S/AS01E against 
prevalence of moderate and severe anemia. 
In children from 6 weeks to 17 months of age at primary 
immunisation for the period 14 days post Dose 3 to the end of 
extension: 
 To evaluate the protective efficacy of RTS,S/AS01E (pooled 
immunisation regimens) against all-cause mortality and fatal 
malaria. 
 To evaluate the total cases of all-cause mortality and fatal 
malaria averted by RTS,S/AS01E (pooled immunisation 
regimens). 
 To evaluate the protective efficacy of RTS,S/AS01E (pooled 
immunisation regimens) against all medical hospitalization. 
 To evaluate the total cases of all medical hospitalization 
averted by RTS,S/AS01E (pooled immunisation regimens). 
 To evaluate the protective efficacy of RTS,S/AS01E (pooled 
immunisation regimens) against pneumonia. 
 To evaluate the total cases of pneumonia averted by 
RTS,S/AS01E (pooled immunisation regimens). 
 To evaluate the protective efficacy of RTS,S/AS01E (pooled 
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immunisation regimens) against sepsis. 
 To evaluate the total cases of sepsis averted by RTS,S/AS01E 
(pooled immunisation regimens). 
Safety 
In children from 6 weeks to 17 months of age at primary 
immunisation for the time period from study start to the end of 
extension: 
 To evaluate the safety of the RTS,S/AS01E vaccine. 
Immunogenicity 
 To analyze the anti-CS antibodies titers at annual timepoints 
during the extension. 
Effect on growth 
In children from 6 weeks to 17 months of age at primary 
immunisation: 
 To evaluate the effect of RTS,S/AS01E on growth at the end 
of extension. 
Study design  Experimental design: Phase III, multi center, double blind 
(observer-blind), randomized, controlled trial with three 
groups in each of two age categories. 
  Males and females enrolled in two age categories: children 
aged 6-12 weeks and children aged 5-17 months. Children 
must be > 28 days of age at screening. Those determined to 
be eligible based on the inclusion and exclusion criteria will 
be enrolled in the study. 
  A maximum of 16 000 children (a minimum of 6000 in each 
age category) will be randomized. 
  Treatment Groups and study vaccination schedule 
children 5-17 months of age:  
  Primary Vaccination on a 0, 1, 2 month schedule Boost at M 20  
  RTS,S/AS01E RTS,S/AS01E  
  RTS,S/AS01E MCC Vaccine*  
  Rabies Vaccine** † MCC Vaccine*  
  *Meningococcal C Conjugate vaccine: Meningitec (Wyeth), NeisVac-C (Baxter) or 
Menjugate (Novartis) 
**Cell culture rabies vaccine: Human Diploid Cell Rabies Vaccine (Sanofi Pasteur) or 
Purified Vero cell culture rabies vaccine (VeroRab) (Sanofi Pasteur) or Purified Chick 
Embryo Cell Culture Vaccine (Rabipur or equivalent) (Novartis). 
† each child will receive all 3 doses of rabies vaccine from the same manufacturer 
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  Treatment Groups and vaccination schedule  
children 6-12 weeks of age: 
  Primary Vaccination on a 0, 1, 2 month schedule Boost at M 20  
  RTS,S/AS01E + Tritanrix HepB/Hib** + OPV RTS,S/AS01E + OPV  
  RTS,S/AS01E + Tritanrix HepB/Hib** + OPV MCC vaccine* + OPV  
  MCC vaccine * † + Tritanrix HepB/Hib** + OPV MCC vaccine* + OPV  
  *Meningococcal C Conjugate vaccine: Meningitec (Wyeth), NeisVac-C (Baxter) or 
Menjugate (Novartis) 
OPV: Oral Polio Vaccine (Polio Sabin [GSK]) 
† each child will receive all 3 doses of MCC from the same manufacturer. 
** DTPwHepB/Hib 
 
 
 Route of administration:  
- Children 5-17 months of age at enrollment will receive 
primary immunizations intramuscularly into the left 
deltoid. 
- Children 6-12 weeks of age at enrollment will receive 
primary immunizations intramuscularly into the 
anterolateral thigh  
(Left: RTS,S/AS01E and Meningococcal C conjugate 
vaccine; Right: Tritanrix HepB/Hib). 
NOTE: OPV will be administered orally. 
- Route of administration for the booster dose comparator 
will be into the left deltoid for ALL children. 
  BCG vaccine, neonatal dose of OPV, measles and yellow 
fever vaccines will be given according to local EPI policy. 
  There will be no routine testing for HIV in this trial. Tests 
will be performed when clinically indicated to guide subject 
management. Voluntary counseling and testing, highly active 
anti-retroviral therapy (HAART) and prevention of mother to 
child transmission (PMCT) are available at all study centers 
according to national policies. 
  The research teams at each study center will ensure that 
insecticide treated bednet use is optimized in each study 
population. 
 
 Surveillance for Efficacy: 
- All subjects presenting to health facilities in the study 
area will be evaluated as potential cases of clinical 
malaria disease. A blood sample will be taken for 
evaluation of malaria parasites in all children who are 
reported to have had a fever within 24 hours of 
presentation or have a measured axillary temperature of 
 37.5 C. 
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 - All subjects presenting for admission through the 
outpatient and emergency departments of hospitals in the 
study areas will be evaluated as potential cases of severe 
malaria disease following a protocol-defined algorithm. 
 - During any hospitalization, the subject’s course will be 
monitored to capture the signs and blood parameters 
indicative of severe malaria disease. If the subject’s 
condition changes from admission and he/she meets one 
of the criteria for additional investigation, these will be 
performed.  
 - Harmonization of case evaluation across centers will be 
assured by training of clinicians in the assessment of 
clinical signs and the standardization of equipment and 
processes used for laboratory investigations.  
 
 Surveillance for Safety:  
(n assumes 6000 enrolled, of which 90% will complete primary 
immunization and 85% complete booster dose and 10 
participating sites) 
 - SAEs will be collected for the duration of the study from 
all subjects  
(to have a minimum of 3620 recipients of a primary 
course of RTS,S/AS01E and 1680 recipients of a booster 
dose in each age category). 
 - Unsolicited AEs (defined as those AEs judged to be 
related to vaccination, or leading to drop-out) will be 
collected for 1 month post each dose in all subjects  
(to have a minimum of 3620 recipients of a primary 
course of RTS,S/AS01E and 1680 recipients of a booster 
dose in each age category). 
 - Unsolicited AEs (all) will be collected for 1 month 
following each vaccine dose for the first 200 subjects in 
each age category enrolled at each center 
(to have approximately 1200 recipients of a primary 
course of RTS,S/AS01E and 560 recipients of a booster 
dose in each age category). 
 - Solicited AEs will be collected for one week following 
each vaccine dose in the first 200 subjects in each age 
category enrolled at each center  
(to have approximately 1200 recipients of a primary 
course of RTS,S/AS01E and 560 recipients of a booster 
dose in each age category). 
 - Verbal autopsy will be performed on all cases of 
mortality occurring outside hospital. 
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 Surveillance for Immunogenicity: 
(n assumes 6000 enrolled, of which 90% will complete primary 
immunization and 85% complete booster dose and 10 
participating sites) 
 - All children will be sampled for anti-HBs and anti-CS 
testing. 
 - Immunogenicity of a primary course will be evaluated 
pre vaccination, 1 month post primary course and 18 
months post primary course in the first 200 subjects in 
each age category enrolled at each center  
(to have approximately 1200 recipients of a primary 
course of RTS,S/AS01E in each age category). 
 - Duration of immunogenicity of a primary course will be 
evaluated 18 and 30 months post primary course in the 
first 200 subjects in each age category enrolled at each 
center (to have approximately 560 recipients of a 
primary course of RTS,S/AS01E in each age category). 
 - Immunogenicity of a booster dose will be evaluated pre-
boost vaccination, 1 month post boost and 12 months 
post boost in the first 200 subjects in each age category 
enrolled at each center  
(to have approximately 560 recipients of a primary 
course of RTS,S/AS01E in each age category). 
 - Immune correlates of protection will be explored by 
sampling all subjects 1 month post primary course and 1 
month post boost and the full details of the analysis will 
be presented in the SAP to compare subjects affected and 
unaffected by malaria disease. 
 - Surveillance for Cellular Immunology: At some study 
centers, subjects may be sampled for evaluation of the 
cellular immune response induced by the RTS,S/AS01E 
vaccine. CMI procedures will be detailed in separate 
protocol, ancillary to this study.  
 - Immunogenicity of the polio serotypes 1, 2 and 3 will be 
evaluated when OPV is given on a primary schedule with 
DTPwHepB/Hib (Tritanrix HepB/Hib) with or without 
RTS,S/AS01E at screening, at 1 month post primary 
course (Visit 5) and following a booster dose at 18 
months post primary (with or without RTS,S/AS01E) at 
1 month post boost (Visit 23) in a subset of subjects in 
the 6-12 weeks age category enrolled at each center. 
  Data collection: where technically possible, this study will 
use electronic case report form (eCRF) by remote data entry 
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(RDE) in preference to conventional paper case report form 
(CRF). 
 Subjects will be randomized using an internet-based system. 
  Duration of the study: the primary study will continue for 32 
months per child, plus a screening period of 1 month. 
  Analysis of co-primary endpoint: clinical disease 
- The analysis of efficacy of a primary schedule of 
RTS,S/AS01E will be carried out after the first 14 
months of follow-up have been completed for the first 
6000 subjects (approximately) enrolled in the age 
category under evaluation. 
 - It is anticipated that enrolment of the 5-17 months age 
category will be faster than in the infant age category and 
thus analysis of the two co-primary efficacy endpoints 
may take place at different times. In order to control the 
overall alpha-level (5%) of the trial both evaluations will 
be performed at a 2.5% alpha level (Bonferroni 
correction) thus, for the evaluation of the co-primary 
endpoint leading to 97.5% confidence intervals (CI).  
 - In both age categories, efficacy against clinical malaria 
of the primary immunization schedule will be measured 
when at least 6000 subjects have 14 months of follow-
up. Assuming at least 5400 evaluable subjects 
(randomized 2:1), an attack rate in controls of 10/100 cyr 
(child years at risk) over the follow-up period and a true 
vaccine efficacy of 30%, the study has 90% power to 
detect a lower limit of the 97.5% CI around estimated 
VE above 0%. 
 - In the event that the attack rate is lower than anticipated 
and there have not been 450 accumulated cases in the 
observation period 14 days to 12 months post Dose 3, 
then the period of observation contributing to the 
primary analysis will be extended. The analysis will be 
conducted when 450 cases have accumulated, or until 
boost (visit 22) (approximately 18 months post dose 3) 
whichever occurs earlier.  
  Analysis of secondary endpoint: severe disease 
- A secondary analysis of severe malaria will be 
performed when 250 episodes of severe malaria meeting 
the primary case definition, pooled over the study centers 
and age categories, have occurred, or at the end of the 
follow-up period (Month 32), whichever occurs first. 
110021 (Malaria-055 PRI) 
Amendment 6 
08-AUG-2012 
- 19 - 
 - 250 episodes give 80% power to detect 30% VE with a 
lower limit of the 95% CI above 0%. Assuming 50% VE 
250 episodes give 90% power to detect a lower limit of 
the 95% CI above 25%. 
  Analysis of secondary endpoint: antibodies to polio serotypes 
1, 2 and 3 
- A secondary analysis of the immune response for polio 
serotypes 1, 2 and 3 when OPV is given on a primary 
schedule co-administered with DTPwHepB/Hib 
(Tritanrix HepB/Hib) with or without RTS,S/AS01E at 
screening, at 1 month post primary course (Visit 5) and 
following a booster dose at 18 months post primary (with 
or without RTS,S/AS01E) at one month post boost. 
  The first 200 subjects enrolled at each center, in each age 
category, will form a subset for additional safety and 
immunology endpoints. Safety evaluations comprise the 
collection of solicited reactogenicity and the use of 
antipyretic, analgesic and systemic antibiotics. 
Immunogenicity evaluations comprise responses to anti-CS 
and anti-HBs antigens and responses to OPV only in the 6-12 
weeks age category. 
Study design of 
the extension 
 Experimental design: Extension to the Phase III, multi-center, 
randomized, controlled trial Malaria-055 
 Blinding: 
- Initial study (D0 to Month 32): Double-Blind 
- Extension: Single blind 
 Study groups: 3 groups in children 6 weeks to 17 months at 
first vaccination. 
- Primary schedule + booster                R3R 
- Primary schedule + control vaccine   R3C 
- Comparator group                              C3C 
 Number of subjects: A maximum of 16 000 children are 
planned to be enrolled in the initial study. All subjects 
enrolled in the primary trial phase for whom 
parents/guardians will give their consent for participation in 
the extension, who received at least one dose of study or 
control vaccine in the primary trial phase and whose Visit 35 
took place before (and including) 30 September 2013, will be 
enrolled. 
 Malaria control: Bednet usage and indoor residual spraying 
will be documented for each subject before the last extension 
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visit using the same methodology of the primary trial phase. 
 Sampling timepoints: Blood samples will be taken at annual 
intervals during the extension (maximum 2 blood samples). 
 Data collection: This study will use electronic case report 
form (eCRF) by remote data entry (RDE). 
 Interval between study visits: Depending on the date of the 
last visit in the primary trial phase (Visit 34), subjects will 
have up to 3 clinic visits plus one field workers visit during 
this extension (Refer to Figure 2). If a subject does not attend 
Visit 34, the schedule of the following visit(s) will be based 
on the assumption that the Visit 34 occurred 32 months post 
Dose 1. 
- Subjects that have their last visit in the primary trial 
phase (Visit 34) BEFORE (and including) 30 June 2012 
will have 3 clinic visits plus one field workers visit in the 
extension. 
- Subjects that have their last visit in the primary trial 
phase (Visit 34) between 1 July 2012 and 30 September 
2013 will have 2 clinic visits plus one field workers visit 
in the extension. 
- No subjects will be enrolled in the extension study (Visit 
35) after 30 September 2013. 
Synopsis table 1 Intervals between study visits for subjects that 
have their last visit in the primary trial phase 
(Visit 34) BEFORE (and including) 30 Jun 2012 
Interval Optimal time for study visit 
(Study Months) 
Maximum interval 
allowed 
Visit 35 On same day as Visit 34* 
(Study Month 32) 
Maximum interval: 
Visit 2 + 44 months 
Visit 34 Visit 36 12 months** 
(Study Month 44) 
Range: 11 to 13 months 
 
Visit 34 Visit 37§ 
(Field workers visit) 
Nov 2013 
23 months** 
(Study Month 55) 
Date: Oct 2013 to Dec 
2013  
Visit 34 Visit 38 Dec 2013 
24 months** 
(Study Month 56) 
Date: Nov 2013 to Jan 
2014  
* If subjects are not present at Visit 34, Visit 35 should be scheduled as soon as 
possible and up to a maximum of 12 months after Visit 34, assuming Visit 34 should 
have occurred at Visit 2 + 32 months 
** If subjects are not present at Visit 34, Visit 36, 37 and 38 should be scheduled 
assuming Visit 34 should have occurred at Visit 2 + 32 months 
§Visit 37 (Field workers visit) has to be conducted within one month before Visit 38 
Amended 08 August 2012 
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 Synopsis table 2 Intervals between study visits for subjects that 
have their last visit in the primary trial phase 
(Visit 34) after 30 Jun 2012 and BEFORE (and 
including) 30 Sep 2013 
Interval Optimal time for study visit 
(Study Months) 
Maximum interval 
allowed 
Visit 35 
On same day as Visit 34* 
(Study Month 32) 
Maximum interval: 
Visit 2 + 44 months or 30 
Sep 2013 at the latest 
Visit 34 Visit 37§ 
(Field workers visit) 
Nov 2013 
11 months** 
(Study Month 43) 
Date: Oct 2013 to Dec 
2013 
Visit 34 Visit 38 Dec 2013 
12 months** 
(Study Month 44) 
Date: Nov 2013 to Jan 
2014  
* If subjects are not present at Visit 34, Visit 35 should be scheduled as soon as 
possible and up to a maximum of 12 months after Visit 34, assuming Visit 34 should 
have occurred at Visit 2 + 32 months. No subjects will be enrolled for Visit 35 after 30 
September 2013. 
** If subjects are not present at Visit 34, Visit 37 and 38 should be scheduled assuming 
Visit 34 should have occurred at Visit 2 + 32 months 
§Visit 37 (Field workers visit) has to be conducted between 1 and 30 days before Visit 
38. 
Amended 08 August 2012 
 Informed consent: Freely given informed consent should be 
obtained from subjects’ parent(s)/LAR(s) prior to 
participation in the extension. The informed consent must be 
signed at the first visit of the extension, Visit 35. To avoid 
any gap in data collection between the initial study and the 
extension, Visit 35 should ideally take place on the same day 
as Visit 34. If subjects are not present at Visit 34, Visit 35 
and signature of informed consent should be scheduled as 
soon as possible and up to a maximum 12 months after 
Visit 34 should have occurred. 
 Surveillance for Efficacy during the extension: 
- Surveillance for severe malaria disease will be 
maintained at all inpatient facilities in the study areas. 
Children will be evaluated according to an algorithm to 
accurately define cases. 
- Surveillance for clinical malaria disease will be 
maintained at the outpatient facilities in the study areas 
of at least 3 participating centers of varying malaria 
transmission intensity. 
- Parasite prevalence and haemoglobin will be assessed 
annually on all subjects. 
 Surveillance for Immunogenicity during the extension: 
- Anti-CS antibodies will be assessed in a subset of 200 
subjects in each age category in at least three centers 
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evaluating efficacy to clinical disease. 
 Surveillance for Safety during the extension: 
- Surveillance to detect SAEs will be maintained at all 
inpatient facilities in the study areas. 
- Verbal autopsy will be performed on all cases of 
mortality occurring outside hospital. 
Case Definitions Clinical malaria 
  
1  definition P. falciparum asexual parasitemia > 5000 parasites/μL  
AND presence of fever (axillary temperature  37.5°C) at the time of 
presentation  
AND occurring in a child who is unwell and brought for treatment to a healthcare 
facility 
OR 
a case of malaria meeting the primary case definition of severe malaria disease 
(refer to Table 6) 
 
  
2  definition 1 P. falciparum asexual parasitemia > 0 
AND presence of fever (axillary temperature  37.5°C) at the time of 
presentation or history of fever within 24 hours of presentation 
AND occurring in a child who is unwell and brought for treatment to a healthcare 
facility 
 
  
2  definition 2 P. falciparum asexual parasitemia > 500 parasites/μL 
AND presence of fever (axillary temperature  37.5°C) at the time of 
presentation 
AND occurring in a child who is unwell and brought for treatment to a healthcare 
facility 
 
  
2  definition 3 P. falciparum asexual parasitemia > 20 000 parasites/μL 
AND presence of fever (axillary temperature  37.5°C) at the time of 
presentation 
AND occurring in a child who is unwell and brought for treatment to a healthcare 
facility 
 
Case Definitions Primary case definition of severe malaria disease 
  P. falciparum > 5000 parasites per L  
  AND with one or more marker of disease severity  Prostration 
 Respiratory distress 
 Blantyre score  2 
 Seizures 2 or more 
 Hypoglycemia < 2.2 mmol/L 
 Acidosis BE -10.0 mmol/L 
 Lactate  5.0 mmol/L 
 Anemia < 5.0 g/dL 
 
  AND without diagnosis of a co-morbidity  Radiographically proven pneumonia 
 Meningitis on CSF examination 
 Positive blood culture 
 Gastroenteritis with dehydration 
 
 FOOTNOTES  
Prostration is defined as, in an acutely sick child, the inability to perform previously-acquired motor function: 
in a child previously able to stand, inability to stand; in a child previously able to sit, inability to sit and in a very 
young child, inability to suck.  
Respiratory distress is defined as lower chest wall indrawing or abnormally deep breathing. 
2 or more seizures occurring in the total time period including 24 hours prior to admission, the emergency 
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room and the hospitalization. 
Radiographically proven pneumonia is a consolidation or pleural effusion as defined in Appendix G on a 
chest x-ray taken within 72 h of admission. 
Meningitis on CSF examination is defined as WC  50 x10 6/L or positive culture of compatible organism or 
latex agglutination positive for Hib, pneumococci or meningococci [Berkley, 2001].  
Gastroenteritis with dehydration is defined as a history of 3 or more loose or watery stools in previous 24 h 
and an observed watery stool with decreased skin turgor (> 2 seconds for skin to return following skin pinch). 
Positive blood culture is defined in Appendix F on a blood culture taken within 72 h of admission. 
Case Definitions Secondary case definitions of severe malaria disease 
  2  definition 1 
“with co-morbidity” 
P. falciparum > 5000 parasites per μL 
AND with one or more marker of disease severity 
 
  2  definition 2 
“without a density threshold” 
P. falciparum > 0 
AND with one or more marker of disease severity 
AND without diagnosis of a co-morbidity 
 
  2  definition 3 
“without HIV” 
P. falciparum > 5000 parasites per μL 
AND with one or more marker of disease severity 
AND without diagnosis of a co-morbidity  
AND without a confirmed diagnosis of HIV infection 
 
Case Definitions Malaria hospitalization 
  
Definition 1 A medical hospitalization with confirmed P. falciparum > 5000 parasites/μL  
(excludes planned admissions for medical investigation/care or elective surgery 
and trauma) 
 
  
Definition 2 A hospitalization which, in the judgment of the principal investigator, P. falciparum 
infection was the sole or a major contributing factor to the presentation 
 
Case Definitions Fatal malaria 
  
1  definition A case of severe malaria meeting the primary case definition of 
severe malaria disease (see primary case definition of severe 
malaria disease [above]) with a fatal outcome  
(i.e. is restricted to hospital mortality and does not include cause 
ascribed by verbal autopsy). 
 
  2  definition 1 
“with co-morbidity” 
A case of severe malaria meeting the secondary case definition 1 
severe malaria disease (see secondary case definitions of severe 
malaria disease [above]) with a fatal outcome  
 
  2  definition 2 
“without a density threshold” 
A case of severe malaria meeting the secondary case definition 2 
severe malaria disease (see secondary case definitions of severe 
malaria disease [above]) with a fatal outcome 
 
  2  definition 3 
“without HIV” 
A case of severe malaria meeting the secondary case definition 3 
severe malaria disease (see secondary case definitions of severe 
malaria disease [above]) with a fatal outcome 
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Case Definitions Incident severe anemia 
  
Definition 1 
A documented hemoglobin < 5.0 g/dL identified at clinical presentation to morbidity 
surveillance system in association with a P. falciparum parasitemia > 5000 
parasites/μL 
 
  
Definition 2 
A documented hemoglobin < 5.0 g/dL identified at clinical presentation to morbidity 
surveillance system in association with a P. falciparum parasitemia > 0 
parasites/μL 
 
  
Definition 3 A documented hemoglobin < 5.0 g/dL identified at clinical presentation to morbidity 
surveillance system 
 
Case Definitions Prevalent anemia 
  
Prevalent severe anemia A documented hemoglobin < 5.0 g/dL identified 
at a cross sectional survey 
 
  
Prevalent moderate anemia A documented hemoglobin < 8.0 g/dL identified 
at a cross sectional survey 
 
Case Definitions All medical hospitalization 
  
1  definition A medical hospitalization of any cause  
(excludes planned admissions for medical investigation/care or elective surgery 
and trauma) 
 
Case Definitions All-cause mortality 
  
Definition 1 A fatality (of any cause)  
(includes mortality in the community and in hospital) 
 
  
Definition 2 A fatality (medical cause)  
(includes mortality in the community and in hospital) 
(excludes trauma, which may be diagnosed by verbal autopsy) 
 
Case Definitions Pneumonia 
  
1  definition cough or difficulty breathing (on history)  
AND tachypnea 
AND lower chest wall indrawing 
 
  
2  definition 1 1  case definition of pneumonia 
AND CXR consolidation or pleural effusion (as defined in 
Appendix G on a chest x-ray taken within 72 h of admission) 
 
  
2  definition 2 1  case definition of pneumonia 
AND CXR consolidation or pleural effusion or other 
infiltrates (as defined in Appendix G on a chest x-ray taken 
within 72 h of admission) 
 
  
2  definition 3 1  case definition of pneumonia 
AND an oxygen saturation less than 90% 
 
 FOOTNOTES  
Tachypnea (  50 breaths per minute < 1 year,  40 breaths per minute  1year). 
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Case Definitions Sepsis 
  
1  definition A child with positive blood culture 
 
 FOOTNOTES 
Positive blood culture as defined in Appendix H on a blood culture taken within 72 h of admission. 
Endpoints Primary 
 
Efficacy against clinical malaria disease when primary 
immunization starts at 6-12 weeks, or 5-17 months of age 
  For a primary schedule, the occurrence of cases of malaria 
meeting the primary case definition for clinical malaria 
disease over a period starting 14 days post Dose 3 (Visit 4 
+14 days) for 12 months in children aged 6-12 weeks at the 
time of Dose 1, or until the time at which 450 subjects 
experience a case, whichever occurs later. If 450 are not 
accumulated by the time of boost (Visit 22), the analysis will 
proceed. 
  For a primary schedule, the occurrence of cases of malaria 
meeting the primary case definition for clinical malaria 
disease over a period starting 14 days post Dose 3 (Visit 4 
+14 days) for 12 months in children aged 5-17 months at the 
time of Dose 1, or until the time at which 450 subjects 
experience a case, whichever occurs later. If 450 are not 
accumulated by the time of boost (Visit 22), the analysis will 
proceed. 
Endpoints Secondary 
 Efficacy against severe malaria disease 
  For a primary schedule (pooled with and without a boost), the 
occurrence of severe malaria disease meeting the primary and 
secondary case definitions up to the time at which 250 
subjects are diagnosed with severe malaria meeting the 
primary case definition. 
 For a primary schedule with and without a boost, the 
occurrence of severe malaria disease meeting the primary and 
secondary case definitions analyzed over the time periods 
starting 14 days post Dose 3 (Visit 4 +14 days) until boost 
(Visit 22), boost (Visit 22) until study end (Visit 34) and 14 
days post Dose 3 (Visit 4 +14 days) until study end (Visit 
34).  
 Efficacy against incident severe anemia and malaria 
hospitalization  
  For a primary schedule with and without a boost, the 
occurrence of incident severe anemia and malaria 
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hospitalization meeting the primary and secondary case 
definitions analyzed over the time periods starting 14 days 
post Dose 3 (Visit 4 +14 days) until boost (Visit 22), boost 
(Visit 22) until study end (Visit 34) and 14 days post Dose 3 
(Visit 4 +14 days) until study end (Visit 34).  
 Efficacy; duration of efficacy of a primary course 
  For a primary schedule without a boost, the occurrence of 
clinical malaria disease meeting the primary case definition 
analyzed over the time periods starting 14 days post Dose 3 
(Visit 4 +14 days) until boost (Visit 22), boost (Visit 22) until 
study end (Visit 34) and 14 days post Dose 3 (Visit 4 +14 
days) until study end (Visit 34). 
 Efficacy; role of a booster 
  For a primary schedule with and without a boost, the 
occurrence of clinical malaria disease meeting the primary 
case definition analyzed over the time period starting at boost 
(Visit 22) until study end (Visit 34).  
 Efficacy under different transmission settings 
  For each site, for a primary schedule with and without a 
boost, the occurrence of clinical malaria disease meeting the 
primary case definition analyzed over the time periods 
starting 14 days post Dose 3 (Visit 4 +14 days) until boost 
(Visit 22), boost (Visit 22) until study end (Visit 34) and 14 
days post Dose 3 (Visit 4 +14 days) until study end (Visit 
34). 
 Efficacy against secondary case definitions of clinical malaria 
disease 
  For a primary schedule with and without a boost, the 
occurrence of clinical malaria disease meeting the secondary 
case definitions analyzed over the time periods starting 14 
days post Dose 3 (Visit 4 +14 days) until boost (Visit 22), 
boost (Visit 22) until study end (Visit 34) and 14 days post 
Dose 3 (Visit 4 +14 days) until study end (Visit 34). 
 Efficacy against prevalence of parasitemia 
  For a primary schedule without a boost, the presence of 
parasitemia at 18 months (Visit 22) and 30 months (Visit 34) 
after a primary schedule.  
 For a booster schedule, the presence of parasitemia 12 
months after a boost (Visit 34). 
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 Efficacy against prevalence of moderate and severe anemia 
  For a primary schedule without a boost, the presence of 
moderate and severe anemia at 18 months (Visit 22) and 30 
months (Visit 34) after a primary schedule.  
  For a booster schedule, the presence of moderate and severe 
anemia 12 months after a boost (Visit 34). 
 Safety of a primary course 
  For each age category, for a primary schedule, the occurrence 
of SAEs from Dose 1 (Visit 2) until 14 months post Dose 1 
(Visit 16).  
 For each age category, for a primary schedule, the occurrence 
of SAEs over a 30-day follow-up period (day of vaccination 
and 29 subsequent days) after each vaccination. 
 For each age category, for a primary schedule without boost, 
the occurrence of SAEs analyzed over the time periods 
starting at Dose 1 (Visit 2) until boost (Visit 22), boost (Visit 
22) until study end (Visit 34) and Dose 1 (Visit 2) until study 
end (Visit 34). 
  For each age category, for a primary schedule, the occurrence 
of solicited symptoms over a 7-day follow-up period (day of 
vaccination and 6 subsequent days) after each vaccination. 
 For each age category, for a primary schedule, the occurrence 
of all unsolicited symptoms over a 30-day follow-up period 
(day of vaccination and 29 subsequent days) after each 
vaccination. 
 For each age category, for a primary schedule, the occurrence 
of unsolicited symptoms related to vaccination or leading to 
withdrawal over a 30-day follow-up period (day of 
vaccination and 29 subsequent days) after each vaccination. 
 Safety of a booster dose 
  For each age category, for a booster dose, the occurrence of 
SAEs analyzed over the time period starting at boost (Visit 
22) until study end (Visit 34). 
 For each age category, for a booster dose, the occurrence of 
SAEs over a 30-day follow-up period (day of vaccination and 
29 subsequent days) after boost. 
 For each age category, for a booster dose, the occurrence of 
solicited symptoms over a 7-day follow-up period (day of 
vaccination and 6 subsequent days) after the boost.  
 For each age category, for a booster dose, the occurrence of 
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all unsolicited symptoms over a 30-day follow-up period (day 
of vaccination and 29 subsequent days) after each 
vaccination. 
 For each age category, for a booster dose, the occurrence of 
unsolicited symptoms over a 30-day follow-up period (day of 
vaccination and 29 subsequent days) after the boost.  
 Immunogenicity of a primary course 
  For each age category, for a primary schedule without a 
boost, the anti-CS antibody titers at screening, 1 month post 
Dose 3 (Visit 5), 18 months post Dose 3 (Visit 22) and 30 
months post Dose 3 (Visit 34). 
 For each age category, for a primary schedule without a 
boost, the anti-HBs antibody titers at screening, 1 month post 
Dose 3 (Visit 5), 18 months post Dose 3 (Visit 22) and 30 
months post Dose 3 (Visit 34). 
 Immunogenicity of a booster dose 
  For each age category, for a booster schedule, the anti-CS 
antibody titers at boost (Visit 22), 1 month post boost (Visit 
23), 12 months post boost (Visit 34).  
 For each age category, for a booster schedule, the anti-HBs 
antibody titers at boost (Visit 22), 1 month post boost (Visit 
23), 12 months post boost (Visit 34). 
 Immunogenicity of polio serotypes 1, 2 and 3 
  To analyze in a subset of African children whose age at first 
dose will be 6-12 weeks the percentage of subjects with 
seroprotective levels of anti-polio 1, 2, 3 antibodies when 
OPV is given on a primary schedule co-administered with 
DTPwHepB/Hib (Tritanrix HepB/Hib) with or without 
RTS,S/AS01E at one month post dose 3 (Visit 5). 
  To analyze in a subset of African children whose age at first 
dose will be 6-12 weeks the percentage of subjects with 
seroprotective levels of anti-polio 1, 2, 3 antibodies when 
OPV is given on a primary schedule (co-administered with 
DTPwHepB/Hib with or without RTS,S/AS01E) and a 
booster dose at 18 months post primary (with or without 
RTS,S/AS01E) at one month post boost (Visit 23). 
 Efficacy against other serious illness 
  For a primary schedule with and without a boost, the 
occurrence of other serious illness meeting the primary and 
secondary case definitions analyzed over the time periods 
starting 14 days post Dose 3 (Visit 4 + 14 days) until boost 
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(Visit 22), boost (Visit 22) until study end (Visit 34) and 14 
days post Dose 3 (Visit 4 + 14 days) until study end (Visit 
34). Other serious illness is all medical hospitalization, sepsis 
and pneumonia. 
 Efficacy against fatal malaria and all-cause mortality 
  For a primary schedule with and without a boost, the 
occurrence of fatal malaria (meeting the case definitions) and 
all-cause mortality analyzed over the time periods starting 14 
days post Dose 3 (Visit 4 +14 days) until study end (Visit 
34). 
 Effect on growth 
  For a primary schedule with and without a boost, to compare 
the height/length for age z-score at study end (Visit 34). 
 For a primary schedule with and without a boost, to compare 
the weight for age z-score at study end (Visit 34). 
 For a primary schedule with and without a boost, to compare 
the mid upper arm circumference for age z-score at study end 
(Visit 34). 
 For children 6-12 weeks at first vaccination, for a primary 
schedule with and without boost, to compare the absolute 
height at study end (Visit 34). 
 Gender-specific efficacy 
  In male and female children, for a primary schedule with and 
without a boost the occurrence of clinical malaria disease 
meeting the primary case definition analyzed over the time 
periods starting 14 days post Dose 3 (Visit 4 +14 days) until 
boost (Visit 22), boost (Visit 22) until study end (Visit 34) 
and 14 days post Dose 3 (Visit 4 +14 days) until study end 
(Visit 34). 
If important differences in efficacy are observed between male 
and female children, then all primary and secondary 
immunological and efficacy endpoints will be presented for male 
and female children. 
 Immunological correlates of protection 
  In cases and non-cases of malaria disease, CS-antibody titers. 
 Safety and immunogenicity in ‘special’ subgroups 
 Note: HIV testing is not a trial procedure. This analysis will 
include all children known to be HIV-infected at enrollment or 
subsequently diagnosed 
110021 (Malaria-055 PRI) 
Amendment 6 
08-AUG-2012 
- 30 - 
 In HIV-infected children, for each age category, for a primary 
schedule with and without a boost, the occurrence of SAEs 
analyzed over the time periods starting at Dose 1 (Visit 2) 
until boost (Visit 22), boost (Visit 22) until study end (Visit 
34) and Dose 1 (Visit 2) until study end (Visit 34). 
  In HIV-infected children, for each age category, for a primary 
schedule and a booster dose, the occurrence of unsolicited 
symptoms related to vaccination or leading to withdrawal 
over a 30-day follow-up period (day of vaccination and 29 
subsequent days) after each vaccination.  
  In HIV-infected children, for each age category, for a primary 
schedule with and without a boost, the anti-CS antibody titers 
at screening, 1 month post Dose 3 (Visit 5), 18 months post 
Dose 3 (Visit 22) and 30 months post Dose 3 (Visit 34).  
  In HIV-infected children for each age category, for a primary 
schedule with and without a boost, the anti-HBs antibody 
titers at screening, 1 month post Dose 3 (Visit 5), 18 months 
post Dose 3 (Visit 22) and 30 months post Dose 3 (Visit 34). 
  In low weight for age children (weight for age z-score -2) 
and in very low weight for age children (weight for age z-
score -3), for each age category, for a primary schedule with 
and without a boost, the occurrence of SAEs analyzed over 
the time periods starting at Dose 1 (Visit 2) until boost (Visit 
22), boost (Visit 22) until study end (Visit 34) and Dose 1 
(Visit 2) until study end (Visit 34). 
  In low weight for age children (weight for age z-score -2) 
and in very low weight for age children (weight for age z-
score -3), for each age category, for a primary schedule and 
a boost, the occurrence of unsolicited symptoms related to 
vaccination or leading to withdrawal over a 30-day follow-up 
period (day of vaccination and 29 subsequent days) after each 
vaccination. 
  In low weight for age children (weight for age z-score -2) 
and in very low weight for age children (weight for age z-
score -3), for each age category, for a primary schedule with 
and without a boost, the anti-CS antibody titers at screening, 
1 month post Dose 3 (Visit 5), 18 months post Dose 3 (Visit 
22) and 30 months post Dose 3 (Visit 34). 
  In low weight for age children (weight for age z-score -2) 
and in very low weight for age children (weight for age z-
score -3), for each age category, for a primary schedule with 
and without a boost, the anti-HBs antibody titers at screening, 
1 month post Dose 3 (Visit 5), 18 months post Dose 3 (Visit 
22) and 30 months post Dose 3 (Visit 34). 
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Endpoints for the 
extension 
Secondary 
Efficacy 
 In each of at least three study centers, the occurrence of 
clinical malaria disease meeting the primary and secondary 
case definitions for clinical malaria over a period starting 14 
days post Dose 3 until the last visit of the extension. 
 Pooled across at least three study centers, the occurrence of 
clinical malaria disease meeting the primary and secondary 
case definitions for clinical malaria over annual time periods. 
 Pooled across all participating study centers, the occurrence 
of severe malaria disease meeting the primary and secondary 
case definitions for severe malaria over a period starting 14 
days post Dose 3 until the last visit of the extension. 
 Pooled across all participating study centers, the occurrence 
of malaria hospitalization meeting the primary and secondary 
case definitions for malaria hospitalization over a period 
starting 14 days post Dose 3 until the last visit of the 
extension. 
 Pooled across all participating study centers, the presence of 
parasitemia at annual timepoints during the extension. 
 Pooled across all participating study centers, the presence of 
moderate and severe anemia at annual timepoints during the 
extension. 
 Pooled across all participating study centers, the occurrence 
of all-cause mortality and fatal malaria meeting the primary 
and secondary case definitions over a period starting 14 days 
post Dose 3 until the last visit of the extension. 
 Pooled across all participating study centers, the occurrence 
of all-medical hospitalization meeting the primary case 
definition over a period starting 14 days post Dose 3 until the 
last visit of the extension. 
 Pooled across all participating study centers, the occurrence 
of pneumonia meeting the primary and secondary case 
definitions over a period starting 14 days post Dose 3 until 
the last visit of the extension. 
 Pooled across all participating study centers, the occurrence 
of sepsis meeting the primary case definition over a period 
starting 14 days post Dose 3 until the last visit of the 
extension). 
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Safety 
 In all participating study centers, the occurrence of SAEs 
from Dose 1 (Day 0) until the end of extension. 
Immunogenicity 
 In a subset of subjects, the anti-CS antibody titers at annual 
timepoints during the extension. 
Effect on growth 
 In all subjects at all participating study centers, to compare 
the height for age z-score at the end of extension. 
Relevant efficacy and immunogenicity endpoints will also be 
analyzed by annual time periods, age category and by site. 
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LIST OF ABBREVIATIONS 
List of abbreviations amended 26 November 2009, 23 January 2012 
Note: Abbreviations for vaccination groups 
The abbreviations below are used to describe the vaccination groups in some 
sections of the protocol. 
R3R: Children to receive 3 doses of RTS,S/AS01E on a 0, 1, 2 schedule with an 
RTS,S/AS01E booster.  
R3C: Children to receive 3 doses of RTS,S/AS01E on a 0, 1, 2 schedule without an 
RTS,S/AS01E booster. 
C3C: Children to receive 3 doses of a comparator vaccine on a 0, 1, 2 schedule with 
a dose of comparator vaccine at Visit 22.  
 
AE Adverse event 
ALT Alanine aminotransferase 
anti-CS Antibody to the P. falciparum circumsporozoite (CS) repeat 
domain 
anti-HBs Antibody to the hepatitis B surface antigen 
ATP According to protocol 
BIOMNIS Biomnis Recherche Clinique, Lyon, France 
CEVAC Center for Vaccinology, Ghent University, Belgium 
CI Confidence interval 
CMI Cell-mediated immunity 
CRF Case report form 
CS Circumsporozoite protein of P. falciparum 
CSF Cerebro-spinal fluid 
CXR Chest X Ray 
DTPw/Hib Diphtheria, Tetanus, Pertussis (whole cell) and Hemophilus 
influenzae type B conjugate vaccine 
110021 (Malaria-055 PRI) 
Amendment 6 
08-AUG-2012 
- 45 - 
DSMB Data safety monitoring board 
eCRF electronic Case Report Form 
ELISA Enzyme-linked immunosorbent assay 
EPI Expanded program on immunization 
EU/mL ELISA unit per milliliter 
FDA Food and Drug Administration, United States 
GCP Good clinical practice  
GMT Geometric mean titer 
GSK GlaxoSmithKline 
HBsAg Hepatitis B surface antigen 
HBV Hepatitis B virus 
Hep B Hepatitis B 
HDC Rabies 
Vaccine 
Human diploid cell rabies vaccine (manufactured by Sanofi 
Pasteur, previously marketed as ‘Imovax®’ the product is now 
marketed as ‘HDC Rabies Vaccine’) 
HIV Human immunodeficiency virus 
HSPH Harvard School of Public Health, Cambridge, Massachusetts, 
USA 
IB Investigator’s brochure 
ICF Informed consent form 
ICH International Committee on Harmonization 
IDMC Independent Data Monitoring Committee 
IEC Independent ethics committee 
IFN-gamma Interferon gamma 
IM Intramuscular 
IMD Immune-mediated disorder 
IPTi Intermittent preventative treatment for malaria (Infants) 
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IRB Institutional review board 
IU International unit 
ITN Insecticide-treated bednet 
kg Kilogram 
LLN Lower limit of normal 
LP Lumbar puncture 
LSM Local safety monitor 
MCC Meningococcal C conjugate vaccine 
MedDRA Medical Dictionary for Regulatory Activities 
mg Milligram 
mL Milliliter 
MPL
®
 3-deacylated monophosphoryl lipid A 
MVI Malaria Vaccine Initiative 
P. falciparum Plasmodium falciparum 
PATH Program for Appropriate Technology in Health 
PCD Passive case detection 
PCEC Purified chick embryo cell culture vaccine: previously 
manufactured by Chiron Behring, the product is now produced 
by Novartis. The product is marketed in the USA as RabAvert
®
, 
elsewhere as Rabipur
®
 
PFS Pre-filled syringe 
PI Principal Investigator 
PMCT Prevention of mother-to-child transmission 
QS 21 ‘Quillaja saponaria 21’: a triterpene glycoside purified from the 
bark of the soap bark tree, Quillaja saponaria 
RBC Red blood cell 
RDE Remote Data Entry 
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RTS,S Particulate antigen, containing both RTS and HBs proteins 
SAE Serious adverse event 
SAP Statistical analysis plan 
SOP Standard operating procedure 
SP Sulfadoxine-pyrimethamine 
ULN Upper limit of normal 
VE Vaccine efficacy 
WC White cells 
WRAIR Walter Reed Army Institute of Research 
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GLOSSARY OF TERMS 
Glossary of terms amended 26 November 2009, 01 December 2010 
Adverse event: Any untoward medical occurrence in a patient or clinical 
investigation subject, temporally associated with the use 
of a medicinal product, whether or not considered related 
to the medicinal product.  
An AE can therefore be any unfavorable and unintended 
sign (including an abnormal laboratory finding), 
symptom, or disease (new or exacerbated) temporally 
associated with the use of a medicinal product. For 
marketed medicinal products, this also includes failure to 
produce expected benefits (i.e. lack of efficacy), abuse or 
misuse. 
Blinding: A procedure in which one or more parties to the trial are 
kept unaware of the treatment assignment in order to 
reduce the risk of biased study outcomes. In a single-
blind trial, the investigator and/or his staff are aware of 
the treatment assignment but the subject is not. In an 
observer-blind study, the subject and the study personnel 
involved in the clinical evaluation of the subjects are 
blinded while other study personnel may be aware of the 
treatment allocation. When the investigator and sponsor 
staff who are involved in the treatment or clinical 
evaluation of the subjects and review/analysis of data are 
also unaware of the treatment assignments, the study is 
double blind. Partially-blind is to be used for study 
designs with different blinding levels between different 
groups, e.g. double-blinded consistency lots which are 
open with respect to the control group. The level of 
blinding is maintained throughout the conduct of the trial, 
and only when the data are cleaned to an acceptable level 
of quality will appropriate personnel be unblinded or 
when required in case of a serious adverse event. 
Central Study Coordinator: An individual assigned by and centrally located at GSK 
Biologicals at Rixensart who is responsible for assuring 
the co-ordination of the operational aspects and proper 
conduct of a clinical study, including compliance with 
International Conference on Harmonization (ICH) 
Harmonized Tripartite Guideline for Good Clinical 
Practice (GCP) and GSK policies and standard operating 
procedures. 
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Data Safety Monitoring 
Board (DSMB): 
Note: called IDMC since 
October 2008 
The DSMB is an independent committee appointed to 
oversee ethical and safety aspects of the conduct of the 
study. See Section 5.1.4.1 for a full overview of the role 
and structure of the DSMB. 
Eligible: Qualified for enrolment into the study based upon strict 
adherence to inclusion/exclusion criteria. 
eTrack: GSK’s clinical trials tracking tool. 
Evaluable: Meeting all eligibility criteria, complying with the 
procedures defined in the protocol, and, therefore, 
included in the according-to-protocol (ATP) analysis (see 
Sections 4.4 and 10.6 for details on criteria for 
evaluability). 
Independent Data 
Monitoring Committee 
(IDMC) (previously 
named DSMB): 
The IDMC is an independent committee appointed to 
oversee ethical and safety aspects of the conduct of the 
study. See Section 5.1.4.1 for a full overview of the role 
and structure of the IDMC. 
Investigational product: A pharmaceutical form of an active ingredient or placebo 
being tested or used as a reference in a clinical trial, 
including a product with a marketing authorization when 
used in a way different from the approved form, or when 
used for an unapproved indication, or when used to gain 
further information about an approved use.  
Local Safety Monitor 
(LSM): 
The overall role of the Local Safety Monitor, an 
experienced physician based in-country, will be to 
support the study investigators and to act as a link 
between the investigators and the Data Safety Monitoring 
Board (DSMB) (see Section 5.1.4.2 for further details on 
the LSM). 
Medical Monitor: An individual medically qualified to assume the 
responsibilities of the sponsor (GSK Biologicals) 
especially in regards to the ethics, clinical safety of a 
study and the assessment of adverse events. 
Pre-patent Period (PPP): The time in days between experimental sporozoite 
challenge and first detection of parasitemia by peripheral 
blood thick smear. 
Protocol amendment: ICH defines a protocol amendment as: “A written 
description of a change(s) to or formal clarification of a 
protocol.” GSK Biologicals further details this to include 
a change to an approved protocol that affects the safety of 
subjects, scope of the investigation, study design, or 
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scientific integrity of the study. 
Protocol administrative 
change: 
A protocol administrative change addresses changes to 
only logistical or administrative aspects of the study.  
N.B. Any change that falls under the definition of a 
protocol amendment (e.g. a change that affects the safety 
of subjects, scope of the investigation, study design, or 
scientific integrity of the study) MUST be prepared as an 
amendment to the protocol.  
Randomization: Process of random attribution of treatment to subjects in 
order to reduce bias of selection. 
Serious Adverse Event: A serious adverse event (SAE) is any untoward medical 
occurrence that: 
a. results in death; 
b. is life-threatening; 
c. requires hospitalization or prolongation of existing 
hospitalization; 
d. results in disability/incapacity; 
e. a seizure within 30 days of vaccination. 
NOTE: In this study all seizures occurring within a 30-
day period of vaccination will be notified as SAEs. Key 
information pertaining to seizures occurring within 7 
days of vaccination will be documented in the CRF/eCRF 
[refer to Bonhoeffer, 2004]. 
f. medical or scientific judgment should be exercised in 
deciding whether reporting is appropriate in other 
situations, such as important medical events that may 
not be immediately life-threatening or result in death 
or hospitalization but may jeopardize the subject or 
may require medical or surgical intervention to 
prevent one of the other outcomes listed in the above 
definition. These should also be considered serious. 
Examples of such events are invasive or malignant 
cancers, intensive treatment in an emergency room or 
at home for allergic bronchospasm and blood 
dyscrasias. 
A full definition of the events that constitute SAEs can be 
found in Section 8.2). 
Amended 01 December 2010 
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Solicited adverse event: Adverse events (AEs) to be recorded as endpoints in the 
clinical study. The presence/occurrence/intensity of these 
events is actively solicited from the subject or an observer 
during a specified post-vaccination follow-up period. 
Study End: Throughout the document, “study end” means the end of 
the primary trial phase at Visit 34 (Month 32). When the 
end of the extension phase at Visit 38 is meant, it will be 
described as such. 
Amended 01 December 2010 
Study Monitor: An individual assigned by the sponsor who is responsible 
for assuring proper conduct of a clinical study. 
Subject: Term used throughout the protocol to denote an 
individual that has been contacted in order to participate 
or participates in the clinical study, either as a recipient of 
the investigational product(s) or as a control. 
Treatment: Term used throughout the clinical study to denote a set of 
investigational product(s) or marketed product(s) or 
placebo intended to be administered to a subject, 
identified by a unique number, according to the study 
randomization or treatment allocation. 
Treatment number: A unique number identifying a treatment to a subject, 
according to the study randomization or treatment 
allocation. 
Unsolicited adverse event: Any adverse event (AE) reported in addition to those 
solicited during the clinical study. Also any “solicited” 
symptom with onset outside the specified period of 
follow-up for solicited symptoms will be reported as an 
unsolicited adverse event. 
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1. INTRODUCTION 
1.1. Malaria 
Four species of the Plasmodium protozoan parasite cause malaria in humans 
(P. falciparum, P. vivax, P. ovale and P. malariae). Of these four parasites, P. falciparum 
is the major cause of severe morbidity and mortality. 
There is no doubt of the importance of P. falciparum malaria as a major cause of human 
suffering and economic drain across sub-Saharan Africa [Breman 2001a; Gallup 2001]. 
In this region, it causes the deaths of between 0.5 and 2.0 million children every year and 
is a common reason for admission to hospital, leading each year to about 300 million 
clinical episodes in children under five years [Breman 2001a]. 
The incidence of malaria in much of Africa is increasing for a variety of reasons: changes 
in agricultural practices, armed conflicts, migration of refugees, increasing drug 
resistance to conventional anti-malarial drugs, and insecticide resistance of the mosquito 
vectors. It is estimated that without effective control the number of cases of clinical 
malaria will more than double over the next 20 years. The burden of malaria at the 
country level correlates closely with the rate of economic development even after 
adjustment for confounding factors, indicating that malaria is an important constraint on 
economic progress [Breman 2001b]. 
Clinical manifestations of P. falciparum disease appear as a result of the parasite 
infection of the red blood cells (RBC). Initial symptoms may include fever, chills, 
headache, joint and muscle pain, sweating, and vomiting. Acute complications may result 
from hemolysis leading to anemia and the propensity of infected RBCs to become 
adhesive and to be sequestered in capillaries thus causing local inflammatory reactions 
and damage to vital organs, leading to cerebral, hepatic, renal or pulmonary malaria. In 
P. falciparum malaria, an untreated acute attack can progress very rapidly and death may 
occur within a short timeframe. 
Efforts to develop vaccines that target each stage of the parasite life cycle, to identify 
protective antigens and to understand the nature of the protective immune responses have 
been ongoing for the past three decades. The approach of GlaxoSmithKline (GSK) 
Biologicals has been to focus on vaccines that target the sporozoite and intra-hepatic 
stages of the parasites (i.e. the pre-erythrocytic stage). 
1.2. Hepatitis 
Hepatitis B is an infection of the liver due to hepatitis B virus (HBV); it is an important 
public health problem across the developing world. World-wide approximately 350 
million people carry HBV and about 1 million chronic carriers die annually [Vryheid 
2001]. The age at infection determines the likelihood of the infection becoming chronic: 
90% if infected in infancy, 30% to 50% if infected between the ages of 1 to 4 years, and 
low in adulthood. For those that become chronically infected during childhood the risk of 
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death from HBV-related liver cancer or cirrhosis in adult life is approximately 25% 
[WHO 2003]. 
1.3. RTS,S candidate vaccine 
The candidate vaccine antigen consists of sequences of the circumsporozoite (CS) protein 
and the hepatitis B surface antigen (HBsAg). The HBsAg contained in the RTS,S 
candidate malaria vaccine is encoded by the hepatitis B virus S protein gene that is 
identical to the gene used to express HBsAg in GSK Biologicals’ Engerix-B® vaccine 
against hepatitis B. As a result, vaccines containing RTS,S are expected to also provide 
protection against hepatitis B. 
RTS,S has been evaluated to demonstration of field efficacy in the pediatric population 
with the AS02 adjuvant (proprietary oil-in-water emulsion formulated with MPL
®
 and 
Stimulon
®
 QS21 immunostimulants). The RTS,S antigen has more recently been 
evaluated with the AS01 adjuvant (liposome formulation with MPL and QS21 
immunostimulants) in a strategy to improve vaccine efficacy (VE) and the duration of 
efficacy. Both the AS02 and AS01 adjuvant systems have a number of similar key 
components (Table 1) and therefore safety data collected with RTS,S administered with 
the AS02 family of adjuvants is supportive of the RTS,S/AS01E development. 
Table 1 Formulations of RTS,S 
 Freeze-dried 
fraction 
Liquid fraction  
Formulation RTS,S 
( g) 
 MPL 
( g) 
QS21 
( g) 
Dose 
Volume 
RTS,S/AS02A 
(0.5 mL dose) 
50 Oil-in-water 
emulsion 
50 50 0.5 mL Efficacy demonstrated in adults in The 
Gambia (Malaria-005a) 
RTS,S/AS02A 
(0.25 mL dose) 
25 Oil-in-water 
emulsion 
25 25 0.25 mL Efficacy against clinical disease in 
children in Mozambique (Malaria-026b) 
RTS,S/AS02D 25 Oil-in-water 
emulsion 
25 25 0.5 mL Pediatric formulation (Malaria-034
c, 
-038d, -040e) 
RTS,S/AS01B 50 Liposomes 50 50 0.5 mL Efficacy in challenge model, adults 
(Malaria-027f), endemic countries 
(Malaria-044g) 
RTS,S/AS01E 25 Liposomes 25 25 0.5 mL Pediatric formulation (Malaria-046
h, 
-047j, -049k, -050m) 
a Bojang 2001; Alloueche 2003; Pinder 2004; Reece 2004; GSK data 
on file, Malaria-005, Clinical Study Report, 2006 
b GSK data on file, Malaria-026, Clinical Study Report, 2004; Alonso 
2004; Alonso 2005 
c GSK data on file, Malaria-034, Clinical Study Report, 2005 
d GSK data on file, Malaria-038, Clinical Study Protocol, 2005 
e GSK data on file, Malaria-040, Clinical Study Protocol, 2005 
f GSK data on file, Malaria-027, Clinical Study Protocol, 2003 
g GSK data on file, Malaria-044, Clinical Study Protocol, 2005 
h GSK data on file, Malaria-046, Clinical Study Protocol, 2006 
j GSK data on file, Malaria-047, Clinical Study Protocol, 2006 
k GSK data on file, Malaria-049, Clinical Study Protocol, 2006 
m GSK data on file, Malaria-050, Clinical Study Protocol, 2007 
1.4. Key clinical, efficacy and immunogenicity data 
A comprehensive summary of the results of reported trials to date can be found in the 
current version of the Malaria Vaccine Investigator Brochure. A brief summary of results 
to date is presented below. The numbers of doses of RTS,S-containing vaccines and the 
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number of recipients to date (March 2008) is tabulated in Table 2. A summary of clinical 
studies of the RTS,S vaccine in children is provided in Table 3. 
Amended 19 August 2008 
Table 2 Approximate number of doses of RTS,S vaccine administered with 
number of recipients (up to March 2008) 
Candidate Malaria 
Vaccine 
Subject  
population 
Recipients Doses  
administered 
RTS,S/AS02A 
Malaria-naïve adults a 302 723 
Adults in sub-Saharan Africa 424 1030 
Children in sub-Saharan Africa 1572 4562 
RTS,S/AS02D 
Children in sub-Saharan Africa 190 550 
Infants in sub-Saharan Africa 276 802 
RTS,S/AS01B 
Malaria-naïve adults a 52 146 
Adults in sub-Saharan Africa 85 242 
RTS,S/AS01E Children in sub-Saharan Africa 90 261 
a subjects who took part in studies conducted in the USA and Belgium, where there is no naturally 
occurring transmission of malaria 
1.4.1. The RTS,S/AS02A candidate malaria vaccine; key clinical 
efficacy, safety and immunogenicity data in children 
Early clinical development of the RTS,S malaria candidate vaccine was initiated in 
studies in malaria-naïve adults in collaboration with the WRAIR in which confirmation 
of the efficacy, safety and immunogenicity of the RTS,S/AS02A vaccine formulation was 
demonstrated [Stoute 1997; Kester 2001]. Two doses of RTS,S/AS02A (0.5 mL) 
provided protection to 37.8% healthy non-immune volunteers against homologous 
sporozoite challenge (pooled results for WRMAL-004 [Report, GSK data on file] & -005 
[Report, GSK data on file]); 3 doses demonstrated protection of 43.2% of subjects 
(pooled results for WRMAL-004 & Malaria-012 [Report, GSK data on file]). In subjects 
not protected, the prepatent period was significantly prolonged in the RTS,S/AS02A 
group compared to control (WRMAL-004, WRMAL-005 & Malaria-012). Protective 
efficacy was low following re-challenge six months after Dose 3 of RTS,S/AS02A, but a 
statistically significant difference between prepatent period for vaccinees compared to 
infectivity control was observed (WRMAL-004, WRMAL-005 & Malaria-012). A strong 
humoral immune response to the RTS,S/AS02A vaccine in terms of anti-CS and anti-
HBs antibodies was demonstrated in all the adult studies in malaria-naïve individuals. 
Evaluations of the CMI response showed consistently that administration of 
RTS,S/AS02A induced strong cellular Th1 T-cell responses, specific to the vaccine 
antigen [Lalvani, 1999; Epstein, 2004; Sun, 2003]. 
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Table 3 Summary of pediatric clinical trials in Africa with the candidate malaria vaccines RTS,S (up to March 2008) 
Study no. Study design Study population Objectives Study groups 
Status (March 
2008) 
Malaria -015 
Double-blind, randomized, 
controlled 
Children 6-11y 
The Gambia 
Primary: safety & immunogenicity 
Secondary: humoral responses 
RTS,S/AS02A (n = 60) ‡ 
Rabies vaccine (n = 30) 
Completed 
Malaria-020 
Double-blind, randomized, 
controlled 
Children 1-5y 
The Gambia 
Primary: safety & immunogenicity 
Secondary: humoral responses 
RTS,S/AS02A (n = 90) ‡ 
Rabies vaccine (n = 45) 
Completed 
Malaria-025 
Double-blind, randomized, 
controlled 
Children 1-4 y 
Mozambique 
Primary: safety & reactogenicity 
Secondary: humoral responses 
RTS,S/AS02A (n = 30) 
Engerix B (n = 30) 
Completed 
Malaria-026 
Double-blind, randomized, 
controlled 
Children 1-4 y 
Mozambique 
Primary: efficacy against clinical disease 
Secondary: safety and immunogenicity 
Cohort 1: RTS,S/AS02A (n = 782) 
Engerix-B or Prevnar and Hiberix (n = 782) 
Cohort 2: RTS,S/AS02A (n = 208) 
Engerix-B or Prevnar and Hiberix (n = 208) 
Completed 
Malaria-034 
Double-blind, randomized, 
controlled 
Children 3-5 y 
Mozambique 
Primary: safety, non-inferiority of ab response to CS 
Secondary: non-inferiority of ab response to HBsAg 
RTS,S/AS02D (n = 100) 
RTS,S/AS02A (n = 100) 
Completed 
Malaria-038 
Double-blind, randomized, 
controlled 
Infants 6-12 w 
Mozambique 
Primary: safety 
Secondary: immunogenicity 
RTS,S/AS02D (n = 110) † 
Engerix-B (n = 110) † 
Ongoing; 
interim data 
available 
Malaria-039* 
Single-blind,  
randomized, controlled 
Children 1-4 y ** 
Mozambique 
Primary: safety 
Secondary: immunogenicity 
n/a Completed 
Malaria-040 
Double-blind, randomized, 
controlled 
Infants 6-10 w 
Tanzania 
Primary: safety & non-inferiority of EPI antigens 
Secondary: immunogenicity & efficacy vs infection 
RTS,S/AS02D + TETRActHib (n = 170) 
Engerix-B + TETRActHib (n = 170) 
Ongoing; 
interim data 
available 
Malaria-046 
Double-blind, randomized, 
controlled 
Children 18 m - 4 y 
Gabon 
Primary: safety, non-inferiority of ab response to CS 
Secondary: safety and immunogenicity 
RTS,S/AS01E (n = 90) 
RTS,S/AS02D (n = 90) 
Completed 
Malaria-047 
Partially-blind, 
randomized, controlled 
Children 5-17 m 
Ghana 
Primary: safety 
Secondary: safety and immunogenicity 
RTS,S/AS01E at 0, 1 m (n = 90) 
RTS,S/AS02D at 0, 1 m (n = 90) 
RTS,S/AS01E at 0, 1, 2 m (n = 90) 
RTS,S/AS02D at 0, 1, 2 m (n = 45) 
Rabies vaccine at 0, 1, 2 m (n = 45) 
RTS,S/AS01E at 0, 1, 7 m (n = 90) 
RTS,S/AS02D at 0, 1, 7 m (n = 90) 
Ongoing; 
interim data 
available 
Malaria-049 
Double-blind, randomized, 
controlled 
Children 5-17 m 
Tanzania & Kenya 
Primary: efficacy against clinical disease 
Secondary: safety and immunogenicity 
RTS,S/AS01E (n = 445) 
Rabies vaccine (n = 445) 
Ongoing 
Malaria-050 
Open, randomized, 
controlled 
Infants 6-10 w 
Tanzania, Ghana & Gabon 
Primary: safety  
Secondary: safety and immunogenicity 
EPI vaccines alone (n=170) 
EPI vaccines & RTS,S/AS01E at 0, 1, 2 m (n=170) 
EPI vaccines & RTS,S/AS01E at 0, 1, 7 m (n=170) 
Ongoing 
* Malaria-039 is the 2-year follow-up of the Malaria-026 study. No study vaccines 
were given during the follow-up period. 
** age at time of primary vaccination 
† Vaccines staggered with TETRActHib doses 
‡ A third of subjects enrolled to receive RTS,S/AS02A got a 1/5 dose volume, a third 1/2 dose volume and a third 
full dose volume. The ‘1/2 dose volume’ contained 25 g antigen and 0.25 L adjuvant. 
n: number of enrolled (to be enrolled) subjects    ab: antibody 
Amended 19 August 2008 
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The RTS,S/AS02A vaccine progressed to evaluation in subjects under conditions of 
natural transmission. In adult males from The Gambia, VE against infection adjusted for 
covariates was 71% (95% CI: 46 to 85; p< 0.001) during the first 2 months and 34% 
(95% CI: 8.0 to 53, p=0.014) for the entire 15 week surveillance period (Malaria-005 
[Report, GSK data on file], [Bojang 2001]). VE, adjusted for covariates, following a 
booster dose given during a second year malaria season was 47% (95% CI: 3 to 71; 
p=0.039). Protection was not limited to the NF54 parasite genotype from which the 
vaccine was derived [Alloueche, 2003]. Safety surveillance over approximately 5 years 
showed no safety signal (Malaria-016, -017 & -018 [Report, GSK data on file]). A strong 
humoral immune response to the RTS,S/AS02A vaccine in terms of anti-CS and anti-
HBs antibodies was demonstrated. Overall, the kinetics of the humoral immune response 
induced by vaccination with RTS,S/AS02A were similar in malaria-naïve and 
experienced populations, while the absolute GMT values appeared to be higher in 
malaria-naïve volunteers. The vaccine induced and boosted Th1-like cellular immunity to 
several T-cell epitopes in a population naturally exposed to malaria [Pinder 2004; Reece 
2004]. 
The RTS,S/AS02A candidate vaccine progressed to clinical evaluation in children. Two 
age de-escalation and dose comparison trials (which compared doses with 10 g, 25 g 
and 50 g of antigen corresponding to volume fractions of RTS,S/AS02A: 0.1 mL, 
0.25 mL and 0.5 mL respectively) enrolled a total of 225 children aged 1 to 11 years from 
The Gambia (Malaria-015 [Report, GSK data on file] & -020 [Report, GSK data on file], 
[Bojang 2001]). From these trials, the 0.25 mL dose was selected due to equivalent 
immunogenicity and slightly less reactogenicity in the 0.25 mL group compared to the 
0.5 mL group; immunogenicity was consistently lowest in the 0.1 mL group. The safety 
and immunogenicity of the RTS,S/AS02A 0.25 mL dose was further confirmed in 
another study, Malaria-025 [Report, GSK data on file], conducted in 1 to 4 year old 
children in Mozambique. 
Subsequently, a large safety, immunogenicity and efficacy trial in children aged 1 to 4 
years from an area of high transmission was conducted in Mozambique, enrolling a total 
of 2022 subjects (Malaria-026 [Report, GSK data on file]; [Alonso 2004]; [Alonso 2005]; 
extension study Malaria-039). In this study, 3 doses of RTS,S/AS02A (0.25 mL dose) 
were administered according to a 0, 1, 2-month schedule to approximately 1000 children. 
The primary endpoint of this trial investigated vaccine efficacy against the onset of 
clinical malaria disease. Up to 18 months post Dose 3, the VE determined as the time to 
the first clinical episode (after adjustment for covariates) was 35.3% (95% CI: 21.6 to 
46.6; p=0.001). VE against multiple attacks was 32.4% (95% CI: 17.6 to 44.5; p=0.0001) 
up to 18 months post Dose 3.  
In this Phase IIb study, severe malaria disease was not specified per-protocol, but cases 
were collected prospectively and evaluated according to an agreed case definition to meet 
safety-monitoring guidelines. The analysis was defined in the SAP. Against severe 
malaria, VE was 48.6% (95% CI 12.3 to 71.0; p=0.02) over 18 months post Dose 3. 
Over the period of months 21 to 33, efficacy appeared to wane when assessed as efficacy 
against first clinical episode (VE 16.6% [95% CI -2.9 to 32.4; p=0.09]), against multiple 
clinical episodes (VE 22.3% [95% CI 0.8 to 39.2; p=0.04). 
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In the overall surveillance period (Months 0 to 33), there was a tendency for the 
proportion of children experiencing a SAE to be lower in the RTS,S/AS02A group 
compared to the control groups in both Cohorts 1 and 2 (23.0% vs. 31.7%, respectively). 
The pattern of morbidity was similar to that previously observed at the study site and 
described in the region. 
Anti-CS antibody GMTs of 180.3 (95% CI 164.0 to 198.2) were recorded 1 month post 
Dose 3 from subjects in Cohort 1. GMTs waned progressively at Month 8½ (GMT 42.9 
[95% CI 38.7 to 47.5]), Month 21 (GMT 16.2 [95% CI 14.5 to 18.1]) and Month 33 
(GMT 10.1 [95% CI 8.8 to 11.4]), but remained significantly higher than those observed 
in recipients of control vaccine (GMT 0.3 [95% CI 0.3 to 0.4] at all timepoints). 
1.4.2. The RTS,S/AS02D candidate malaria vaccine; key clinical 
efficacy, safety and immunogenicity data in infants 
The target population for the candidate malaria vaccine is infants living in malaria 
endemic parts of Africa. With this target population in mind, a 0.5 mL variant of the 
0.25 mL dose of RTS,S/AS02A (RTS,S/AS02D) was developed for compatibility with 
standard auto-disable EPI syringe. Following demonstration of proof-of-concept of 
efficacy in children in Mozambique, 2 trials have looked at the RTS,S/AS02D vaccine in 
infants in Africa. 
In Malaria-038, a dose of RTS,S/AS02D was given at 10, 14 and 18 weeks of age, with 
an EPI vaccine, TETRActHib (DTPw/Hib vaccine, Aventis Pasteur, Lyon, France) at 8, 
12 and 16 weeks of age. Results of this trial have been published [Aponte, 2007]. The 
vaccine was shown to have a good safety profile and was well-tolerated: no safety signal 
was identified and the reactogenicity was similar to that of the DTPw/Hib vaccine 
administered as part of the trial. Grade 3 reactogenicity was rare and no Grade 3 local 
symptoms were reported. 33 SAEs were reported for 17 recipients of RTS,S/AS02D and 
35 SAEs for 17 recipients of Engerix-B control vaccine. 
RTS,S/AS02D was shown to be immunogenic; anti-CS Geometric Mean antibody Titers 
(GMT) of 199.9 EU/mL (95% CI: 150.9 to 264.7) were achieved. Efficacy assessed as 
time to first infection over a 3 month period after the third dose was 65.9% (95% CI: 42.6 
to 79.8, p < 0. 0001). 
Malaria-040 was initiated following an assessment of safety of the first 3 doses of 
vaccine in Malaria-038. In Malaria-040, a dose of RTS,S/AS02D was given at 6, 10 and 
14 weeks of age, in co-administration with an EPI vaccine, TETRActHib (DTPw/Hib 
vaccine). 
RTS,S/AS02D and TETRActHib in co-administration demonstrated an acceptable general 
reactogenicity profile that was similar to that observed in Malaria-038 when the vaccines 
were administered in a staggered fashion. RTS,S/AS02D local reactogenicity in co-
administration was similar to that observed when it was given alone in Malaria-038. 
Reactogenicity of TETRActHib was similar whether it was administered in a co-
administered fashion with RTS,S/AS02D or with Engerix-B. Grade 3 reactogenicity was 
rare. 13 SAEs were reported for 13 recipients of RTS,S/AS02D and 19 SAEs for 19 
recipients of Engerix-B. 
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Non-inferiority criteria of all co-administered EPI antigens (DTPw/Hib) were met for all 
the co-administered EPI antigens (D, T, Pw, Hib): anti-HBs antibody titers were 
667.4 mIU/mL (95% CI 533.8 to 834.4). Anti-CS antibody GMTs in co-administration 
were 69.5 ELU/mL (95% CI 53.9 to 89.6). 
1.4.3. RTS,S/AS01 vaccine; key clinical efficacy, safety and 
immunogenicity data 
The RTS,S/AS01 vaccine has been developed with the aim of improving the immune 
response to the antigen while retaining a similar safety profile to that of RTS,S/AS02A. 
Data from three trials of RTS,S/AS01 are currently available—Malaria-027, carried out 
in malaria-naive adults in the USA, Malaria-044 in adults in a malaria-endemic region of 
Kenya and Malaria-046 in children 18 months to 4 years of age in a malaria-endemic 
region of Gabon. 
Preliminary clinical data for the RTS,S/AS01B vaccine in malaria-naïve adults are 
available for Malaria-027 [Report GSK data on file], a double-blind comparison of 
RTS,S/AS02A and RTS,S/AS01B, with mosquito challenge followed by re-challenge 6 
months after primary challenge. Following primary challenge, VE tended to be higher in 
the RTS,S/AS01B group compared to the RTS,S/AS02A group (50.0% [95% CI: 32.9, 
67.1] vs 31.8% [95% CI: 17.6, 47.6], respectively); VE was significantly greater in both 
vaccine groups compared to infectivity control (p 0.001). Following re-challenge 5/9 
subjects (55.6%) in the RTS,S/AS01B and RTS,S/AS02A groups overall were infected; 
all infectivity control subjects became infected; the point estimate for VE was 44.4% 
[95% CI: 10.9, 79.2]. Safety and reactogenicity were comparable in both the 
RTS,S/AS01B and RTS,S/AS02A groups. Two SAEs were reported in two subjects from 
the RTS,S/AS01B group and one SAE was reported in a subject from the challenge 
control group; none were fatal and none were considered to be related to study vaccine. 
RTS,S/AS01B and RTS,S/AS02A were both highly immunogenic for anti-CS antibodies 
and anti-HBs antibodies. Anti-CS antibody GMTs were significantly greater in the 
RTS,S/AS01B group compared to the RTS,S/AS02A group at 1 month post dose 2 
(p<0.0001), 2 weeks post dose 3 (p=0.0079) and 3 months post dose 3 (p=0.0173). GMTs 
for anti-CS antibodies were significantly greater in subjects who were protected 
compared to those not protected following primary challenge at 1 month post dose 1 
(p=0.0076), 1 month post dose 2 (p=0.0004), 2 weeks post dose 3 (p<0.0001) and 3 
months post dose 3 (p=0.0018). In subjects who underwent re-challenge (i.e. protected 
subjects), all were still seropositive for anti-CS antibodies and had seroprotective anti-
HBs titers at 10 months post dose 3. CS-specific CD4+ T-cell responses were greater in 
subjects from the RTS,S/AS01B group compared to the RTS,S/AS02A group, and in 
subjects who were protected compared to non-protected subjects following primary 
challenge. 
Clinical data for the RTS,S/AS01B vaccine in semi-immune adults are available for 
Malaria-044, a double-blind, controlled study of RTS,S/AS02A and RTS,S/AS01B in 
adults living in Kenya. The two vaccines RTS,S/AS02A and RTS,S/AS01B in Kenya, 
induced similar levels of protective efficacy against infection over a 14 week period 
(29.5% [95% CI: -15.4 to 56.9, p=0.164] and 31.7% [95% CI: -11.6 to 58.2, p=0.128], 
respectively); pooled data yielded an unadjusted VE of 31% (95% CI: -4.7 to 54.4, 
p=0.081). The efficacy results for RTS,S/AS02A were consistent with previous studies in 
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semi-immune adults. Safety and reactogenicity were comparable in both the 
RTS,S/AS01B and RTS,S/AS02A groups. In total, 1/85 (1.2%) subjects from the 
RTS,S/AS02A group, 5/85 (5.9%) subjects from the RTS,S/AS01B group and 5/85 
(5.9%) subjects from the rabies group reported a SAE. None were considered to be 
related to study vaccine and none were fatal. A strong humoral immune response to the 
RTS,S/AS01B and RTS,S/AS02A vaccines in terms of anti-CS and anti-HBs antibodies 
was demonstrated. At each post vaccination timepoint GMTs for anti-CS antibodies were 
higher in the RTS,S/AS01B group compared to the RTS,S/AS02A group. Although 
GMTs for anti-CS antibodies decreased by 10 months post Dose 3, at least 96% of 
subjects were seropositive. GMTs for anti-HBs antibodies were comparable in the 
RTS,S/AS01B group and RTS,S/AS02A group up to 10 months post Dose 3. GMTs 
against HBs decreased by 10 months post Dose 3, however, seroprotection rates remained 
above 94% of subjects in both vaccine groups. 
Clinical data for the RTS,S/AS01E vaccine in semi-immune children are available for 
Malaria-046, a double-blind, controlled study of RTS,S/AS01E and RTS,S/AS02D in 
children aged 18 months to 4 years from Gabon. Both RTS,S/AS01E and RTS,S/AS02D 
were well tolerated. Local reactogenicity of Grade 3 severity was rare. One child in each 
group had Grade 3 swelling and there was no Grade 3 pain. There were no Grade 3 
solicited general symptoms reported. No unsolicited symptom was considered to be 
causally related to vaccine in either group. In total, to 1 month post Dose 3, 8/90 (8.9%) 
subjects reported SAEs in the RTS,S/AS01E group and 5/90 (5.6%) subjects reported 
SAEs in the RTS,S/AS02D group; none were fatal and none were considered to be 
related to study vaccine. RTS,S/AS01E and RTS,S/AS02D were both highly 
immunogenic for anti-CS antibodies. Anti-CS antibody GMTs were similar at one month 
post Dose 3 in both the RTS,S/AS01E (207.3 EU/mL [95% CI: 172.0 to 249.9]) and 
RTS,S/AS02D (183.1 EU/mL [95% CI: 150.6 to 222.5]) vaccine groups. Anti-HBs 
antibody GMTs in both vaccine groups post Dose 3 were high and similar (> 20 
000 mIU/mL). Seroprotection for anti-HBs antibodies following both RTS,S/AS01E and 
RTS,S/AS02D vaccines was 100% post Dose 3. 
Partial clinical data for the RTS,S/AS01E vaccine in infants aged 6 to 10 weeks at first 
dose are available for Malaria-050, a phase II randomized, open, controlled study of the 
safety and immunogenicity of RTS,S/AS01E, when incorporated into an Expanded 
Program on Immunization (EPI) regimen that includes DTPwHepB/Hib, OPV, measles 
and yellow fever vaccination in infants living in malaria-endemic regions on two 
schedules, either at 6, 10 and 14 weeks of age (012 schedule) or at 6, 10 weeks and 9 
months of age (017 schedule) (where the third dose of RTS,S/AS01E was co-
administered with measles vaccine). RTS,S/AS01E showed a satisfactory safety profile 
with no SAEs that were judged by the investigators to be related to vaccination. The 
overall profile of adverse events was compatible with morbidity patterns in sub-Saharan 
Africa. This study also analyzed the antibody responses to all EPI antigens. Pre-defined 
non-inferiority criteria were met for all antigens in the RTS,S/AS01E 012 and 017 
schedules, except for the polio 3 responses in the RTS,S/AS01E 012 schedule. After 
receiving a neonatal dose of OPV followed by 3 doses given at the time of the 
DTPwHepB/Hib seroprotection rates for polio 3 were 87% in the group receiving 
RTS,S/AS01E in co-administration and 96% in the comparator group. A figure of 87% is 
consistent with seroprotection rates in the literature [WHO 1995, WHO 1997]. This 
unexpected finding will be further evaluated in this study. The consistency of this finding 
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will be assessed by measuring the polio serotypes 1, 2 and 3 responses induced by a 
primary series of OPV (4 doses commencing in the neonatal period) in a subset of 
children at all centers in the 6 to 12 weeks age category. All subjects in this age category 
will also receive a booster dose of OPV at study month 20 to assess the value of a booster 
dose when RTS,S/AS01E is given in co-administration with EPI antigens. The DSMB 
will review the analysis of polio 1, 2 and 3 titres and advice on the need to offer 
additional doses to children in the trial. 
Amended 19 August 2008 
Amended 24 October 2008 
1.5. Rationale for the study 
The study has been designed to address the key safety and efficacy information required 
for vaccine licensure. In addition, other disease endpoints that allow the evaluation of the 
full public health impact and cost effectiveness of vaccine implementation are included. 
Co-primary objectives will investigate efficacy against clinical disease in children from 
5-17 months of age at first dose and the efficacy in infants 6-12 weeks of age who receive 
the vaccine in co-administration with EPI antigens (i.e. DTPwHepB/Hib; 
TritanrixHepB/Hib). 
All participating centers will use standardized case definitions for efficacy endpoints and 
a structured approach to case-assessment. Cases of clinical disease will be pooled across 
participating centers to evaluate the primary endpoint of efficacy against clinical disease 
in each age category. Secondary objectives will assess the efficacy of the vaccine on 
severe malaria disease, severe anemia and malaria hospitalization. Analysis by site will 
allow the evaluation of efficacy under different conditions of malaria transmission and 
randomization to a booster dose will allow the evaluation of the duration of efficacy of a 
primary course and the requirement for boosting. Additional objectives include 
determination of efficacy of the vaccine against all medical hospitalization, non-malaria 
serious illness, fatal malaria and all-cause mortality. In addition immunological correlates 
of protection will be investigated. 
Analyses are planned at the following timepoints during the trial: 
 A primary analysis to investigate efficacy against clinical malaria disease after 
approximately 6000 children 5-17 months of age at first dose (4000 RTS,S/AS01E 
recipients) have completed 14 months of follow up post dose 1. 
 A primary analysis to investigate efficacy against clinical malaria disease after 
approximately 6000 infants 6 to 12 weeks of age at first dose (4000 RTS,S/AS01E 
recipients) have completed 14 months of follow up post dose 1. 
 A secondary analysis for evaluation of efficacy against severe disease when there are 
250 accumulated cases, or at study end, whichever occurs earlier. 
 A secondary analysis for evaluation of efficacy, safety and immunogenicity when all 
children have completed 18 month follow-up post Dose 3 (Visit 22). 
 A secondary analysis for evaluation of the antibody responses to polio serotypes 1, 2 
and 3 in the 6-12 weeks age category one month post boost (Visit 23). 
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Amended 19 August 2008 
Amended 24 October 2008 
Amended 23 January 2012 
Further details of these planned analyses are provided in Sections 10.5.1, 10.5.2, 10.7.2, 
10.7.3, 10.7.4 and 10.7.5. 
 A final analysis will be carried out at the end of the trial and will include further 
investigations of vaccine efficacy against a range of manifestations of malaria 
disease and evaluate the booster dose. Further details of the final analysis may be 
found in Sections 10.5.3 and 10.7.6. 
 An additional analysis will be conducted at the end of the extension: including an 
evaluation of safety and efficacy against clinical malaria, severe malaria and 
prevalent parasitemia. 
Amended 23 January 2012 
1.5.1. Rationale for the choice of adjuvant 
Safety, reactogenicity, immunogenicity and efficacy have previously been evaluated for 
RTS,S/AS02A and RTS,S/AS02D (refer to Section 1.4.1) and RTS,S/AS01B and 
RTS,S/AS01E (refer to Section 1.4.3). 
Both adult formulations (RTS,S/AS02A and RTS,S/AS01B) and both pediatric 
formulations (RTS,S/AS02D and RTS,S/AS01E) have been shown to be equally 
reactogenic with a similar safety profile in their respective target age groups. 
Compared to RTS,S/AS02A, RTS,S/AS01B has been shown to be substantially more 
immunogenic for the anti-CS antibody response in malaria-naive adults (Malaria-027) 
and adults in a malaria-endemic region (Malaria-044). CS-specific CD4+ T-cell 
responses induced by RTS,S/AS01B were higher in malaria-naïve adults (Malaria-027). 
In a bridging study in children in Gabon (Malaria-046) RTS,S/AS01E induced equivalent 
humoral immune responses compared to RTS,S/AS02D (with a trend for greater immune 
response in recipients of RTS,S/AS01E). 
In the challenge trial in malaria naïve adults, there was a trend for efficacy to be higher 
with the RTS,S/AS01B formulation and both the humoral and cellular immune responses 
tended to be higher in the protected than the non-protected vaccinees. In the subsequent 
trial conducted in Kenya looking at protection against infection under natural 
transmission, efficacy of the two vaccine formulations was similar. 
AS01 has been chosen as the adjuvant of this trial based on the data available to date 
which shows an equivalent safety and reactogenicity profile compared to AS02 and in 
most studies enhanced humoral and cellular responses. With regard to efficacy, currently 
the available information is protection against infection in the challenge model at 
WRAIR (Malaria-027) and natural challenge in adults in Kenya (Malaria-044). It is 
expected that in children the improved immunogenicity profile seen in adult studies, will 
translate into enhanced level of protective efficacy and duration of protection against 
clinical disease. 
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1.5.2. Rationale for evaluation of booster 
In this study, some children will receive a booster dose of RTS,S/AS01E at Month 20. 
Evidence that a booster dose may be necessary comes from the long-term follow up of 
children enrolled in the Malaria-026 study in Mozambique who received RTS,S/AS02A 
(0.25mL dose). In that study, VE was determined over a 33 month period commencing 
14 days post Dose 3. While the vaccine retained efficacy in the period between Months 
21 and 33 of the study, efficacy was lower than observed previously (Malaria Vaccine 
Investigator Brochure). 
Amended 19 August 2008 
The duration of efficacy associated with the RTS,S/AS01E formulation may be superior 
to that of RTS,S/AS02. In this study, randomization to a booster dose will allow 
definitive evaluation of the duration of efficacy of a primary course of the RTS,S/AS01E 
vaccine and the requirement for boosting. 
1.5.3. Rationale for analysis by site 
Field sites have been selected to represent the range of malaria transmission settings 
across sub-Saharan Africa including the intense seasonal transmission of West Africa and 
perennial transmission in East Africa. To determine efficacy under different conditions of 
malaria transmission, clinical malaria disease will be analyzed by site. 
1.5.4. Rationale for the primary case definition of clinical malaria 
disease 
The primary and secondary case definitions of clinical malaria disease are presented in 
Section 5.2.1. 
The primary case definition reflects the burden of disease presenting to outpatient and 
inpatient departments across Africa and will have a minimum specificity of 80% at each 
site based on substantial previous research. Cases meeting the case definition of severe 
malaria disease will be included in the analysis of clinical malaria disease (whether or not 
they meet the case definition for clinical malaria disease as above). 
The case detection methodology will be passive case detection at health facilities within 
the study area. In the participating centers High quality health care, to which all subjects 
will have access, will be available at all study centers ensuring that a high proportion of 
clinically significant cases will be captured by the surveillance system. This approach 
will capture cases representative of those presenting to outpatient and inpatient 
departments. 
The challenge in developing a case definition is to achieve adequate specificity. This is 
because the symptomatology of malaria overlaps with that of common childhood 
infections. When a child presents with a febrile illness in an endemic country, it is often 
difficult on clinical grounds alone to know whether the malaria infection is the cause of 
the child’s illness or an incidental finding. A clinical diagnosis based on symptoms and a 
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blood slide reading is therefore sensitive but not specific. As parasite density increases, 
the likelihood that the clinical presentation is due to the P. falciparum infection increases. 
Smith first proposed methodology to calculate the specificity and sensitivity associated 
with threshold values of parasitemia in clinical case definitions [Smith, 1994]. This 
methodology has been adopted frequently for malaria research and has been evaluated 
across Africa and used in the evaluation of malaria interventions [Dicko, 2005; 
Greenwood, 1987; McGuinness, 1998; Mwangi, 2005; Saúte, 2003; Smith, 1994]. 
In children aged 1 to 5 years of age the parasite density thresholds for clinical case 
definitions, have been measured as 2500 in Kenya [Mwangi, 2005], 3200 in Mali [Dicko, 
2005], 3500 Ghana [McGuinness, 1998], and 5000 in Gambia, Tanzania and 
Mozambique [Greenwood, 1987; Smith, 1994; Saúte, 2003]. Fewer estimates are 
available in children under the age of one year, but threshold values tend to be lower 
[Mwangi, 2005; Saúte, 2003]. 
A parasite density threshold of 5000 parasites/ L will be used for this study, because it 
will guarantee a minimum specificity in all transmission settings and age groups of 80%. 
The approach of applying one threshold value across age groups and sites is practical for 
pooling and interpretation of data. 
The primary case definition has the requirement of the objective criterion of documented 
temperature  37.5°C; this is to further increase the specificity by reducing the number of 
cases of asymptomatic parasitemia that are captured by the definition. 
We intend to evaluate as secondary case definitions 3 additional definitions. The first 
definition is highly sensitive allowing for the possibility of a history of fever as well 
objective fever in the presence of parasitemia >0. The second definition has a cut off for 
parasitemia of >500; the limited research done to date suggests that this will be 
adequately specific in children under the age of 1 year. The third definition is highly 
specific, requiring an objective fever and a parasitemia of >20 000. 
The approach we present here is in full accord with the recommendation of the WHO 
consultation on measures of malaria vaccine efficacy [Moorthy, 2007]. 
1.5.5. Rationale for the primary case definition of severe malaria 
disease 
The primary and secondary case definitions of severe malaria disease are presented in 
Section 5.2.2. 
A case definition which reflects the picture of severe malaria disease that typically leads 
to hospitalization across Africa has been chosen. The analysis of the primary case 
definition will include cases occurring in children who are HIV infected or malnourished 
and the data collected will be highly relevant to policy makers. 
The markers of severity of malaria disease will include those that: 
 are associated with a poor outcome (mortality or sequelae) 
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 can be standardized across sites (with adequate training) 
 minimize redundancy. 
Other markers of severity were considered, but not included because: 
 they apply only to a small fraction of the number of cases 
 methodology is difficult to implement and standardize across sites 
 they are not part of accepted practice or research methodology. 
As described in 1.5.4, a parasite density threshold has been implemented to improve the 
specificity of the primary case definition by reducing the number of cases of co-
morbidity. 
In children admitted to hospital in Africa, concurrent co-morbid infections are frequent. It 
is not clear whether the parasitemia is co-incidental and does not contribute to the clinical 
picture, whether this is the chance concurrence of two common childhood diseases, or 
whether there is a definite synergy in the etiology of the two diseases. This is complicated 
to disentangle, because the symptomatology of the common infections in a seriously sick 
child is broadly overlapping [O’Dempsey, 1993; Mulholland, 2005]. What would be the 
effect of the vaccine on serious illnesses, where malaria is a co-infection is unpredictable. 
Therefore to ensure high specificity of the primary case definition and a clearly 
interpretable result, other important co-morbidity will be actively sought for and 
excluded. Therefore in the evaluation of a child hospitalized for an acute medical 
condition, an algorithm will be followed that ensures that the disease picture is well-
characterised and the appropriate diagnostic tests are taken (including blood and cerebro-
spinal fluid [CSF] culture and chest X-rays [CXR]). The intention is to exclude cases of 
pneumonia, meningitis, sepsis and gastroenteritis with severe dehydration. Whilst 
excluding co-morbidity ensures that the primary case definition is maximally specific, in 
public health terms whether the vaccine also has an effect on severe disease with 
concurrent malaria infection and other morbidity is very important. Therefore a 
secondary case definition that examines the effect of the vaccine on severe malaria 
disease with co-morbidity included will be examined (refer to Table 8). 
One of the greatest challenges in developing this definition is to distinguish between 
severe gastroenteritis and malaria as a cause of prostration. The mechanism underlying 
the prostration is thought to be fundamentally different in the two diseases: in malaria it 
is primarily intravascular volume depletion, whereas in gastroenteritis it is predominantly 
intracellular fluid depletion. The WHO definition of 3 or more loose or watery stools in 
24 hours defines gastroenteritis of any severity. However, only severe gastroenteritis 
associated with severe dehydration (  10% loss of body weight) causes prostration, and 
therefore criteria characterizing the severity have been added to the definition. The 
Integrated Management of Childhood Illness (IMCI) approach defines severe dehydration 
as diarrhea plus two or more of: lethargy / altered consciousness (=prostration), sunken 
eyes, skin pinch > 2 seconds, unable to drink/drinks poorly [WHO, 2001]. However, a 
recent review found that the best signs of severe dehydration were prolonged capillary 
refill time, reduced skin turgor, abnormal respiratory pattern (tachypnea and 
deep/acidotic breathing) [Steiner, 2004]. Of these three signs only an assessment of skin 
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turgor discriminates between intravascular and intracellular volume depletion. The case 
definition therefore includes a decrease in skin turgor with the WHO definition of 
gastroenteritis in order to identify and exclude from the case definition of severe malaria 
cases of prostration due to severe gastroenteritis. 
In order to ensure harmonization of case assessment across sites, physicians will follow a 
standard algorithm for case assessment (Appendix E) and there will be training, 
monitoring and evaluation of performance at the start and during the trial. A full 
discussion of the merits of this case definition is made in the WHO consultation report 
[Moorthy, 2007]. 
1.5.6. Rationale for the methodology of analysis of clinical malaria 
endpoint 
The incidence of episodes of clinical malaria up to 12 months follow-up will be analyzed 
separately for the two age categories (6-12 weeks and 5-17 months at first vaccination). 
As the primary analysis, first or only episodes of clinical malaria over a 12 months 
follow-up period for all subjects will be evaluated. Episodes after the first will not be 
included in the primary analysis and subjects will be censored at their first or only 
episode, consent withdrawal, death or end of follow-up period, whichever occurs first. 
As an analysis method for evaluating first or only episodes a Cox regression model will 
be used, modeling the time to first or only episode as a function of group assignment, and 
study site as a covariate. Vaccine efficacy (VE) will be defined as 1 minus Hazard Rate 
(HR). 95% Confidence intervals (CI) and p-values (likelihood Ratio test) on VE 
estimates will be calculated from the Cox model. VE estimates resulting from HR are 
appropriate as it is likely the vaccine protects by reducing the risk of disease following an 
infectious bite by a fixed proportion. Cox regression allows for seasonal variation of 
malaria incidence and adding study site as a covariate allows for different levels of 
baseline risk and different patterns of seasonality. The primary analysis will be 
unadjusted for other covariates; however both unadjusted and adjusted estimates of VE 
will be presented. As a secondary analysis, estimates of VE including multiple episodes 
will also be calculated. 
1.5.7. Rationale for sample size 
This is the definitive Phase 3 trial of the RTS,S/AS01E that will support the licensure 
application to the European Medicines Agency (EMEA) and African national regulatory 
authorities. It is designed with conservative estimates of malaria disease rates to deliver 
reliably the primary endpoint of efficacy against clinical malaria disease over one year in 
each of the two age categories. In the event that the rate of disease is higher than 
predicted, then the estimate of effect will be delivered with greater precision. 
The secondary endpoints of this trial are also important for regulators and health policy 
decision makers; this sample size will allow the vaccine effect on severe malaria disease 
and malaria hospitalization, and will define vaccine efficacy under different malaria 
transmission patterns and booster strategy. In addition, a safety database of this size is 
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required as this is the first time that this novel adjuvant has been presented to regulatory 
authorities in a pediatric vaccine for wide spread implementation. 
1.5.8. Rationale for the methodology of analysis of severe malaria 
endpoint 
In a secondary analysis, VE against severe malaria disease will first be evaluated when 
250 subjects (both age categories together) have reported an episode of severe malaria 
meeting the primary case definition. The primary analysis will compare the pooled 
RTS,S/AS01E groups (with or without RTS,S/AS01E booster dose) versus control. As 
severe malaria disease is relatively rare and most subjects are unlikely to experience more 
than 1 episode over the course of the trial, primary analysis will evaluate the proportion 
of subjects affected by severe malaria disease. VE against severe malaria disease will be 
estimated as 1-RR where RR is the risk ratio (proportion of subjects reporting severe 
malaria disease in the RTS,S/AS01E group over the proportion in controls) together with 
95% CIs. The primary analysis will be unadjusted for covariates. Secondary analyses 
adjusted for covariates and analysis of multiple episodes of severe malaria disease will 
also be performed. 
1.5.9. Rationale for choice of cohort for primary analysis 
As the trial primarily generates data to support registration of a malaria vaccine given as 
3 doses within specified time intervals, in eligible children, ATP analyses will be 
considered primary. However, both ITT and ATP analyses will be performed. 
1.5.10. Choice of comparator vaccines 
The choice of comparator vaccine is guided by the principles of benefit to the control 
group without compromising the evaluation of clinical study endpoints. 
1.5.10.1. Rationale for the use of Meningococcal C conjugate vaccine as a 
control 
Children aged 6-12 weeks in the control group will receive 3 doses of a Meningococcal C 
Conjugate Vaccine (MCC) on a 0, 1, 2-month schedule followed by a booster dose of 
MCC at Month 20.  
A number of alternative comparator vaccines were considered for use in the 6 to 12 week 
age group in this study but were deemed not to be suitable. One key consideration in this 
age group was that it is necessary to have a vaccine that can safely be co-administered 
with EPI antigens; for this reason rabies vaccine, the control vaccine for the older age 
category, was not selected. Also considered were vaccines against pneumococcal 
infection, which is a common cause of pneumonia children in Africa. However, for 
reasons that are not clear malaria and pneumococcal pneumonia often occur together in 
African children [O’Dempsey 1993; Mulholland, 2005]. If malaria infection contributes 
to the pathogenicity of pneumococcal disease and other common infections, then 
controlling malaria may have additional benefits beyond the effect on malaria disease 
alone. A suggestion that this is the case was seen in studies of bednets, which showed 
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non-specific beneficial affects on childhood morbidity and mortality. Understanding the 
full potential impact of this vaccine on malaria and other morbidities will be an asset for 
public health authorities evaluating its usefulness. 
MCC was chosen because it is acceptably safe and immunogenic when given on a 0, 1, 2-
month schedule, can be coadministered with DTPw Hep B/Hib + OPV and does not 
compromise the evaluation of study endpoints. Although meningitis C disease is not 
common in sub-Saharan Africa, there have been outbreaks of meningococcal C disease in 
the 1970s and early 1980s in Nigeria [Whittle, 1975] and Burkina Faso [Broome, 1983]. 
A proportion of cases seen in outbreaks in Nigeria and Ethiopia in the 1980s were also 
due to serogroup C and some serogroup C cases have been described from The Gambia 
and Mozambique [Kwara, 1998]. The MCC vaccine will therefore be of benefit to the 
participants in the event of an outbreak. 
While a 2-dose plus boost regimen is now in place for MCC in the UK, the safety of a 3-
dose co-administered regimen in infancy is well-established, having been implemented as 
national policy between 1999 and 2005. During this period, all three MCCs proposed for 
use in this study (Menjugate [Novartis], NeisVac-C [Baxter] and Meningitec [Wyeth]) 
were used in the UK [Miller, 2002]. A booster in the second year of life has been shown 
to be necessary when children receive primary immunization in early life [Miller, 2002]. 
All children who receive a primary course of MCC will receive a booster dose. 
Children in the 6-12 week age category who received a primary course of RTS,S/AS01E 
may be randomized to receive a dose of MCC at time of boost. Similarly, children in the 
5-17 month category may be randomized to receive a dose of MCC at time of boost. A 
single dose of MCC in the second year of life (or later) is also an immunizing regimen. 
To ensure vaccine availability, MCC from three manufacturers will be sourced for this 
trial (Novartis, Baxter and Wyeth). It will be ensured that an individual child will receive 
all 3 doses of MCC from the same manufacturer. 
Product data from Wyeth on Meningitec indicates that it may be coadministered with 
Hepatitis B vaccine. However, one trial of GSK’s DTPwHepB/Hib vaccine (Tritanrix 
HepB™/Hib) showed a trend towards lower anti-HBs antigen seroprotection rate when 
the vaccine was coadministered with Meningitec in children in the Philippines (refer to 
Table 4). There is no product data to support the co-administration of Menjugate 
[Novartis] and NeisVac-C [Baxter] with hepatitis B antigen. Therefore for all three MCC 
vaccines the anti-HBs antibody response will be monitored and a rescue plan defined in 
the study protocol (refer to Section 5.1.4.4). 
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Table 4 Immunogenicity of Hepatitis B antigens in coadministration with 
DTPw Hib and MCC 
Group  Seroprotection 
% 
95% CI GMT 95% CI 
LL UL LL UL 
TritanrixHepB + Hiberix 91.6 84.1 96.3 104.5 76.0 143.7 
TritanrixHepB/Hib + Meningitec 83.2 74.4 89.9 71.1 52.1 97.1 
1.5.10.2. Rationale for the use of rabies vaccine as a control 
Children aged 5-17 months randomized to receive control vaccine will receive 3 doses of 
a cell-culture rabies vaccine on a 0, 1, 2-month schedule.  
Without vaccination or post exposure treatment, infection with rabies invariably leads to 
death. Children are a group at particular risk; rabies is most common in people under the 
age of 15 years, and approximately 40% of all cases occur in children aged between 5 
and 14 years [Plotkin, 2004]. 
Estimates of risks of infection with rabies in Africa are available from the WHO. The 
WHO no longer publish the ‘World survey of rabies’ (the last edition was 1998), but data 
is available through Rabnet (http://www.who.int/globalatlas/default.asp). A recent paper 
evaluating the burden of rabies in Africa estimated that 294 million people in Africa are 
at risk of exposure to rabies, with models indicating that 23 000 people a year in Africa 
die as a result of infection [Knobel, 2005]. 
Rabies vaccine has been evaluated on a number of different vaccination schedules. 
According to product information distributed by Sanofi Pasteur Inc, PA, USA in 
December 2005 for their Human Diploid Cell Rabies Vaccine, “high titer antibody 
responses of the Sanofi Pasteur SA Rabies Vaccine made in human diploid cells have 
been demonstrated in trials conducted in England [Aoki 1975], Germany [Cox, 1976; 
Kuwert, 1978], France [Ajjan, 1978] and Belgium [Costy-Berger, 1978]. Seroconversion 
was often obtained with only one dose. With two doses one month apart, 100% of the 
recipients developed specific antibody and the geometric mean titer of the group was 
approximately 10 international units. In the US, Sanofi Pasteur SA Rabies Vaccine 
resulted in geometric mean titers (GMT) of 12.9 IU/mL at Day 49 and 5.1 IU/mL at Day 
90 when three doses were given intramuscularly during the course of one month. The 
range of antibody responses was 2.8 to 55.0 IU/mL at Day 49 and 1.8 to 12.4 IU at Day 
90 [Bernard 1982]. The definition of a minimally accepted antibody titer varies among 
laboratories and is influenced by the type of test conducted. CDC currently specifies a 1:5 
titer (complete inhibition) by the rapid fluorescent focus inhibition test (RFFIT) as 
acceptable. The World Health Organization (WHO) specifies a titer of 0.5 IU”. 
To ensure vaccine availability, three cell culture rabies vaccines from two manufacturers 
will be sourced for this trial (Sanofi-Pasteur and Novartis). While the cell-culture sources 
of the vaccines differ, they are largely equivalent in terms of safety profile, 
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immunogenicity and efficacy [Plotkin, 2004]. It will be ensured that an individual child 
will receive all 3 doses of cell culture rabies vaccine from the same product. 
Amended 24 October 2008 
1.6. Rationale for the extension 
The strategy underlying the development of the RTS,S/AS01E malaria vaccine is that it 
would target the most vulnerable age group: infants and young children. It would provide 
protection from the most severe forms of the disease whilst allowing natural blood stage 
immunity to develop due to continued exposure to infections. However, there is a 
theoretical concern that the protection conferred by a malaria vaccine in young children 
may impair their ability to acquire natural immunity to the blood stage form of P. 
falciparum and that, if the vaccine efficacy decreases over time, these children would 
become vulnerable to malaria. This could result in a higher susceptibility to severe 
malaria and/or a higher frequency of clinical malaria disease in vaccinated children 
compared to children of the same age that were not vaccinated. This long term follow-up 
probably represents the last opportunity to evaluate the duration of vaccine efficacy and 
the long term safety of RTS,S/AS01E relative to a control group in a large multi-country 
study. 
The design of the extension study takes advantage of the fact that enrolment to the 
primary trial phase will take approximately 18 months to complete and continues 
surveillance until December 2013 (corresponding to last subject last visit - estimated 
December 2013). Importantly this extension does not follow up subjects beyond the point 
of the final analysis. However the extension is described as single blind because cleaning 
of the data may take place after unblinding. 
The extension will collect data on severe malaria disease; malaria hospitalization and 
parasite prevalence in the 11 participating centres using the same methodologies and case 
definitions as in the primary trial phase. Occurrence of SAEs will be monitored in all 11 
centres. Surveillance for clinical malaria disease will take place at least at 3 centres with 
varying transmission levels. Immunogenicity endpoints will also be collected on a subset 
of individuals from both age categories at least in these 3 centres. 
Mean follow-up time: The last study visit of the extension (Visit 38) is scheduled in 
December 2013 (interval: Nov 2013-Jan 2014). This means a variable number of months 
after vaccination by individual children. Based on the actual enrolment, the mean follow-
up time will be: 
- 5-17 months: 49 months post Dose 1 (range: 41-55) 
- 6-12 weeks: 41 months post Dose 1 (range: 32-48) 
Amended 01 December 2010 
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2. OBJECTIVES 
2.1. Primary objectives 
2.1.1. Efficacy coprimary objectives: Efficacy against clinical malaria 
disease when primary immunization starts at 6-12 weeks, or 5-17 months of 
age 
 To evaluate the protective efficacy of RTS,S/AS01E against clinical malaria disease 
caused by Plasmodium falciparum in African children whose age at first dose will be 
6-12 weeks and will receive vaccine in coadministration with DTPwHepB/Hib 
antigens (Tritanrix HepB/Hib) and OPV. Duration of follow up will be for a 
minimum of 12 months and a maximum of 18 months after completion of the 
primary course (Primary Analysis). 
 To evaluate the protective efficacy of RTS,S/AS01E against clinical malaria disease 
caused by Plasmodium falciparum in African children whose age at first dose will be 
from 5-17 months. Duration of follow up will be for a minimum of 12 months and a 
maximum of 18 months after completion of the primary course (Primary Analysis). 
Amended 19 August 2008 
Refer to Section 10.1 for definition of the primary endpoints. 
Refer to Section 5.2 for case definitions for efficacy endpoints. 
2.2. Secondary objectives 
2.2.1. Efficacy secondary objectives 
2.2.1.1. Efficacy against severe malaria disease 
 To evaluate the protective efficacy of RTS,S/AS01E on a primary schedule with and 
without booster dose against severe malaria disease. Duration of follow up will 
extend to 30 months after completion of primary course. 
2.2.1.2. Efficacy against incident severe anemia and malaria hospitalization 
 To evaluate the protective efficacy of RTS,S/AS01E on a primary schedule with and 
without booster dose against incident severe anemia and malaria hospitalization. 
Duration of follow up will extend to 30 months after completion of primary course. 
2.2.1.3. Efficacy; duration of efficacy of a primary course 
 To evaluate the duration of protective efficacy of a primary schedule of 
RTS,S/AS01E with no booster dose against clinical malaria disease. Duration of 
follow up will extend to 30 months after completion of primary course. 
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2.2.1.4. Efficacy; the role of a booster 
 To evaluate the protective efficacy of RTS,S/AS01E against clinical malaria disease 
with and without a booster dose given 18 months after completion of a primary 
schedule. Duration of follow up will be for 12 months after a booster dose. 
2.2.1.5. Efficacy under different transmission settings 
 To evaluate the protective efficacy of RTS,S/AS01E on a primary schedule with and 
without booster dose against clinical malaria disease under different conditions of 
malaria transmission. Field site will be used as a proxy for transmission setting. 
Duration of follow up will extend to 30 months after completion of primary course. 
2.2.1.6. Efficacy against secondary case definitions of clinical malaria disease 
 To evaluate the protective efficacy of RTS,S/AS01E on a primary schedule with and 
without booster dose against secondary case definitions of clinical malaria disease. 
Duration of follow up will extend to 30 months after completion of primary course. 
2.2.1.7. Efficacy against prevalence of parasitemia 
 To evaluate the protective efficacy of RTS,S/AS01E against prevalence of 
parasitemia 18 and 30 months after a primary schedule and 12 months after a booster 
dose. 
2.2.1.8. Efficacy against prevalence of moderate and severe anemia 
 To evaluate the protective efficacy of RTS,S/AS01E against prevalence of moderate 
and severe anemia 18 and 30 months after a primary schedule and 12 months after a 
booster dose. 
Refer to Section 5.2 for case definitions for efficacy endpoints. 
2.2.2. Safety secondary objectives 
2.2.2.1. Safety of a primary course 
 For each age category, to evaluate the safety of a primary schedule of RTS,S/AS01E 
in African children. Duration of follow up will be for 14 months after receipt of the 
first dose (Primary Analysis). 
 For each age category, to evaluate the safety of a primary schedule of RTS,S/AS01E 
without a boost. Duration of follow up will be for 32 months after receipt of first 
dose. 
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2.2.2.2. Safety of a booster dose 
 For each age category, to evaluate the safety of a booster dose of RTS,S/AS01E 
administered 18 months after completion of primary course. Duration of follow up 
will be for 12 months after receipt of boost. 
2.2.3. Immunogenicity secondary objectives 
2.2.3.1. Immunogenicity of a primary course 
 For children aged 5-17 months at first vaccination, to evaluate the anti-CS and anti-
HBs immunogenicity of a primary schedule of RTS,S/AS01E without a boost. 
Duration of follow up will be for 32 months after receipt of first dose. 
 For children aged 6-12 weeks at first vaccination, to evaluate the anti-CS and anti-
HBs immunogenicity of a primary schedule of RTS,S/AS01E without a boost when 
coadministered with DTPwHepB/Hib (Tritanrix HepB/Hib). Duration of follow up 
will be for 32 months after receipt of first dose. 
2.2.3.2. Immunogenicity of a booster dose 
 For children aged 5-17 months at first vaccination, to evaluate the anti-CS and anti-
HBs immunogenicity of a booster dose of RTS,S/AS01E administered 18 months 
after completion of primary course. Duration of follow up will be for 12 months after 
receipt of boost. 
 For children aged 6-12 weeks at first vaccination, to evaluate the anti-CS and anti-
HBs immunogenicity of a booster dose of RTS,S/AS01E administered 18 months 
after completion of primary course of RTS,S/AS01E coadministered with 
DTPwHepB/Hib (Tritanrix HepB/Hib). Duration of follow up will be for 12 months 
after receipt of boost. 
2.2.3.3. Antibodies to polio serotypes 1, 2 and 3 
 To describe antibody responses to polio serotypes 1, 2 and 3 when OPV is given on a 
primary schedule co-administered with DTPwHepB/Hib (Tritanrix HepB/Hib) with 
or without RTS,S/AS01E at one month post dose 3. 
 To describe antibody responses to polio serotypes 1, 2 and 3 when OPV is given on a 
primary schedule (co-administered with DTPwHepB/Hib with or without 
RTS,S/AS01E) and a booster dose at 18 months post primary (with or without 
RTS,S/AS01E) at one month post boost. 
Amended 19 August 2008 
Amended 24 October 2008 
Refer to Section 10.2 for definitions of secondary endpoints. 
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2.3. Additional Secondary Objectives 
2.3.1. Additional efficacy secondary objectives 
Amended 19 August 2008 
2.3.1.1. Efficacy against other serious illness 
 To evaluate the protective efficacy of RTS,S/AS01E against other serious illness 
when given on a primary schedule with or without boost. Other serious illness is all-
cause hospitalization, sepsis and pneumonia. Duration of follow-up will extend to 30 
months after completion of primary course. 
Refer to Section 5.2 for case definitions for efficacy endpoints. 
2.3.1.2. Efficacy against fatal malaria and all-cause mortality 
 To evaluate the protective efficacy of RTS,S/AS01E against fatal malaria and all-
cause mortality when given on a primary schedule with or without boost. Duration of 
follow up will extend to 30 months after completion of primary course. 
2.3.1.3. Effect on growth 
 To evaluate the effect of RTS,S/AS01E when given on a primary schedule with and 
without a booster dose on growth. 
2.3.1.4. Gender-specific efficacy 
 To evaluate the vaccine efficacy of RTS,S/AS01E in male and female children when 
given on a primary schedule with and without a boost. 
2.3.2. Additional immunogenicity secondary objectives 
Amended 19 August 2008 
2.3.2.1. Immunological correlates of protection 
 To evaluate the association between CS-antibody response and protection against 
malaria disease. 
2.3.3. Additional safety and immunogenicity secondary objectives 
Amended 19 August 2008 
2.3.3.1. Safety and immunogenicity in ‘special’ subgroups 
 To evaluate safety and immunogenicity of a primary course or a booster dose of 
RTS,S/AS01E in low weight for age (i.e. z-score  -2) and very low weight for age 
(i.e. z-score  -3) children. 
 To evaluate safety and immunogenicity of a primary course or a booster dose of 
RTS,S/AS01E in HIV-infected children. 
- Note: HIV testing is not a trial procedure. This analysis will include all children 
known to be HIV-infected at enrollment or subsequently diagnosed. 
Refer to Section 10.3 for definitions of these additional secondary endpoints. 
Amended 19 August 2008 
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2.4. Secondary objectives for the extension 
2.4.1. Efficacy 
In children from 6 weeks to 17 months of age at primary immunisation for the period 14 
days post Dose 3 to the end of extension: 
 For each of the RTS,S/AS01E immunisation regimens primary alone or primary plus 
boost, to evaluate the protective efficacy against clinical malaria disease caused by 
Plasmodium falciparum in each of at least 3 transmission settings. 
 For each of the RTS,S/AS01E immunisation regimens primary alone or primary plus 
boost, to evaluate the total cases of clinical malaria disease caused by Plasmodium 
falciparum averted in each of at least 3 transmission settings. 
 To evaluate the protective efficacy of RTS,S/AS01E (pooled immunisation 
regimens) against severe malaria disease. 
 To evaluate the total cases of severe malaria disease averted by RTS,S/AS01E 
(pooled immunisation regimens). 
 To evaluate the protective efficacy of RTS,S/AS01E (pooled immunisation 
regimens) against malaria hospitalization. 
 To evaluate the total cases of malaria hospitalization averted by RTS,S/AS01E 
(pooled immunisation regimens). 
In children from 6 weeks to 17 months of age at primary immunisation, at annual 
timepoints during the extension: 
 To evaluate the protective efficacy of RTS,S/AS01E against prevalence of 
parasitemia. 
 To evaluate the protective efficacy of RTS,S/AS01E against prevalence of moderate 
and severe anemia. 
In children from 6 weeks to 17 months of age at primary immunisation for the period 14 
days post Dose 3 to the end of extension: 
 To evaluate the protective efficacy of RTS,S/AS01E (pooled immunisation 
regimens) against all-cause mortality and fatal malaria. 
 To evaluate the total cases of all-cause mortality and fatal malaria averted by 
RTS,S/AS01E (pooled immunisation regimens). 
 To evaluate the protective efficacy of RTS,S/AS01E (pooled immunisation 
regimens) against all medical hospitalization. 
 To evaluate the total cases of all medical hospitalization averted by RTS,S/AS01E 
(pooled immunisation regimens). 
 To evaluate the protective efficacy of RTS,S/AS01E (pooled immunisation 
regimens) against pneumonia. 
110021 (Malaria-055 PRI) 
Amendment 6 
08-AUG-2012 
- 75 - 
 To evaluate the total cases of pneumonia averted by RTS,S/AS01E (pooled 
immunisation regimens). 
 To evaluate the protective efficacy of RTS,S/AS01E (pooled immunisation 
regimens) against sepsis. 
 To evaluate the total cases of sepsis averted by RTS,S/AS01E (pooled immunisation 
regimens). 
2.4.2. Safety 
In children from 6 weeks to 17 months of age at primary immunisation for the time period 
from study start to the end of extension: 
 To evaluate the safety of the RTS,S/AS01E vaccine. 
2.4.3. Immunogenicity 
 To analyze the anti-CS antibodies titers at annual timepoints during the extension. 
2.4.4. Effect on growth 
In children from 6 weeks to 17 months of age at primary immunisation: 
 To evaluate the effect of RTS,S/AS01E on growth at the end of extension. 
Amended 01 December 2010 
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3. STUDY DESIGN OVERVIEW 
Figure 1 Study design 
 
Amended 23 January 2012 
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Figure 2 Study design of the extension 
 
Amended 01 December 2010 
Amended 08 August 2012 
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Study design Amended 19 August 2008 
Study design Amended 24 October 2008 
Study design Amended 26 November 2009 
Study design Amended 01 December 2010 
3.1. Study design 
 Experimental design: Phase III, multi center, double blind (observer-blind), 
randomized, controlled trial with three groups in each of two age categories. 
 Males and females enrolled in two age categories: children aged 6-12 weeks and 
children aged 5-17 months. Children must be > 28 days of age at screening. Those 
determined to be eligible based on the inclusion and exclusion criteria will be 
enrolled in the study. 
 A maximum of 16 000 children (a minimum of 6000 in each age category) will be 
randomized. 
 Treatment Groups and study vaccination schedule 
children 5-17 months of age:  
 Primary Vaccination on a 0, 1, 2 month schedule Boost at M 20  
 RTS,S/AS01E RTS,S/AS01E  
 RTS,S/AS01E MCC Vaccine*  
 Rabies Vaccine** † MCC Vaccine*  
 *Meningococcal C Conjugate vaccine: Meningitec (Wyeth), NeisVac-C (Baxter) or 
Menjugate (Novartis). 
**Cell culture rabies vaccine: Human Diploid Cell Rabies Vaccine (Sanofi Pasteur) or 
Purified Chick Embryo Cell Culture Vaccine (Rabipur or equivalent) (Novartis) or Purified 
Vero cell culture rabies vaccine (VeroRab or equivalent) (Sanofi Pasteur). 
† each child will receive all 3 doses of rabies vaccine from the same manufacturer 
 
 Treatment Groups and vaccination schedule  
children 6-12 weeks of age: 
 Primary Vaccination on a 0, 1, 2 month schedule Boost at M 20  
 RTS,S/AS01E + Tritanrix HepB/Hib** + OPV RTS,S/AS01E + OPV  
 RTS,S/AS01E + Tritanrix HepB/Hib** + OPV MCC vaccine* + OPV  
 MCC vaccine * † + Tritanrix HepB/Hib** + OPV MCC vaccine* + OPV  
 *Meningococcal C Conjugate vaccine: Meningitec (Wyeth), NeisVac-C (Baxter) or 
Menjugate (Novartis) 
OPV: Oral Polio Vaccine (Polio Sabin [GSK]) 
† each child will receive all 3 doses of MCC from the same manufacturer. 
**** DTPwHepB/Hib 
 
 Route of administration: 
- Children 5-17 months of age at enrollment will receive primary 
immunizations intramuscularly into the left deltoid. 
- Children 6-12 weeks of age at enrollment will receive primary immunizations 
intramuscularly into the anterolateral thigh  
(Left: RTS,S/AS01E and Meningococcal C conjugate vaccine; Right: 
Tritanrix HepB/Hib). 
110021 (Malaria-055 PRI) 
Amendment 6 
08-AUG-2012 
- 79 - 
NOTE: OPV will be administered orally. 
- Route of administration for the booster dose comparator will be into the left 
deltoid for ALL children. 
 BCG vaccine, neonatal dose of OPV, measles and yellow fever vaccines will be 
given according to local EPI policy. 
 There will be no routine testing for HIV in this trial. Tests will be performed when 
clinically indicated to guide subject management. Voluntary counseling and 
testing, Highly Active Anti-Retroviral Therapy (HAART) and Prevention of 
Mother to Child Transmission (PMCT) are available at all study centers according 
to national policies. 
 The research teams at each study center will ensure that insecticide treated bednet 
use is optimized in each study population. 
 Surveillance for Efficacy: 
- All subjects presenting to health facilities in the study area will be evaluated 
as potential cases of clinical malaria disease. A blood sample will be taken for 
evaluation of malaria parasites in all children who are reported to have had a 
fever within 24 hours of presentation or have a measured axillary temperature 
of  37.5 C. 
- All subjects presenting for admission through the outpatient and emergency 
departments of hospitals in the study areas will be evaluated as potential cases 
of severe malaria disease following a protocol-defined algorithm. 
- During any hospitalization, the subject’s course will be monitored to capture 
the signs and blood parameters indicative of severe malaria disease. If the 
subject’s condition changes from admission and he/she meets one of the 
criteria for additional investigation, these will be performed.  
- Harmonization of case evaluation across centers will be assured by training of 
clinicians in the assessment of clinical signs and the standardization of 
equipment and processes used for laboratory investigations.  
 Surveillance for Safety:  
(n assumes 6000 enrolled, of which 90% will complete primary immunization and 85% 
complete booster dose and 10 participating sites). 
- SAEs will be collected for the duration of the study from all subjects (to have 
a minimum of 3620 recipients of a primary course of RTS,S/AS01E and 1680 
recipients of a booster dose in each age category).  
- Unsolicited AEs (defined as those AEs judged to be related to vaccination, or 
leading to drop-out) will be collected for 1 month post each dose in all 
subjects (to have a minimum of 3620 recipients of a primary course of 
RTS,S/AS01E and 1680 recipients of a booster dose in each age category). 
- Unsolicited AEs (all) will be collected for 1 month following each vaccine 
dose for the first 200 subjects in each age category enrolled at each center (to 
have approximately 1200 recipients of a primary course of RTS,S/AS01E and 
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560 recipients of a booster dose in each age category). 
- Solicited AEs will be collected for one week following each vaccine dose in 
the first 200 subjects in each age category enrolled at each center (to have 
approximately 1200 recipients of a primary course of RTS,S/AS01E and 560 
recipients of a booster dose in each age category). 
- Verbal autopsy will be performed on all cases of mortality occurring outside 
hospital. 
 Surveillance for Immunogenicity: 
(n assumes 6000 enrolled, of which 90% will complete primary immunization and 85% 
complete booster dose and 10 participating sites) 
- All children will be sampled for anti-HBs and anti-CS testing. 
- Immunogenicity of a primary course will be evaluated pre vaccination, 1 
month post primary course and 18 months post primary course in the first 200 
subjects in each age category enrolled at each center (to have approximately 
1200 recipients of a primary course of RTS,S/AS01E in each age category). 
- Duration of immunogenicity of a primary course will be evaluated 18 and 30 
months post primary course in the first 200 subjects in each age category 
enrolled at each center (to have approximately 560 recipients of a primary 
course of RTS,S/AS01E in each age category). 
- Immunogenicity of a booster dose will be evaluated pre-boost vaccination, 1 
month post boost and 12 months post boost in the first 200 subjects in each 
age category enrolled at each center (to have approximately 560 recipients of 
a primary course of RTS,S/AS01E in each age category). 
- Immune correlates of protection will be explored by sampling all subjects 1 
month post primary course and 1 month post boost and the full details of the 
analysis will be presented in the SAP to compare subjects affected and 
unaffected by malaria disease. 
- Surveillance for Cellular Immunology: At some study centers, subjects may 
be sampled for evaluation of the cellular immune response induced by the 
RTS,S/AS01E vaccine. CMI procedures will be detailed in separate protocol, 
ancillary to this study.  
- Immunogenicity of the polio serotypes 1, 2 and 3 will be evaluated when OPV 
is given on a primary schedule with DTPwHepB/Hib (Tritanrix HepB/Hib) 
with or without RTS,S/AS01E at screening, at 1 month post primary course 
(Visit 5) and following a booster dose at 18 months post primary (with or 
without RTS,S/AS01E) at 1 month post boost (Visit 23) in a subset of subjects 
in the 6-12 weeks age category enrolled at each center. 
 Data collection: where technically possible, this study will use electronic case 
report form (eCRF) by remote data entry (RDE) in preference to conventional 
paper case report form (CRF). 
 Subjects will be randomized using an internet-based system. 
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 Duration of the study: the primary study will continue for 32 months per child, 
plus a screening period of 1 month. 
 Analysis of co-primary endpoint: clinical disease 
- The analysis of efficacy of a primary schedule of RTS,S/AS01E will be 
carried out after the first 14 months of follow-up have been completed for the 
first 6000 subjects (approximately) enrolled in the age category under 
evaluation. 
- It is anticipated that enrolment of the 5-17 months age category will be faster 
than in the infant age category and thus analysis of the two co-primary 
efficacy endpoints may take place at different times. In order to control the 
overall alpha-level (5%) of the trial both evaluations will be performed at a 
2.5% alpha level (Bonferroni correction) thus, for the evaluation of the co-
primary endpoint leading to 97.5% Confidence Intervals (CI).  
- In both age categories, efficacy against clinical malaria of the primary 
immunization schedule will be measured when at least 6000 subjects have 14 
months of follow-up. Assuming at least 5400 evaluable subjects (randomized 
2:1), an attack rate in controls of 10/100 cyr (children years at risk) over the 
follow-up period and a true vaccine efficacy of 30%, the study has 90% power 
to detect a lower limit of the 97.5% CI around estimated VE above 0%. 
- In the event that the attack rate is lower than anticipated and there have not 
been 450 accumulated cases in the observation period 14 days to 12 months 
post dose 3, then the period of observation contributing to the primary 
analysis will be extended. The analysis will be conducted when 450 cases 
have accumulated, or until boost (visit 22) (approximately 18 months post 
dose 3) whichever occurs earlier. 
 Analysis of secondary endpoint: severe disease 
- A secondary analysis of severe malaria will be performed when 250 episodes 
of severe malaria meeting the primary case definition, pooled over the study 
centers and age categories, have occurred, or at the end of the follow-up 
period (Month 32), whichever occurs first. 
- 250 episodes give 80% power to detect 30% VE with a lower limit of the 95% 
CI above 0%. Assuming 50% VE 250 episodes give 90% power to detect a 
lower limit of the 95% CI above 25%. 
 Analysis of secondary endpoint: antibodies to polio serotypes 1, 2 and 3 
- A secondary analysis of the immune response for polio serotypes 1, 2 and 3 
when OPV is given on a primary schedule co-administered with 
DTPwHepB/Hib (Tritanrix HepB/Hib) with or without RTS,S/AS01E at 
screening, at 1 month post primary course (Visit 5) and following a booster 
dose at 18 months post primary (with or without RTS,S/AS01E) at one month 
post boost. 
 The first 200 subjects enrolled at each center, in each age category, will form a 
subset for additional safety and immunology endpoints. Safety evaluations 
comprise the collection of solicited reactogenicity and the use of antipyretic, 
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analgesic and systemic antibiotics. Immunogenicity evaluations comprise 
responses to anti-CS and anti-HBs antigens and responses to OPV only in the 6-12 
weeks age category. 
3.2. Study design of the extension 
 Experimental design: Extension to the Phase III, multi-center, randomized, 
controlled trial Malaria-055 
 Blinding: 
- Initial study (D0 to Month 32): Double-Blind 
- Extension: Single-blind 
 Study groups: 3 groups in children 6 weeks to 17 months at first vaccination. 
- Primary schedule + booster                R3R 
- Primary schedule + control vaccine   R3C 
- Comparator group                              C3C 
 Number of subjects: A maximum of 16 000 children are planned to be enrolled in 
the initial study. All subjects enrolled in the initial study for whom 
parents/guardians will give their consent for participation in the extension, who 
received at least one dose of study or control vaccine in the primary trial phase and 
whose Visit 35 took place before (and including) 30 September 2013, will be 
enrolled. 
 Malaria control: Bednet usage and indoor residual spraying will be documented 
once for each subject before the last extension visit using the same methodology of 
the primary trial phase. 
 Sampling timepoints: Blood samples will be taken at annual intervals during the 
extension (maximum 2 blood samples). 
 Data collection: This study will use electronic case report form (eCRF) by remote 
data entry (RDE). 
 Interval between study visits: Depending on the date of the last visit of the primary 
trial phase (Visit 34), subjects will have up to 3 clinic visits plus one field workers 
visit during this extension (Refer to Figure 2). If a subject does not attend Visit 34, 
the schedule of the following visit(s) will be based on the assumption that the 
Visit 34 occurred 32 months post Dose 1. 
- Subjects that have their last visit in the primary trial phase (Visit 34) BEFORE 
(and including) 30 June 2012 will have 3 clinic visits plus one field workers 
visit in the extension. 
- Subjects that have their last visit in the primary trial phase (Visit 34) between 
1 July 2012 and 30 September 2013 will have 2 clinic visits plus one field 
workers visit in the extension. 
- No subjects will be enrolled in the extension study (Visit 35) after 30 
September 2013. 
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Table 5 Intervals between study visits for subjects that have their last visit 
in the primary trial phase (Visit 34) BEFORE (and including) 30 Jun 2012 
Interval Optimal time for study visit 
(Study Months) 
Maximum interval 
allowed 
Visit 35 On same day as Visit 34* 
(Study Month 32) 
Maximum interval: Visit 
2 + 44 months 
Visit 34 Visit 36 12 months** 
(Study Month 44) 
Range: 11 to 13 months 
 
Visit 34 Visit 37§ 
(Field workers visit) 
Nov 2013 
23 months** 
(Study Month 55) 
Date: Oct 2013 to Dec 
2013  
Visit 34 Visit 38 Dec 2013 
24 months** 
(Study Month 56) 
Date: Nov 2013 to Jan 
2014  
* If subjects are not present at Visit 34, Visit 35 should be scheduled as soon as possible 
and up to a maximum of 12 months after Visit 34, assuming Visit 34 should have occurred 
at Visit 2 + 32 months 
** If subjects are not present at Visit 34, Visit 36, 37 and 38 should be scheduled assuming 
Visit 34 should have occurred at Visit 2 + 32 months 
§Visit 37 (Field workers visit) has to be conducted between 1 and 30 days before Visit 38. 
Amended 08 August 2012 
Table 6 Intervals between study visits for subjects that have their last visit 
in the primary trial phase (Visit 34) after 30 Jun 2012 and BEFORE 
(and including) 30 Sep 2013 
Interval Optimal time for study visit 
(Study Months) 
Maximum interval 
allowed 
Visit 35 
On same day as Visit 34* 
(Study Month 32) 
Maximum interval: Visit 
2 + 44 months or 30 Sep 
2013 at the latest 
Visit 34 Visit 37§ 
(Field workers visit) 
Nov 2013 
11 months** 
(Study Month 43) 
Date: Oct 2013 to Dec 
2013 
Visit 34 Visit 38 Dec 2013 
12 months** 
(Study Month 44) 
Date: Nov 2013 to Jan 
2014  
* If subjects are not present at Visit 34, Visit 35 should be scheduled as soon as possible 
and up to a maximum of 12 months after Visit 34, assuming Visit 34 should have occurred 
at Visit 2 + 32 months. No subjects will be enrolled for Visit 35 after 30 September 2013. 
** If subjects are not present at Visit 34, Visit 37 and 38 should be scheduled assuming 
Visit 34 should have occurred at Visit 2 + 32 months 
§Visit 37 (Field workers visit) has to be conducted between 1 and 30 days before Visit 38. 
Amended 08 August 2012 
 Informed consent: Freely given informed consent should be obtained from 
subjects’ parent(s)/LAR(s) prior to participation in the extension. The informed 
consent must be signed at the first visit of the extension, Visit 35. To avoid any 
gap in data collection between the initial study and the extension, Visit 35 should 
ideally take place on the same day as Visit 34. If subjects are not present at Visit 
34, Visit 35 and signature of informed consent should be scheduled as soon as 
possible and up to a maximum 12 months after Visit 34 should have occured. 
110021 (Malaria-055 PRI) 
Amendment 6 
08-AUG-2012 
- 84 - 
 Surveillance for Efficacy during the extension: 
- Surveillance for severe malaria disease will be maintained at all inpatient 
facilities in the study areas. Children will be evaluated according to an 
algorithm to accurately define cases. 
- Surveillance for clinical malaria disease will be maintained at the outpatient 
facilities in the study areas of at least 3 participating centers of varying 
malaria transmission intensity. 
- Parasite prevalence and haemoglobin will be assessed annually on all subjects. 
 Surveillance for Immunogenicity during the extension: 
- Anti-CS antibodies will be assessed in a subset of 200 subjects in each age 
category in at least three centers evaluating efficacy to clinical disease. 
 Surveillance for Safety during the extension: 
- Surveillance to detect SAEs will be maintained at all inpatient facilities in the 
study areas. 
- Verbal autopsy will be performed on all cases of mortality occurring outside 
hospital. 
Amended 01 December 2010 
4. STUDY COHORT 
4.1. Number of subjects / centers 
This study will be conducted at a number of malaria-endemic countries in sub Saharan 
Africa. Full details of the geography, demographics, healthcare provision and relevant 
site-specific information for each center are provided in documentation accompanying 
this protocol. 
A maximum of 16 000 children (a minimum of 6000 in each age category [i.e. children 6-
12 weeks of age and children 5-17 months of age at first vaccination]) will be 
randomized. 
4.2. Inclusion criteria for the primary trial phase 
Amended 01 December 2010 
All subjects must satisfy the following criteria at study entry: 
 A male or female child of: 
- 5-17 months (inclusive) of age at time of first vaccination, 
- or between 6-12 weeks (inclusive) of age at time of first vaccination  
and  
NOT have already received a dose of vaccine against diphtheria, tetanus or 
pertussis or Hemophilus influenzae type B 
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and 
must be > 28 days of age at screening. 
Amended 19 August 2008 
 Signed informed consent or thumb-printed and witnessed informed consent obtained 
from the parent(s)/guardian(s) of the child. 
 Subjects who the investigator believes that their parents/guardians can and will 
comply with the requirements of the protocol (e.g. return for follow-up visits) should 
be enrolled in the study. 
4.2.1. Inclusion criteria for the extension 
To take part in the extension, all subjects must satisfy the following criteria: 
 Subjects who were enrolled and who received at least one vaccine dose in the 
primary trial phase. 
 Subjects who were present for Visit 35 on or before 30 September 2013. 
 Subjects who the investigator believes that their parents/guardians can and will 
comply with the requirements of the protocol (e.g. return for follow-up visits) should 
be enrolled in the study. 
Amended 01 December 2010 
4.3. Exclusion criteria for enrolment for the primary trial phase 
Amended 01 December 2010 
The following criteria should be checked at the time of study entry. If any apply, the 
subject must not be included in the study: 
 Acute disease at the time of enrolment (acute disease is defined as the presence of a 
moderate or severe illness with or without fever). All vaccines can be administered 
to persons with a minor illness such as diarrhea, mild upper respiratory infection 
with or without low-grade febrile illness, i.e. axillary temperature < 37.5°C). 
 Acute or chronic, clinically significant pulmonary, cardiovascular, hepatic or renal 
functional abnormality, as determined by physical examination or laboratory 
screening tests. 
 Anemia defined as: 
- hemoglobin < 5.0 g/dL. 
- or hemoglobin < 8 g/dL associated with clinical signs of heart failure or severe 
respiratory distress. 
Amended 19 August 2008 
Amended 24 October 2008 
Amended 26 November 2009 
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 Major congenital defects. 
 History of allergic reactions, significant IgE-mediated events or anaphylaxis to 
previous immunizations.  
 Children with a past history of a neurological disorder or atypical febrile seizure (a 
febrile seizure is atypical if it meets one of the following criteria: not associated with 
fever; lasts > 5 minutes; focal (not generalized); followed by transient or persistent 
neurological abnormality; occurs in a child < 6 months of age). 
 Children with malnutrition requiring hospital admission. 
 Children currently meeting the criteria for HIV disease of Stage III or Stage IV 
severity as defined by the World Health Organization [WHO, 2005] (please refer to 
Appendix I for current guidelines). NB: a previous history of having Stage III or 
Stage IV HIV disease is NOT an exclusion criterion. 
 History of allergic disease or reactions likely to be exacerbated by any component of 
the vaccine. 
 Concurrently participating in another clinical study, at any time during the study 
period, in which the subject has been or will be exposed to a drug or vaccine that is 
not licensed for that indication (by one of the following authorities: FDA or EU 
member state or WHO [with respect to prequalification]) with the exception of 
studies with the objective of improving the drug treatment or clinical management of 
severe malaria disease. 
 Use of a drug or vaccine that is not approved for that indication (by one of the 
following authorities: FDA or EU member state or WHO [with respect to 
prequalification]) other than the study vaccines within 30 days preceding the first 
dose of study vaccine, or planned use during the study period.  
 Previous participation in any other malaria vaccine trial. 
 Receipt of a vaccine within the preceding 7 days 
Amended 19 August 2008 
 Any other findings that the investigator feels would increase the risk of having an 
adverse outcome from participation in the trial. 
 Any other findings that the investigator feels would result in data collected being 
incomplete or of poor quality.  
4.4. Elimination criteria during the study 
The following criteria should be checked at each visit subsequent to the first visit. If any 
become applicable during the study, it will not require withdrawal of the subject from the 
study but may determine a subject’s evaluability in the according-to-protocol (ATP) 
analysis. See Section 10.6 for definition of study cohorts to be evaluated. 
 Use of a drug or vaccine that is not licensed for that indication (by one of the 
following authorities: FDA or EU member state or WHO [with respect to 
prequalification]) other than the study vaccine during the study period with the 
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exception of studies with the objective of improving the drug treatment or clinical 
management of severe malaria disease. 
 Administration of a vaccine not foreseen by the study protocol within 30 days of any 
dose of RTS,S/AS01E or control vaccine with the exception of vaccines against 
polio, diphtheria, tetanus, pertussis, hepatitis B, Hemophilus influenzae type b, BCG, 
measles, pneumococcal disease or yellow fever which may not be given within one 
week of vaccination. 
4.5. Contraindications to subsequent vaccination 
4.5.1. Indications for deferral of vaccination 
The following events constitute contraindications to administration of RTS,S/AS01E or 
control vaccine at that point in time; if any one of these AEs occur at the time scheduled 
for vaccination, the subject may be vaccinated at a later date, within the time window 
specified in the protocol, or withdrawn at the discretion of the investigator. AEs should 
be followed-up according to the instructions in Section 8.6: 
 Acute disease at the time of vaccination (acute disease is defined as the presence of a 
moderate or severe illness with or without fever. All vaccines can be administered to 
persons with a minor illness such as diarrhea, mild upper respiratory infection with 
or without low-grade febrile illness, i.e. Axillary temperature <37.5°C). 
 Axillary temperature of  37.5 C. 
 Administration of a vaccine not foreseen by the study protocol within 30 days of any 
dose of RTS,S/AS01E or control vaccine with the exception of vaccines against 
polio, diphtheria, tetanus, pertussis, hepatitis B, Hemophilus influenzae type b, BCG, 
measles, pneumococcal disease or yellow fever which may not be given within one 
week of vaccination. 
 Children currently meeting the criteria for HIV disease of Stage III or Stage IV 
severity as defined by the World Health Organization [WHO, 2005] (please refer to 
Appendix I for current guidelines). 
4.5.2. Absolute contraindications to further vaccination 
The following AEs constitute absolute contraindications to further administration of, 
RTS,S/AS01E or comparator vaccine; if any of these AEs occur during the study, the 
subject must not receive additional doses of the RTS,S/AS01E vaccine, but may continue 
other study procedures at the discretion of the investigator. AEs should be followed-up 
according to the instructions in Section 8.6. It is expected that the subject would continue 
full safety monitoring procedures, as per protocol. In children enrolled to the 6-12 week 
age category, the completion of infant immunization schedules is covered in Section 
5.1.4.6. 
 Acute allergic reaction, significant IgE-mediated event or anaphylactic shock 
following the administration of vaccine investigational product. 
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 Infants enrolled in the 6-12 week age category who receive a dose of a DTP-
combination vaccine not foreseen in the protocol prior to the completion of the 
TritanrixHepB/Hib series, must not receive further doses of RTS,S/AS01E. 
 Any other findings that the investigator feels would increase the risk of having an 
adverse outcome from participation in the trial. 
5. CONDUCT OF STUDY 
5.1. Ethics and regulatory considerations  
The study will be conducted according to Good Clinical Practice (GCP), the Declaration 
of Helsinki and local rules and regulations of the country. 
Amended 19 August 2008 
Submission of the protocol and any protocol amendments to regulatory agencies will 
occur in accordance with local regulatory requirements. For some countries, submission 
to the local regulatory authority may not be required. When submission to the local 
regulatory authority is required, the timing of the submission relative to IEC/IRB 
submission or approval and whether or not the authority will provide their approval of or 
favorable opinion on the protocol or amendment before it can be implemented will 
depend on local regulatory requirements. 
5.1.1. Institutional Review Board/Independent Ethics Committee 
(IRB/IEC) 
The IRB/IEC must be constituted according to the local laws/customs of each 
participating country. The ICH Harmonized Tripartite Guideline for Good Clinical 
Practice recommends that the IRB/IEC should include: 
a. At least five members. 
b. At least one member whose primary area of interest is in a non-scientific area. 
c. At least one member who is independent of the institution/study site. 
Only those IRB/IEC members who are independent of the investigator and the sponsor of 
the study should vote/ provide opinion on a study-related matter. 
A list of the professions of the IRB/IEC members will be obtained by the Principal 
Investigators (PIs) or their delegates. 
This protocol and any other documents that the IRB/IEC may need to fulfill its 
responsibilities, including subject recruitment procedures and information about 
payments and compensation available to subjects will be submitted to each IRB/IEC by 
the PIs or their delegates. Written and dated unconditional approval from the IRB/IEC of 
the protocol and amendment (if any and applicable), written informed consent form, 
consent form updates (if any), subject recruitment procedure(s) (e.g. advertisements), and 
any other written information to be provided to subjects must be in the possession of the 
investigator and GSK before commencement of the study. This approval must refer to the 
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study by study title and number with exact protocol version and date, and should identify 
the documents reviewed and state the date of review. Relevant GSK Biologicals’ data 
will be supplied by the Principal Investigator to the independent IRB/IEC for review and 
approval of the protocol. Verification of the unconditional approval of the IRB/IEC will 
be transmitted by the PIs to the GSK Biologicals’ Central Study Coordinator using the 
standard notification form prior to shipment of vaccine supplies and materials to the site. 
No deviations from, or changes to, the protocol should be initiated without prior written 
sponsor and IRB/IEC approval of an appropriate amendment, except when necessary to 
eliminate immediate hazards to the subjects or where permitted by all applicable 
regulatory requirements or when the change(s) involves only logistical or administrative 
aspects of the study (e.g. change of monitor[s], telephone number[s]). Administrative 
changes and amendments not submitted for approval are submitted to the IRB/IEC for 
information only. However, written verification that such documents were submitted 
should be obtained. Approvals/ verifications must be transmitted in writing to the GSK 
Biologicals clinical study monitor by the PI. 
The IRB/IEC must be informed by the PI of: 
 all subsequent protocol amendments, informed consent changes or revisions of other 
documents originally submitted for review 
 serious and/or unexpected adverse events occurring during the study, where required 
 all subsequent protocol administrative changes (for information) 
 new information that may affect adversely the safety of the subjects or the conduct of 
the study 
 regular updates and/or request for re-approval, where required 
 when the study has been completed, where required. 
If a trial is prematurely terminated or suspended for reasons including, but not limited to, 
safety or ethical issues or severe non-compliance, the sponsor will promptly inform the 
regulatory authorities of the termination or suspension and the reason(s) for the 
termination or suspension. If required by applicable regulations, the investigator must 
inform the IEC/IRB promptly and provide the reason for the suspension or termination 
(see Appendix A for further details). 
5.1.2. Informed consent 
A summary of the recruitment plan and informed consent process to be followed at each 
site is provided in the accompanying site-specific documents. The following principles 
will also apply. 
In obtaining and documenting informed consent, the investigator should comply with the 
applicable regulatory requirement(s), and should adhere to GCP and to the ethical 
principles that have their origin in the Declaration of Helsinki. Prior to the beginning of 
the trial, the investigator should have the IRB/IEC’s written approval/favorable opinion 
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of the written informed consent form and any other written information to be provided to 
the subjects and/or subjects’ parents/guardians. 
Informed consent will be obtained in accordance with 21 CFR 50.25. 
Freely given informed consent should be obtained from subjects’ parents/guardians prior 
to clinical trial participation. 
Information should be given in both oral and written form whenever possible and as 
deemed appropriate by the IRB/IEC. 
An investigator or designate will describe the protocol to potential subjects’ 
parents/guardians face to face. The Informed Consent Form may be read to the subjects’ 
parents/guardians, but in any event, the investigator or designate shall give the subjects’ 
parents/guardians ample opportunity to inquire about details of the study and ask any 
questions before dating and signing (or thumbprinting, in the case of illiterate persons) 
the Informed Consent Form. 
While informed consent information can be presented to groups at an initial information 
session, each subject’s parents/guardian must be given the opportunity to individually 
pose questions to the investigator or designate prior to the subject’s parents/guardians 
dating and signing/thumbprinting the Informed Consent Form. 
Informed Consent Forms must be in a language fully comprehensible to the prospective 
subjects’ parents/guardians. Informed consent shall be documented by the use of a 
written consent form approved by the IRB/IEC and signed and dated by the subjects’ 
parents/guardians and by the person who conducted the informed consent discussion. The 
signature confirms the consent is based on information that has been understood. All 
illiterate individuals will have the study and the Informed Consent Form explained to 
them point by point by the interviewer in the presence of an impartial witness. The 
witness will personally sign and date the consent form. Oral witnessed consent will 
replace written consent only in countries where the local custom is contrary or if the 
subject’s parents’/guardians’ incapacity precludes this and provided that the local legal 
obligations are fulfilled. 
Each subject’s signed informed consent form must be kept on file by the investigator for 
possible inspection by Regulatory Authorities and/or GSK Biologicals’ professional and 
Regulatory Compliance persons. The subjects’ parents/guardians should receive a copy 
of the signed and dated written informed consent form and any other written information 
provided to the subjects’ parents/guardians, and should receive copies of any signed and 
dated consent form updates. Any amendments to the written information will be provided 
to subjects’ parents/guardians. 
Both the informed consent discussion and the written informed consent form and any 
other written information to be provided to the subjects’ parents/guardians should include 
explanations of the following: 
a. That the trial involves research. 
b. The purpose of the trial. 
110021 (Malaria-055 PRI) 
Amendment 6 
08-AUG-2012 
- 91 - 
c. The trial treatment(s) and the probability for random assignment to each treatment. 
d. The trial procedures to be followed, including all invasive procedures. 
e. The subject’s parents’/guardians’ responsibilities. 
f. Those aspects of the trial that are experimental. 
g. The reasonably foreseeable risks or inconveniences to the subjects and, when 
applicable, to an embryo, fetus or nursing infant. 
h. The reasonable expected benefits. When there is no intended clinical benefit to 
subjects, the subjects’ parents/guardians should be made aware of this. 
i. The alternative procedure(s) or course(s) of treatment/ methods of prevention that 
may be available to subjects, and their important potential benefits and risks. 
j. The compensation and/or treatment available to subjects in the event of trial-related 
injury. 
k. The anticipated prorated payment, if any, to subjects’ parents/guardians for 
participating in the trial. 
l. The anticipated expenses, if any, to subjects’ parents/guardians for participating in 
the trial. 
m. That the subjects’ participation in the trial is voluntary and subjects’ 
parents/guardians may refuse to participate or withdraw from the trial, at any time, 
without penalty or loss of benefits to which subjects are otherwise entitled. 
n. That the monitor(s), the auditor(s), the IRB/IEC, and the regulatory authority(ies) 
will be granted direct access to the subject’s original medical records for verification 
of clinical trial procedures and/or data, without violating the confidentiality of 
subjects, to the extent permitted by the applicable laws and regulations and that, by 
signing a written informed consent, the subject’s parents/guardians are authorizing 
such access. 
o. That records identifying subjects will be kept confidential and, to the extent 
permitted by the applicable laws and/or regulations, will not be made publicly 
available. If the results of the trial are published, subjects’ identity will remain 
confidential. 
p. That the subjects’ parents/guardians will be informed in a timely manner if 
information becomes available that may be relevant to the subjects’ 
parents/guardians willingness for continued participation in the trial. 
q. The person(s) to contact for further information regarding the trial and the rights of 
trial subjects, and who to contact in the event of trial-related injury. 
r. The foreseeable circumstances and/or reasons under which a subject’s participation 
in the trial may be terminated. 
s. The expected duration of a subject’s participation in the trial. 
t. The approximate number of subjects involved in the trial. 
GSK Biologicals will prepare a model Informed Consent Form which will embody all the 
elements described above. While it is strongly recommended that this model document be 
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followed as closely as possible, the informed consent requirements given in this 
document are not intended to pre-empt any local regulations which require additional 
information to be disclosed for informed consent to be legally effective. Clinical 
judgment, local regulations and requirements should guide the final structure and content 
of the document. 
The investigator has the final responsibility for the final presentation of Informed 
Consent Form, respecting the mandatory requirements of local regulations. The consent 
form generated by the investigator with the assistance of the sponsor’s representative, 
must be approved (along with the protocol, and any other necessary documentation) by 
the IRB/IEC and be acceptable to GSK Biologicals. 
5.1.3. Storage of study documentation at investigator’s sites 
All study documentation containing personal information relating to study subjects will 
be kept in a secure locked area at the investigator’s sites. Such documentation will only 
be made available to authorized personnel. All electronic data kept at the investigator’s 
site are kept secure. Computer access is only available to authorized personnel. 
5.1.4. Safety Monitoring Plan 
This trial is overseen by a Data Safety Monitoring Board (DSMB) operating under a 
charter assisted by a Local Safety Monitor (LSM) at each site. 
5.1.4.1. Data Safety Monitoring Board (DSMB)/Independent Data Monitoring 
Committee (IDMC) 
The role of the DSMB includes the review of the implementation and progress of the 
study. It provides initial, regular, and closing advice on safety-related issues to GSK 
Biologicals. Its advice is based on the interpretation of study data with reference to the 
study protocol. 
The DSMB will meet before the initiation of the study (pre-initiation review), 6-monthly 
during the enrollment phase and annually thereafter. They will review the Protocol and 
Statistical Analysis Plan (SAP). Other unscheduled meetings may be required. Meetings 
may be face to face or via teleconference. Meetings must be documented and minutes 
made available to the sponsors. The DSMB may, if deemed necessary, convene a meeting 
with, or request further information from the Principal Investigators, the Medical 
Monitor/Local Safety Monitors and GSK Biologicals’ and MVI’s designated project 
representatives at any stage of the study. 
The DSMB may recommend to the sponsor to suspend the enrollment to the trial and/or 
vaccination across all sites based on their review of safety data arising in this trial or 
other relevant trials of the same product. 
In October 2008, the Data Safety Monitoring Board Terms of Reference (Charter) was 
revised to match the GSK Biologicals standard template and format. The membership 
and functioning rules of the DSMB in place have not been changed, but their role has 
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been clarified and their name modified to Independent Data Monitoring Committee 
(IDMC). 
Amended 26 November 2009 
Amended 23 January 2012 
5.1.4.1.1. Data Reviewed by the DSMB 
The DSMB will be informed of: 
 All SAEs. SAEs judged to be related or fatal or occurring within 1 week of 
vaccination will be sent to the DSMB within 24 hours. 
 Unblinded SAE summary tables will be produced 6-monthly during the enrolment 
phase, and annually thereafter, in advance of DSMB meetings. 
 All withdrawals of study subjects by the Principal Investigator or the 
parent(s)/guardian(s) of a subject due to adverse events. 
 New information that may affect adversely the safety of the subjects or the conduct 
of the study. 
 All subsequent protocol amendments, informed consent changes or revisions of other 
documents originally submitted for review. 
 All subsequent protocol modifications (for information). 
5.1.4.2. Local Safety Monitor (LSM) 
The overall role of the Local Safety Monitors (LSM), who are experienced clinicians 
based in-country, will be to support the clinical investigators and to act as a link between 
the investigators and the DSMB. 
The LSM’s role will include: 
 Acting as the study volunteer’s advocate. 
 Promptly communicating relevant safety information to the DSMB. 
 Initiate the discussion of the need Request the investigator to unblind in emergency 
a subject if deemed necessary to allow for adequate treatment. 
 Temporary suspension of vaccination at the site (for which they are responsible) for 
a major safety concern. 
Amended 24 October 2008 
Amended 26 November 2009 
Amended 08 August 2012 
5.1.4.2.1. Data Reviewed by the LSM 
The relevant LSM must be informed by the investigator on an ‘as received’ basis of: 
 All SAEs within 24 hours. 
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 All withdrawals of study subjects by the Principal Investigators or the parent(s)/ 
guardian(s) of a subject due to adverse events. 
5.1.4.3. Process if the trial is suspended 
If the Principal Investigator or LSM suspends the trial at their site, they must immediately 
notify the DSMB, and GSK Biologicals (the study sponsor) via the contacts for safety 
reporting (refer to Section 8.7.2). 
If the trial is suspended, the DSMB will review all available information and make a 
recommendation to the study sponsor (GSK Biologicals) whether to recommence the trial 
or to stop the trial permanently. 
It is the responsibility of the sponsor (GSK Biologicals) to make the decision whether or 
not the trial should be stopped permanently. 
5.1.4.4. Rescue plan for HBs 
The rescue plan for this trial will be overseen by the DSMB. 
At the time of the primary analysis in infants 6 to 12 weeks of age at enrollment after 14 
months of follow-up, anti HBs antibody titers 1 month post Dose 3 will be analyzed in all 
children in this age category. 
Any children who are found not to be seroprotected against anti-HBs will receive a 
booster dose of Hepatitis B vaccine in a timely manner. 
5.1.4.5. Monitoring of polio serotypes 1, 2 and 3 seroprotection 
There has been an unexpected finding in a phase 2 trial of lower seroprotection rates to 
polio 3 when OPV is given in co-administration with RTS,S/AS01E + DTPwHepB/Hib 
than with DTPwHepB/Hib alone (Section 1.4.3). Polio 3 titers in the co-administration 
group whilst lower than in the comparator group remain consistent with seroprotection 
levels in the published literature [WHO 1995, WHO 1997]. The consistency of this 
finding will be assessed by measuring the polio serotypes 1, 2 and 3 response induced by 
a primary series of OPV (4 doses commencing in the neonatal period) in a subset of 
children at all centers. Also all subjects will receive a booster dose of OPV at 20 months 
of age and seroprotection rates measured afterwards to assess the value of a booster dose 
when RTS,S/AS01E is given in co-administration with EPI antigens. 
The DSMB will review the analysis of polio serotypes 1, 2 and 3 titres and advise on the 
need to offer additional doses to children in the trial. 
Amended 19 August 2008 
Amended 24 October 2008 
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5.1.4.6. Completion of immunization course for infants withdrawn during 
vaccination course 
Infants may be withdrawn by the investigator for medical reasons or by their 
parent(s)/guardian(s) for any reason. If there is no contraindication, in the opinion of the 
Principal Investigator, for the infant receiving additional doses of licensed vaccine for D, 
T, Pw, Hib, hepatitis B and OPV, the importance of completion of a 3 dose regimen will 
be explained to the parent(s)/guardian(s). The parent(s)/guardian(s) will be offered the 
choice of completing a course of Tritanrix HepB
™
/Hib + OPV administered by the study 
team or completing their country’s recommended EPI schedule at their local EPI clinic. 
5.2. Case definitions 
5.2.1. Clinical malaria disease 
Table 7 Case definitions for clinical malaria 
1  definition P. falciparum asexual parasitemia > 5000 parasites/μL  
AND presence of fever (axillary temperature  37.5°C) at the time of presentation  
AND occurring in a child who is unwell and brought for treatment to a healthcare facility 
OR 
a case of malaria meeting the primary case definition of severe malaria disease (refer to 
Table 8) 
2  definition 1 P. falciparum asexual parasitemia > 0 
AND presence of fever (axillary temperature  37.5°C) at the time of presentation or 
history of fever within 24 hours of presentation 
AND occurring in a child who is unwell and brought for treatment to a healthcare facility 
2  definition 2 P. falciparum asexual parasitemia > 500 parasites/μL 
AND presence of fever (axillary temperature  37.5°C) at the time of presentation 
AND occurring in a child who is unwell and brought for treatment to a healthcare facility 
2  definition 3 P. falciparum asexual parasitemia > 20 000 parasites/μL 
AND presence of fever (axillary temperature  37.5°C) at the time of presentation 
AND occurring in a child who is unwell and brought for treatment to a healthcare facility 
5.2.2. Severe malaria disease 
Severe malaria disease will be diagnosed based on symptoms and signs occurring at 
presentation or developing during admission according to the case definitions in Table 8. 
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Table 8 Primary case definition of severe malaria disease 
P. falciparum > 5000 parasites per μL 
AND with one or more marker of disease severity  Prostration 
 Respiratory distress 
 Blantyre score  2 
 Seizures 2 or more 
 Hypoglycemia < 2.2 mmol/L 
 Acidosis BE -10.0 mmol/L 
 Lactate  5.0 mmol/L 
 Anemia < 5.0 g/dL 
AND without diagnosis of a co-morbidity   Radiographically proven pneumonia 
 Meningitis on CSF examination 
 Positive blood culture 
 Gastroenteritis with dehydration 
 Prostration is defined as, in an acutely sick child, the inability to perform 
previously-acquired motor function: in a child previously able to stand, inability to 
stand; in a child previously able to sit, inability to sit and in a very young child, 
inability to suck. 
 Respiratory distress is defined as lower chest wall indrawing or abnormally deep 
breathing. 
 2 or more seizures occurring in the total time period including 24 h prior to 
admission, the emergency room and the hospitalization. 
 Radiographically proven pneumonia is a consolidation or pleural effusion as 
defined in Appendix G on a chest x-ray taken within 72 h of admission. 
 Meningitis on CSF examination is defined as WC  50 x10 6/L or positive culture 
of compatible organism or latex agglutination positive for Hib, pneumococci or 
meningococci [Berkley, 2001]. 
 Gastroenteritis with dehydration is defined as a history of 3 or more loose or 
watery stools in previous 24 h and an observed watery stool with decreased skin 
turgor (> 2 seconds for skin to return following skin pinch). 
 Positive blood culture as defined in Appendix H on a blood culture taken within 
72 h of admission. 
Secondary case definitions of severe malaria disease are given in Table 9. Note that HIV 
testing will be guided by clinical judgment and local policy and informed consent and 
counseling will always be performed. 
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Table 9 Secondary case definitions of severe malaria disease 
2  definition 1 
“with co-morbidity” 
P. falciparum > 5000 parasites per μL 
AND with one or more marker of disease severity 
2  definition 2 
“without a density threshold” 
P. falciparum > 0 
AND with one or more marker of disease severity 
AND without diagnosis of a co-morbidity 
2  definition 3 
“without HIV” 
P. falciparum > 5000 parasites per μL 
AND with one or more marker of disease severity 
AND without diagnosis of a co-morbidity  
AND without a confirmed diagnosis of HIV infection 
5.2.3. Malaria hospitalization 
Table 10 Case definitions for malaria hospitalization 
Definition 1 A medical hospitalization with confirmed P. falciparum > 5000 parasites/μL  
(excludes planned admissions for medical investigation/care or elective surgery and trauma) 
Definition 2 A hospitalization which, in the judgment of the principal investigator, P. falciparum infection 
was the sole or a major contributing factor to the presentation 
5.2.4. Fatal malaria 
Table 11 Case definitions for fatal malaria 
1  definition A case of severe malaria meeting the primary case definition of severe malaria 
disease (see Table 8) with a fatal outcome  
(i.e. is restricted to hospital mortality and does not include cause ascribed by verbal 
autopsy). 
2  definition 1 
“with co-morbidity” 
A case of severe malaria meeting the secondary case definition 1 severe malaria 
disease (see Table 9) with a fatal outcome  
2  definition 2 
“without a density threshold” 
A case of severe malaria meeting the secondary case definition 2 severe malaria 
disease (see Table 9) with a fatal outcome 
2  definition 3 
“without HIV” 
A case of severe malaria meeting the secondary case definition 3 severe malaria 
disease (see Table 9) with a fatal outcome 
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5.2.5. Severe anemia 
Table 12 Case definitions of incident severe anemia 
Definition 1 
A documented hemoglobin < 5.0 g/dL identified at clinical presentation to 
morbidity surveillance system in association with a P. falciparum parasitemia > 
5000 parasites/μL 
Definition 2 
A documented hemoglobin < 5.0 g/dL identified at clinical presentation to 
morbidity surveillance system in association with a P. falciparum parasitemia > 0 
parasites/μL 
Definition 3 A documented hemoglobin < 5.0 g/dL identified at clinical presentation to 
morbidity surveillance system 
Table 13 Case definitions of prevalent anemia 
Prevalent severe anemia A documented hemoglobin < 5.0 g/dL identified at a cross sectional survey 
Prevalent moderate anemia A documented hemoglobin < 8.0 g/dL identified at a cross sectional survey 
5.2.6. All hospitalizations 
Table 14 Case definitions for all medical hospitalization 
1  definition A medical hospitalization of any cause  
(excludes planned admissions for medical investigation/care or elective surgery and trauma) 
5.2.7. All-cause mortality 
Table 15 Case definitions for all-cause mortality 
Definition 1 A fatality (of any cause)  
(includes mortality in the community and in hospital) 
Definition 2 A fatality (medical cause)  
(includes mortality in the community and in hospital) 
(excludes trauma, which may be diagnosed by verbal autopsy) 
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5.2.8. Pneumonia 
Pneumonia will be diagnosed based on symptoms and signs and CXR occurring at 
presentation according to the case definitions in Table 16. 
Table 16 Case definitions for pneumonia 
Amended 26 November 2009 
1  definition cough or difficulty breathing (on history)  
AND tachypnea 
AND lower chest wall indrawing 
2  definition 1 1  case definition of pneumonia 
AND CXR consolidation or pleural effusion as defined in Appendix G on a chest 
x-ray taken within 72 h of admission. 
2  definition 2 1  case definition of pneumonia 
AND CXR consolidation or pleural effusion or other infiltrates as defined in 
Appendix G on a chest x-ray taken within 72 h of admission. 
2  definition 3 1  case definition of pneumonia 
AND an oxygen saturation less than 90% 
 Tachypnea (  50 breaths per minute < 1 year,  40 breaths per minute  1year). 
5.2.9. Sepsis 
Table 17 Case definitions for sepsis 
1  definition A child with positive blood culture 
 Positive blood culture as defined in Appendix H, on a blood culture taken within 72 
hours of admission. 
5.3. Efficacy endpoint capture 
5.3.1. Surveillance for clinical malaria disease 
All subjects presenting to health facilities in the study area will be evaluated as potential 
cases of clinical malaria disease. A blood sample for the evaluation of malaria parasites 
will be taken for all children who are reported to have had a fever within 24 hours of 
presentation or have a measured axillary temperature of 37.5 C. 
Data points that will be captured in the CRF/eCRF for all cases of suspected clinical 
malaria disease are: history of fever; temperature; parasite density; treatment 
administered. 
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Note that the data on all subjects investigated for malaria will be captured in the 
CRF/eCRF regardless of whether the case was confirmed. 
The clinical management of subjects presenting with suspected malaria is described in the 
site-specific documentation accompanying this protocol.  
A blood sample for parasite genotyping will be taken for any subject investigated for 
malaria. 
Amended 24 October 2008 
5.3.2. Surveillance for severe malaria disease 
All subjects presenting for admission through the outpatient and emergency departments 
of hospitals in the study areas will be evaluated as potential cases of severe malaria 
disease following the algorithm in Appendix E. 
During the hospitalization, the subject’s course will be monitored to capture the signs and 
blood parameters indicative of severe malaria disease. If the subject’s condition changes 
from admission and he/she meets one of the criteria for additional investigations, these 
will be performed. 
Harmonization of case evaluation across centers will be assured by training of clinicians 
in the assessment of clinical signs and the standardization of equipment and processes 
used for laboratory investigations (refer to Appendix E to Appendix I). On all 
admissions, data will be captured to support the endpoints of clinical malaria disease, 
severe malaria disease, other serious illness, malaria-specific and all medical 
hospitalization and mortality. 
The clinical management of subjects presenting with suspected malaria is described in the 
site-specific documentation accompanying this protocol. 
A blood sample for parasite genotyping will be taken for any subject investigated for 
malaria. 
Amended 24 October 2008 
5.3.3. Cross-sectional surveys 
Two cross-sectional surveys to assess VE against prevalent parasitemia and anemia will 
be performed at 18 months post Dose 3 and 12 months post boost. 
Children who are symptomatic at cross-sectional surveys will be assessed by a clinician 
and managed as appropriate. 
At these visits, a blood sample will be taken for parasite genotyping. 
Amended 24 October 2008 
5.3.4. Cross-sectional survey in the extension 
Depending on the date of the last visit in the initial study (Visit 34), subjects will have up 
to 2 blood samples (Visit 36 and Visit 38) during this extension to measure asexual 
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P. falciparum density, parasite genotyping and hemoglobin, and to perform, in a 
immunology subset, anti-CS antibody testing. 
Children who are symptomatic at these cross-sectional surveys will be assessed by a 
clinician and managed as appropriate. 
Amended 01 December 2010 
5.3.5. Verbal autopsy process 
Verbal autopsies (VA) will be carried out on all children who die outside a health facility 
to ascribe the cause of death. The questionnaire used will be based on the INDEPTH 
standard and adapted to be locally appropriate [WHO, 2007]. To support the timely 
reporting of SAEs, the diagnoses will be made according to the usual processes of each 
centre. 
At study end and at the end of the extension, all forms will be read by a central panel 
composed of 3 experienced VA reviewers. Each form will be read by each of the three 
reviewers independently. They will record 1) the disease or condition directly leading to 
death, 2) any morbid conditions leading to the condition that directly causes death and 3) 
any other significant conditions contributing to the death, but not related to the disease or 
condition causing it [SAVVY, 2006]. The diagnoses will be coded according to an 
adapted form of the International Classification Disease (ICD). If a minimum of 2 
reviewers are in agreement a cause of death is ascribed. If there is no agreement between 
the three reviewers a consensus meeting will be held where an agreement is reached 
wherever possible or the cause of death is recorded as unknown. 
Amended 19 August 2008 
Amended 01 December 2010 
5.4. Subject identification 
Subject numbers will be assigned sequentially to subjects consenting to participate in the 
study, according to the range of subject numbers allocated to each study centre. 
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5.5. Outline of study procedures 
Table 18 List of study procedures 
 Screen 1 Dose 1  Dose 2  Dose 3      Boost     End 
STUDY DAY -30 to 0 0 1 to 6 30 31 to 36 60 61 to 66      B +1 to 
B +6 
    
STUDY MONTH -1 to 0 0  1  2  3 4-13 14 15-19 20  21 22-30 31 32 
VISIT 1 2 a to f 3 g to l 4 m to q 5 6-15 30 16 17-21 30 22 r to w 23 24-32 30 33 34 
STUDY PROCEDURES                  
Informed consent ●                 
Assign Subject Number ●                 
Issue identification card ○                 
Check identification card  ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ 
Collect demographics 2 ○ ●                
Medical history ○ ● 3                
Physical examination ○ ●  ○  ○      ○      
Anthropometry 4  ●  ○5  ○5  ●6    ●     ● 
Temperature (prior to vaccination)  ●  ●  ●      ●      
Check inclusion/exclusion criteria ● ●                
Randomization  ● 7                
Assign treatment number  ●                
Check elimination criteria     ●  ●  ● ● ● ● ●  ● ● ● ● 
Check contraindications to vaccination  ●  ●  ●      ●      
Administer & document study vaccine (RTS,S 
or comparator) 
 ●  ●  ●      ●      
Administer & document TritanrixHepB/Hib6  ●  ●  ●            
Administer & document OPV6  ●  ●  ●      ●      
Record previous doses of Hepatitis B vaccine  ●                
Record previous doses of BCG and OPV6  ●                
Recording of pneumococcal vaccine doses 9  ●      ●    ●     ● 
Recording of Hemophilus vaccine doses 10  ●      ●    ●     ● 
Recording of Vitamin A administration9  ●      ●    ●     ● 
Recording of doses of IPTi 11  ●      ●    ●     ● 
Recording of concomitant EPI vaccine doses 12  ●  ●  ●  ●    ●  ●    
Recording of concomitant medication 13  ● ● ● ● ● ● ●    ● ● ●    
Record distance to nearest inpatient facility  ●          ●      
Record distance to nearest outpatient facility  ●          ●      
Document feeding history 15            ●      
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 Screen 1 Dose 1  Dose 2  Dose 3      Boost     End 
STUDY DAY -30 to 0 0 1 to 6 30 31 to 36 60 61 to 66      B +1 to 
B +6 
    
STUDY MONTH -1 to 0 0  1  2  3 4-13 14 15-19 20  21 22-30 31 32 
VISIT 1 2 a to f 3 g to l 4 m to q 5 6-15 30 16 17-21 30 22 r to w 23 24-32 30 33 34 
Documentation of bednets and residual 
spraying 16 
         ●      ●  
Participation status review 17          ●  ●     ● 
SAFETY DATA                   
Recording of solicited symptoms 18, 19  ● ● ● ● ● ●     ● ●     
Recording of unsolicited AEs 20, 21, 28  ● ● ● ● ● ● ●    ● ● ●    
Morbidity surveillance/record SAEs 20 ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● 
Recording of AEs of specific interest 29 ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● 
Document rescue plan22                 ● 
EFFICACY DATA                  
Clinical Malaria Disease 23  ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● 
Severe malaria, hospitalization, other serious 
illness 
 ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● 
BLOOD COLLECTION                  
Blood sample taken ●       ●    ●  ●   ● 
Parasite density            ●     ● 
Parasite genotyping            ●     ● 
Hemoglobin ●       ●    ●  ●   ● 
Antibodies to CS 24 ●        ●    ●  ●   ● 
Antibodies to HBs 25 ●        ● 26    ●  ●   ● 
Antibodies to polio serotypes 1, 2 and 327 ●       ●      ●    
ANALYSIS                  
Primary analysis 14½ months post Dose 1          ●        
Secondary analysis at Month 20            ●      
Secondary analysis for polio serotypes 1, 2 and 
3 antibody responses 
             ●    
Final analysis                 ● 
 
Amended 19 August 2008 
Amended 24 October 2008 
Amended 01 December 2010 
Amended 23 January 2012 
Table notes overleaf 
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Table notes 
1. All children must be > 28 days of age at screening. 
2. Including sex, date of birth, ethnicity, gestation (gestation to be solicited in children in the 6 to 12 week age category only). 
3. Known HIV positivity will be documented at enrollment (not an exclusion criterion). 
4. Anthropometry consists of length/height (children < 2 years, measure length: children  2 years measure standing height), weight, mid-upper arm circumference (Refer to Appendix K). 
5. Measure weight only: to be carried out in children in 6 to 12 week age category only. 
6. In 6 to 12 week age category only. 
7. Randomization must occur after informed consent and completion of screening activities, but may be done in preparation for visit 2. 
9. Since birth or previous enquiry. Record dates of doses. 
10. In children in 5 to 17 month age category only. Since birth or previous enquiry. Record dates of doses. 
11. i.e. Intermittent Preventative Treatment for Malaria (Infants). Since birth or previous enquiry. Record dates of doses. 
12. Record concomitant vaccine doses not specified per protocol (i.e. within 30 days of a vaccine dose. e.g. measles, polio mass vaccination) 
13. For the first 200 children enrolled in each age category at each site, record concomitant medication (anti-pyretics, analgesics, systemic antibiotics on the 6 days subsequent to vaccination)  
15. Refer to Section 5.6 for wording of questions. 
16. Refer to Appendix J. 
17. i.e. Study conclusion page of the primary trial phase, detailed in Section 9.2.1. 
18. First 200 subjects enrolled in each age category at each site will be evaluated. 
19. Solicited symptoms are listed in Section 8.4.1. For the evaluation of fever, subject’s temperature should be recorded in the CRF/eCRF. 
20. Seizures occurring within 7 days of vaccination will be recorded in the CRF/eCRF as mentioned in Section 8.2. 
21. Ongoing surveillance at health facilities will be captured in appropriate CRF/eCRF module. 
22. Document in CRF the date of hepatitis B booster administration if in accordance with rescue plan. 
23. Data points to be collected are specified at each presentation with suspected clinical malaria disease (see Section 5.3.1). 
24. All subjects will have specimens taken:  to evaluate vaccine response, the first 200 subjects in each age category at each site will be analyzed; to evaluate correlates of protection, a 
subset will be analyzed ; to evaluate the vaccine response in ‘special subgroups’ a subset will be analyzed.  
25. All subjects will have specimens taken. To evaluate vaccine response: 
 
the first 200 subjects in each age category at each site at the first 2 timepoints will be analyzed.  
to evaluate the vaccine response in ‘special subgroups’ a subset will be analyzed.  
26. All samples in the 6 to 12 week category will be analyzed to support a rescue plan of hepatitis B response in children in the 6 to 12 week age category. 
27. First 200 subjects enrolled in the 6 to 12 week age category at each site will be sampled. 
28. All unsolicited AEs will be reported for 30 days following each vaccine dose for the first 200 children enrolled in each age category at each site and reported in the CRF/eCRF. 
     For all subjects, unsolicited AEs judged to be related to vaccination or leading to drop out occurring within 30 days following administration of each dose of vaccine will be recorded in  
      the CRF/eCRF. 
29. AEs of specific interest include seizures, rashes and mucocutaneous lesions within 30 days of vaccination, and immune-mediated disorders (IMD) over the entire study period. Refer to Section 
8.4.1 for the details on reporting requirements for each AE of specific interest. 
30. To fulfill the obligation of monthly contacts with all subjects, where home visits are conducted in addition to the scheduled visits, these should be recorded in the Additional Follow-up Visits module 
of the CRF/eCRF. 
● is used to indicate a study procedure that requires documentation in the individual CRF/eCRF: ○ is used to indicate a study procedure that does not require documentation in the individual 
CRF/eCRF. 
Amended 19 August 2008 
Amended 26 November 2009 
Amended 01 December 2010 
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Table 19 List of study procedures of the extension 
     
STUDY DAY     
STUDY MONTH 32 44 55 56 
VISIT 35 36 9 37 38 
STUDY PROCEDURES     
Informed consent addendum ●    
Check identification card ○ ○ ○ ○ 
Check inclusion criteria for extension ●    
Check elimination criteria  ●  ● 
Anthropometry 1  ●  ● 
Recording of pneumococcal vaccine doses 9  ●  ● 
Recording of Vitamin A administration 2  ●  ● 
Recording of concomitant medication 3  ●  ● 
Record distance to nearest inpatient facility    ● 
Record distance to nearest outpatient facility    ● 
Documentation of bednets and residual spraying 4   ●  
Participation status review 5    ● 
SAFETY DATA      
Morbidity surveillance/record SAEs 6 ● ●  ● 
Recording of IMDs 11 ● ●  ● 
EFFICACY DATA     
Clinical Malaria Disease 7 ● ●  ● 
Severe malaria, hospitalization, other serious 
illness 
● ● 
 
● 
BLOOD COLLECTION     
Blood sample taken 10  ●  ● 
Parasite density  ●  ● 
Parasite genotyping  ●  ● 
Hemoglobin  ●  ● 
Antibodies to CS 8  ●  ● 
ANALYSIS     
Extension analysis    ● 
 
Amended 01 December 2010 
Amended 08 August 2012 
Table notes overleaf 
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Table notes 
1. Anthropometry consists of length/height (children < 2 years, measure length: children  2 years measure standing height), weight, mid-upper arm circumference (Refer to Appendix K). 
2. Since birth or previous enquiry. Record dates of doses. 
3. Refer to Section 6.9.2  
4. Use of bednets and residual spraying will be checked once during the extension at Visit 37, between 1 and 30 days before Visit 38. 
5. i.e. Study conclusion page of the extension, detailed in Section 9.2.1. 
6. All SAEs will be recorded in the CRF/eCRF as mentioned in Section 8.2. 
7. Data points to be collected are specified at each presentation with suspected clinical malaria disease (see Section 5.3.1). These data will only be collected from all subjects of each of the at 
least 3 selected sites. 
8. Anti-CS antibody samples will be collected only on the first 200 subjects in each age category of the primary trial phase of each of the at least 3 selected sites.  
9. Subjects having their Visit 34 after 30 June 2012 and before (and including) 30 September 2013 will not have Visit 36. 
10. Subjects having their Visit 34 between 1 July 2012 and 30 September 2013 will have one blood sample taken at Visit 38. The first 200 subjects in each of the at least 3 selected sites will 
have 1.05 mL blood samples taken, and these samples will be analyzed, to evaluate the immunological vaccine response. From all other subjects, blood samples of 0.45 mL will be analysed. 
11. AEs of specific interest include seizures, rashes and mucocutaneous lesions within 30 days of vaccination, and immune-mediated disorders (IMD) over the entire study period. Refer to 
section 8.4.1 for the details on reporting requirements for each AE of specific interest. 
● is used to indicate a study procedure that requires documentation in the individual CRF/eCRF. 
 ○ is used to indicate a study procedure that does not require documentation in the individual CRF/eCRF. 
 
Amended 01 December 2010 
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It is the investigator’s responsibility to ensure that the intervals between visits/contacts, 
tabulated in Table 20 are strictly followed. 
Table 20 Intervals between study visits 
Interval Length of interval 
Visit 2  Visit 3 21 to 42 days 
Visit 3  Visit 4 21 to 42 days 
Visit 4  Visit 5 21 to 42 days 
Visit 4  Visit 16 12 months  1 month*,** 
Visit 4  Visit 22 18 months  1 month 
Visit 22  Visit 23 21 to 42 days 
Visit 22  Visit 34 12 months  1 month*** 
* For first 6000 5-17 months old children or February 2011 at the latest, even if 
the length of the interval is less than indicated 
** For all 6-12 weeks old infants or April 2012 at the latest, even if the length of 
the interval is less than indicated 
*** For all children: December 2013 at the latest, even if the length of the interval 
is less than indicated 
Amended 01 December 2011 
5.5.1. Intervals between study visits for the extension 
Table 21 Intervals between study visits for subjects that have their last visit in 
the primary trial phase (Visit 34) BEFORE (and including) 30 Jun 
2012 
Interval Optimal time for study visit 
(Study Months) 
Maximum interval 
allowed 
Visit 35 On same day as Visit 34* 
(Study Month 32) 
Maximum interval: Visit 
2 + 44 months 
Visit 34 Visit 36 12 months** 
(Study Month 44) 
Range: 11 to 13 months 
 
Visit 34 Visit 37§ 
(Field workers visit) 
Nov 2013 
23 months** 
(Study Month 55) 
Date: Oct 2013 to Dec 
2013  
Visit 34 Visit 38 Dec 2013 
24 months** 
(Study Month 56) 
Date: Nov 2013 to Jan 
2014  
* If subjects are not present at Visit 34, Visit 35 should be scheduled as soon as possible 
and up to a maximum of 12 months after Visit 34, assuming Visit 34 should have occurred 
at Visit 2 + 32 months 
** If subjects are not present at Visit 34, Visit 36, 37 and 38 should be scheduled 
assuming Visit 34 should have occurred at Visit 2 + 32 months 
§Visit 37 (Field workers visit) has to be conducted between 1 and 30 days before Visit 38. 
Amended 08 August 2012 
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Table 22 Intervals between study visits for subjects that have their last visit in 
the primary trial phase (Visit 34) after 30 Jun 2012 and BEFORE (and 
including) 30 Sep 2013 
Interval Optimal time for study visit 
(Study Months) 
Maximum interval 
allowed 
Visit 35 
On same day as Visit 34* 
(Study Month 32) 
Maximum interval: Visit 
2 + 44 months or 30 Sep 
2013 at the latest 
Visit 34 Visit 37§ 
(Field workers visit) 
Nov 2013 
11 months** 
(Study Month 43) 
Date: Oct 2013 to Dec 
2013 
Visit 34 Visit 38 Dec 2013 
12 months** 
(Study Month 44) 
Date: Nov 2013 to Jan 
2014  
* If subjects are not present at Visit 34, Visit 35 should be scheduled as soon as possible 
and up to a maximum of 12 months after Visit 34, assuming Visit 34 should have occurred 
at Visit 2 + 32 months. No subjects will be enrolled for Visit 35 after 30 September 2013. 
** If subjects are not present at Visit 34, Visit 37 and 38 should be scheduled assuming 
Visit 34 should have occurred at Visit 2 + 32 months 
§Visit 37 (Field workers visit) has to be conducted between 1 and 30 days before Visit 38. 
Amended 01 December 2010 
Amended 08 August 2012 
5.6. Detailed description of study stages/visits 
When materials are provided by GSK Biologicals, it is MANDATORY that all clinical 
samples (including serum samples) will be collected and stored using exclusively those 
materials in the appropriate manner. The use of other materials could result in the 
exclusion of the subject from the ATP analysis (See Section 10.6 for definition of study 
cohorts to be evaluated). The investigator must ensure that his/her personnel and the 
laboratory(ies) under his/her supervision comply with this requirement. However, when 
GSK Biologicals does not provide material for collecting and storing clinical samples, 
then appropriate materials from the investigator’s site are to be used. Refer to Appendix 
B and Appendix C. 
The vaccinees will be observed closely for at least 30 minutes, with appropriate medical 
treatment readily available in case of an anaphylactic reaction following the 
administration of vaccines. 
The subjects’ parents/guardians will be instructed to contact the investigator immediately 
should the subject manifest any signs or symptoms they perceive as serious. 
Study Visits Amended 19 August 2008 
Study Visits Amended 24 October 2008 
Study Visits Amended 01 December 2010 
Visit 1: Screening 
Day -30 to Day 0 
 Obtain signed, dated, thumb printed informed consent from the parent(s)/guardian(s). 
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 Assign subject number. 
 Issue identification card. 
 Check inclusion/exclusion criteria. 
 Collect demographics. 
- Gestation at birth will be solicited in children in the 6 to 12 week age category 
by the question ‘was the baby born in the 37th week of gestation or later?’. If no, 
the approximate duration of gestation in weeks, at birth will be recorded.  
 Carry out physical examination and take medical history. 
 Blood sample to collect 1.8 mL blood for analysis of: 
- Hemoglobin. 
- Serology (antibodies to CS, HBs and polio 1, 2, 3). 
 Record any SAEs that may have occurred as a result of study procedures. 
Visit 2: Vaccination 1 
Day 0 
 Check study identification card of vaccinee. 
 Collect demographics. 
 Carry out physical examination, take medical history, anthropometry. 
 Check inclusion/exclusion criteria. 
 Check contraindications to vaccination. 
 Randomize subject (note: must occur after informed consent). 
 Record pre-vaccination body temperature. 
 Record previous doses of hepatitis B vaccine and pneumococcal vaccine. 
 Record previous doses of Hemophilus vaccine (vaccinees in the 5 to 17 month age 
category only) since birth. 
 Record previous doses of BCG and OPV since birth (vaccinees in the 6 to 12 week 
age category only).  
 Record previous Vitamin A administration since birth. 
 Record concomitant vaccine doses not specified per protocol (i.e. within 30 days of a 
vaccine dose. e.g. measles, polio mass vaccination). 
 Record previous doses of IPTi. 
 Record distance to nearest inpatient and to nearest outpatient facility. 
 Record Treatment Number. 
 Administer the first dose of RTS,S/AS01E or comparator vaccine. 
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 Administer in infants of the 6 to 12 weeks age category, OPV and the first dose of 
TritanrixHepB/Hib. 
Each child will be assessed for at least 30 minutes after vaccination to evaluate and treat 
any acute adverse events. Advise parents to contact the investigator immediately if their 
child manifests any signs or symptoms they perceive as serious.  
 Record any post-vaccination SAEs. 
 Record any post-vaccination unsolicited adverse events. 
 In first 200 children in each age category at each site only:  
- Record any post-vaccination solicited symptoms. 
- Record concomitant medication (anti-pyretics, analgesics, systemic antibiotics 
on the day of vaccination). 
Follow-up visits a to f 
Days 1, 2, 3, 4, 5 and 6 
these visits are only for the first 200 subjects in each age category enrolled at each site 
 Check study identification card of vaccinee. 
 Record local (pain, redness and swelling at the injection site) and general (fever, 
irritability / fussiness, drowsiness, loss of appetite) solicited adverse events. 
 Record SAEs experienced by the vaccinee since the last visit. 
 Record unsolicited adverse events experienced by the vaccinee since the last visit. 
 Record concomitant medication (anti-pyretics, analgesics, systemic antibiotics on the 
6 days subsequent to vaccination). 
Visit 3: Vaccination 2 
Day 30 
 Check study identification card of vaccinee. 
 Carry out physical examination. 
 Measure body weight in infants from the 6 to 12 weeks age category only. 
 Check contraindications to vaccination. 
 Check elimination criteria. 
 Record pre-vaccination body temperature. 
 Record concomitant vaccine doses not specified per protocol (i.e. within 30 days of a 
vaccine dose. e.g. measles, polio mass vaccination). 
 Administer the second dose of RTS,S/AS01E or comparator vaccine. 
 Administer in infants of the 6 to 12 weeks age category, OPV and the second dose of 
TritanrixHepB/Hib. 
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Each child will be assessed for at least 30 minutes after vaccination to evaluate and treat 
any acute adverse events. Advise parents to contact the investigator immediately if their 
child manifests any signs or symptoms they perceive as serious. 
 Record any post-vaccination SAEs. 
 Record any post-vaccination unsolicited adverse events. 
 In first 200 children in each age category at each site only: 
- Record any post-vaccination solicited symptoms. 
- Record concomitant medication (anti-pyretics, analgesics, systemic antibiotics 
on the day of vaccination). 
Follow-up visits g to l 
Days 31, 32, 33, 34, 35 and 36 
these visits are only for the first 200 subjects in each age category enrolled at each site 
 Check study identification card of vaccinee. 
 Record local (pain, redness and swelling at the injection site) and general (fever, 
irritability / fussiness, drowsiness, loss of appetite) solicited adverse events. 
 Record SAEs experienced by the vaccinee since the last visit. 
 Record unsolicited adverse events experienced by the vaccinee since the last visit. 
 Record concomitant medication (anti-pyretics, analgesics, systemic antibiotics on the 
6 days subsequent to vaccination). 
Visit 4: Vaccination 3 
Day 60 
 Check study identification card of vaccinee. 
 Carry out physical examination. 
 Measure body weight in infants from the 6 to 12 weeks age category only. 
 Check contraindications to vaccination. 
 Check elimination criteria. 
 Record pre-vaccination body temperature. 
 Record any post-vaccination SAEs. 
 Record concomitant vaccine doses not specified per protocol (i.e. within 30 days of a 
vaccine dose. e.g. measles, polio mass vaccination). 
 Administer the third dose of RTS,S/AS01E or comparator vaccine. 
 Administer in infants of the 6 to 12 weeks age category, OPV and the third dose of 
TritanrixHepB/Hib. 
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Each child will be assessed for at least 30 minutes after vaccination to evaluate and treat 
any acute adverse events. Advise parents to contact the investigator immediately if their 
child manifests any signs or symptoms they perceive as serious. 
 Record any post-vaccination SAEs. 
 Record any post-vaccination unsolicited adverse events. 
 In first 200 children in each age category at each site only: 
- Record any post-vaccination solicited symptoms. 
- Record concomitant medication (anti-pyretics, analgesics, systemic antibiotics 
on the day of vaccination). 
Follow-up visits m to q 
Days 61, 62, 63, 64, 65 and 66 
these visits are only for the first 200 subjects in each age category enrolled at each site 
 Check study identification card of vaccinee. 
 Record local (pain, redness and swelling at the injection site) and general (fever, 
irritability / fussiness, drowsiness, loss of appetite) solicited adverse events. 
 Record SAEs experienced by the vaccinee since the last visit. 
 Record unsolicited adverse events experienced by the vaccinee since the last visit. 
 Record concomitant medication (anti-pyretics, analgesics, systemic antibiotics on the 
6 days subsequent to vaccination). 
Visit 5: follow up post Dose 3 
Month 3 
 Check study identification card of vaccinee. 
 Measure anthropometry in infants from the 6 to 12 weeks age category only. 
 Record concomitant vaccine doses not specified per protocol (i.e. within 30 days of a 
vaccine dose. e.g. measles, polio mass vaccination). 
 Record unsolicited adverse events experienced by the vaccinee since the last visit. 
 Record SAEs experienced by the vaccinee since the last visit. 
 Check elimination criteria. 
 Record pneumococcal vaccine doses since visit 2. 
 Record Hemophilus vaccine doses since visit 2 in vaccinees in the 5 to 17 month old 
category only. 
 Record IPTi doses since visit 2. 
 Record Vitamin A administration since visit 2. 
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 Record doses of IPTi since visit 2. 
 Blood sample: 
- First 200 children vaccinated in each site in the 6 to 12 week old category: 
1.8 mL blood for analysis of: 
Hemoglobin. 
Serology (antibodies to CS, HBs, polio 1, 2, 3). 
- All other children 1.2 mL blood for analysis of: 
Hemoglobin. 
Serology (antibodies to CS, HBs). 
 In first 200 children in each age category at each site only:  
- Record concomitant medication (anti-pyretics, analgesics, systemic antibiotics 
on the 6 days subsequent to vaccination). 
Visits 6 to 15: follow up post Dose 3 
Months 4 to 13 
 Check study identification card of vaccinee. 
 Check elimination criteria. 
 Record SAEs experienced by the vaccinee since the last visit. 
Visits 16: follow up post Dose 3 
Month 14 
For first 6000 5-17 months old children or February 2011 at the latest, even if the length 
of the interval is less than indicated 
For all 6-12 weeks old infants or April 2012 at the latest, even if the length of the interval 
is less than indicated 
 Check study identification card of vaccinee. 
 Check elimination criteria. 
 Document bednet use and residual spraying (refer to Appendix J). 
 Participation status review. 
 Record SAEs experienced by the vaccinee since the last visit. 
Visits 17 to 21: follow up post Dose 3 
Months 15 to 19 
 Check study identification card of vaccinee. 
 Check elimination criteria. 
 Record SAEs experienced by the vaccinee since the last visit. 
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Visit 22: Booster Vaccination 
Month 20 
 Check study identification card of vaccinee. 
 Carry out physical examination, anthropometry. 
 Check contraindications to vaccination. 
 Check elimination criteria. 
 Record covariates (distance to nearest inpatient and to nearest outpatient facility). 
 Document feeding history: 
- record whether or not child is currently breastfeeding.  
if NO: record age (in months) at which breastfeeding was stopped.  
- record age of introduction of solid food. 
- record whether child was bottle-fed with milk formula as a young infant 
 Record pneumococcal vaccine doses since visit 5. 
 Record Hemophilus vaccine doses since visit 5 in vaccinees in the 5 to 17 month old 
category only. 
 Record IPTi doses since visit 5. 
 Record pre-vaccination body temperature. 
 Record Vitamin A administration since visit 5. 
 Record concomitant vaccine doses not specified per protocol (i.e. within 30 days of a 
vaccine dose. e.g. measles, polio mass vaccination). 
 Record concomitant medication. 
 Participation status review. 
 Administer the booster dose of RTS,S/AS01E or comparator vaccine.  
 Administer in infants of the 6 to 12 weeks age category OPV. 
Each child will be assessed for at least 30 minutes after vaccination to evaluate and treat 
any acute adverse events. Advise parents to contact the investigator immediately if their 
child manifests any signs or symptoms they perceive as serious. 
 Record any post-vaccination SAEs. 
 Record any post-vaccination unsolicited adverse events. 
 In first 200 children in each age category at each site only:  
- Record any post-vaccination solicited symptoms. 
- Record concomitant medication (anti-pyretics, analgesics, systemic antibiotics 
on the day of vaccination). 
 Blood sample to collect 1.2 mL blood for analysis of: 
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- Hemoglobin. 
- Serology (antibodies to CS, HBs). 
 In addition, blood will be drawn from all subjects for:  
- Blood sample for malaria parasite density. 
- Blood sample for parasite genotyping. 
Follow-up visits r to w 
Days Boost +1, +2, +3, +4, +5 and +6 
these visits are only for the first 200 subjects in each age category enrolled at each site 
 Check study identification card of vaccinee. 
 Record concomitant medication (anti-pyretics, analgesics, systemic antibiotics on the 
6 days subsequent to vaccination). 
 Record local (pain, redness and swelling at the injection site) and general (fever, 
irritability / fussiness, drowsiness, loss of appetite) solicited adverse events. 
 Record SAEs experienced by the vaccinee since the last visit. 
 Record unsolicited adverse events experienced by the vaccinee since the last visit. 
Visit 23: follow up post Booster 
Month 21 
 Check study identification card of vaccinee. 
 Record concomitant vaccine doses not specified per protocol (i.e. within 30 days of a 
vaccine dose. e.g. measles, polio mass vaccination). 
 Check elimination criteria. 
 Record unsolicited adverse events experienced by the vaccinee since the last visit. 
 Record SAEs experienced by the vaccinee since the last visit. 
 In first 200 children in each age category at each site only: 
- Record concomitant medication (anti-pyretics, analgesics, systemic antibiotics 
on the 6 days subsequent to vaccination). 
 Blood sample:  
- First 200 children vaccinated in each site in the 6 to 12 week old category: 
1.8 mL blood for analysis of: 
Hemoglobin. 
Serology (antibodies to CS, HBs, polio 1, 2, 3). 
- All other children 1.2 mL blood for analysis of: 
Hemoglobin. 
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Serology (antibodies to CS, HBs). 
Visits 24 to 32: follow up post Booster 
Months 22 to 30 
 Check study identification card of vaccinee. 
 Check elimination criteria. 
 Record SAEs experienced by the vaccinee since the last visit. 
Visit 33: follow up post Booster 
Month 31 
 Check study identification card of vaccinee. 
 Check elimination criteria. 
 Record SAEs experienced by the vaccinee since the last visit. 
 Document bednet use and residual spraying. 
Visit 34: follow up post Booster 
Month 32 
For all children: December 2013 at the latest, even if the length of the interval is less 
than indicated 
 Check study identification card of vaccinee. 
 Anthropometry. 
 Participation status review. 
 Record SAEs experienced by the vaccinee since the last visit. 
 Check elimination criteria. 
 Record pneumococcal vaccine doses since visit 22. 
 Record Hemophilus vaccine doses since visit 22 in vaccinees in the 5 to 17 month 
old category only. 
 Record IPTi doses since visit 22. 
 Record Vitamin A administration since visit 22. 
 Document rescue plan. 
 Blood sample to collect 1.2 mL blood for analysis of: 
- Hemoglobin. 
- Serology (antibodies to CS, HBs). 
 In addition, blood will be drawn from all subjects for:  
- Blood sample for malaria parasite density. 
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- Blood sample for parasite genotyping. 
5.7. Detailed description of study visits during the extension 
Depending on the date of the last visit in the primary trial phase (Visit 34), subjects will 
have up to 3 clinic visits plus one field workers visit during this extension. If a subject 
does not attend Visit 34, the schedule of the following visit(s) will be based on the 
assumption that the Visit 34 occurred 32 months post Dose 1. 
 Subjects that have their last visit in the primary trial phase (Visit 34) BEFORE (and 
including) 30 June 2012 will have 3 clinic visits plus one field workers visit in the 
extension. 
 Subjects that have their last visit in the primary trial phase (Visit 34) between 1 July 
2012 and 30 September 2013 will have 2 clinic visits plus one field workers visit in 
the extension. 
 No subjects will be enrolled in the extension study (Visit 35) after 30 September 
2013. 
Visit 35: extension 
Month 32 
Amended 08 August 2012 
 Obtain signed, dated, thumb printed informed consent addendum from the 
parent(s)/guardian(s). 
 Check study identification card of vaccinee. 
 Check inclusion criteria. 
 Record SAEs experienced by the vaccinee since the last visit. 
 Record Immune Mediated Diseases (IMDs). 
Visit 36: Extension 
Month 44 
This visit is only for subjects who had their Visit 34 before (and including) 30 June 2012 
Amended 08 August 2012 
 Check study identification card of vaccinee. 
 Check elimination criteria. 
 Anthropometry. 
 Record pneumococcal vaccine doses since the last visit. 
 Record Vitamin A administration since the last visit. 
 Recording of concomitant medication (Refer to Section 6.9.2). 
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 Record SAEs experienced by the vaccinee since the last visit. 
 Record Immune Mediated Diseases (IMDs). 
 Blood sample: 
- The first 200 children enrolled in the primary trial phase at each of at least 3 
sites collecting data on clinical malaria disease in each of the two age categories 
(6-12 week old and 5-17 month old): 1.05 mL blood for analysis of: 
Hemoglobin. 
Parasite density. 
Parasite genotyping. 
Serology (antibodies to CS). 
- All other children in the 6-12 week and 5-17 month old categories: 0.45 mL of 
blood for analysis of: 
Hemoglobin. 
Parasite density. 
Parasite genotyping. 
 Visit 37: Extension 
Field worker visit 
Month 55 or end 2013 whichever occurs earlier, and within one month before Visit 38 
November 2013 
Amended 08 August 2012 
 Check study identification card of vaccinee. 
 Document bednet use and residual spraying (refer to Appendix J). 
 Visit 38: Extension 
Month 56 or end 2013 whichever occurs earlier 
December 2013 
Amended 08 August 2012 
 Check study identification card of vaccinee. 
 Check elimination criteria. 
 Anthropometry. 
 Record pneumococcal vaccine doses since the last visit. 
 Record Vitamin A administration since the last visit. 
 Recording of concomitant medication (Refer to Section 6.9.2). 
 Record distance to nearest inpatient facility. 
 Record distance to nearest outpatient facility. 
 Participation status review. 
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 Record SAEs experienced by the vaccinee since the last visit. 
 Record Immune Mediated Diseases (IMDs). 
 Blood sample: 
- The first 200 children enrolled in the primary trial phase at each of at least 3 
sites collecting data on clinical malaria disease in each of the two age categories 
(6-12 week old and 5-17 month old): 1.05 mL blood for analysis of: 
Hemoglobin. 
Parasite density. 
Parasite genotyping. 
Serology (antibodies to CS). 
- All other children in the 6-12 week and 5-17 month old categories: 0.45 mL of 
blood for analysis of: 
Hemoglobin. 
Parasite density. 
Parasite genotyping. 
5.8. Sample handling and analysis 
5.8.1. Treatment and storage of biological samples 
See Appendix B of the protocol for details of treatment and storage of biological samples. 
See Appendix C for instructions for shipment of biological samples. 
5.8.2. Laboratory assays 
See Appendix E for indications for laboratory assays in the evaluation of potential cases 
of severe malaria disease. 
5.8.2.1. Hematology 
Hematology (hemoglobin, white blood cell counts, platelets) will be assessed using 
automated machines, in the laboratory, according to manufacturer instructions and 
standard operating procedures.  
5.8.2.2. Biochemistry 
Biochemistry (Bilirubin, ALT, creatinine) will be assessed using automated machines, in 
the laboratory, according to manufacturer instructions and standard operating procedures.  
Amended 19 August 2008 
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Glucose, lactate and base excess determination will be assessed immediately after blood 
sampling, using bed-side Abbot i-STAT
™
 portable machines or an equivalent validated 
machine [Bingham, 1999; Sediame, 1999], according to manufacturer instructions and 
standard operating procedures.  
5.8.2.3. Microbiology 
For details of microbiology testing on blood and body fluid, please refer to Appendix H. 
5.8.2.4. Parasitology 
All slides will be made in duplicate and stored. For each episode, the parasite density will 
be determined, independently by two readers and in the case of non-concordance a third 
read will be carried out.  
Methods for the sampling, reading, the criteria for concordance and the formula for the 
attribution of a final parasite density and the QC processes to assure standardization 
across sites are detailed in Appendix F. 
For the investigation of parasite genotypes, blood will be applied to Whatman FTA Mini 
Cards (or equivalent) for subsequent extraction of nucleic acid material. 
Amended 24 October 2008 
5.8.2.5. Radiology 
Methods for taking and interpreting chest x-rays (CXR) are provided in Appendix G. 
5.8.2.6. Humoral Immunology 
Table 23 Laboratory immunological assays to be performed 
Assay Marker 
Assay  
method 
Test kit/ 
Manufacturer 
Assay unit 
Assay  
cut-off 
Laboratory 
Anti-CS antibodies R32LR ELISA In-house ELISA EU/mL 0.5 CEVAC 
Anti-HBs 
antibodies 
 ELISA In-house ELISA mIU/mL 10* CEVAC 
Anti-polio 1, 2, 3 
antibodies  
 Neutralization In-house 
Dilution 
factor 
8 BIOMNIS 
*: seroprotective level  
CEVAC: Center for Vaccinology, Ghent University, Belgium 
BIOMNIS: Biomnis Recherche Clinique, Lyon, France 
ELISA: Enzyme-linked Immunosorbent Assay 
Amended 19 August 2008 
Amended 24 October 2008 
Amended 23 January 2012 
5.8.3. Blood sampling 
Samples will not be labeled with information that directly identifies the subjects but will 
be coded with the identification number for the subject. 
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Collected samples will be stored for up to 15 years (counting from when the last subject 
performed the last study visit), unless local rules, regulations or guidelines require 
different timeframes or different procedures, which will then be in line with the subject 
consent. These extra requirements need to be communicated formally to and discussed 
and agreed with GSK Biologicals. 
Table 24 Summary of blood sampling timepoints/immunological assays and 
volumes to be collected in children 6-12 weeks of age at first 
vaccination 
Blood sampling  
timepoint 
Test 
Estimated No. 
subjects 
Laboratory 
Priority 
ranking 
Volume of 
whole blood 
required 
Study 
month 
Clinic 
Visit No. 
Screening 1 
Hemoglobin 8000 on-site 1 0.2 mL 
Anti-CS antibodies 8000** CEVAC 2 
1.0 mL 
Anti-HBs antibodies 8000** CEVAC 3 
Anti-polio 1, 2, 3 
antibodies 
2000** BIOMNIS 4 0.6 mL 
    Total for Clinic Visit 1 1.8 mL† 
       
Month 3 5 
Hemoglobin 8000 on-site 3 0.2 mL 
Anti-CS antibodies 8000** CEVAC 2 
1.0 mL 
Anti-HBs antibodies 8000** CEVAC 1 
Anti-polio 1, 2, 3 
antibodies 
2000** BIOMNIS 4 0.6 mL 
    Total for Clinic Visit 5 
1.2 mL 
(1.8 mL§)† 
       
Month 20 22 
Parasite density 8000 on-site 1 --‡ 
Parasite genotyping  HSPH 5 0.25 mL- 
Hemoglobin 8000 on-site 4 0.2 mL 
Anti-CS antibodies 8000** CEVAC 2 
1.0 mL 
Anti-HBs antibodies 8000** CEVAC 3 
    Total for Clinic Visit 22 1.45 mL † 
       
Month 21 23 
Hemoglobin 8000 on-site 3 0.2 mL 
Anti-CS antibodies 8000** CEVAC 1 
1.0 mL 
Anti-HBs antibodies 8000** CEVAC 2 
Anti-polio 1, 2, 3 
antibodies 
2000** BIOMNIS 4 0.6 mL 
    Total for Clinic Visit 23 
1.2 mL 
(1.8 mL§)† 
       
Month 32 34 
Parasite density 8000 on-site 1 --‡ 
Parasite genotyping  HSPH 5 0.25 mL  
Hemoglobin 8000 on-site 4 0.2 mL 
Anti-CS antibodies 8000** CEVAC 2 
1.0 mL 
Anti-HBs antibodies 8000** CEVAC 3 
    Total for Clinic Visit 34 1.45 mL † 
       
**: a subset will be analyzed; refer to footnotes of Table 18;  †: Refer to Section 5.8.3.1 
§ 1.8 mL to be drawn only in the first 200 subjects;  ‡ A volume of 16 L is required for this test 
CEVAC: Center for Vaccinology, Ghent University, Belgium 
BIOMNIS: Biomnis Recherche Clinique, Lyon, France 
HSPH: Harvard School of Public Health, Cambridge, Massachusetts, USA 
Amended 19 August 2008, Amended 24 October 2008 
Amended 23 January 2012 
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Table 25 Summary of blood sampling timepoints/immunological assays and 
volumes to be collected in children 5-17 months of age at first 
vaccination 
Blood sampling  
timepoint 
Test 
Estimated No. 
subjects 
Laboratory 
Priority 
ranking 
Volume of 
whole blood 
required 
Study 
month 
Clinic 
Visit No. 
Screening 1 
Hemoglobin 8000 on-site 1 0.2 mL 
Anti-CS antibodies 8000** CEVAC 2 
1.0 mL 
Anti-HBs antibodies 8000** CEVAC 3 
    Total for Clinic Visit 1 1.2 mL† 
       
Month 3 5 
Hemoglobin 8000 on-site 3 0.2 mL 
Anti-CS antibodies 8000** CEVAC 1 
1.0 mL 
Anti-HBs antibodies 8000** CEVAC 2 
    Total for Clinic Visit 5 1.2 mL† 
       
Month 20 22 
Parasite density 8000 on-site 1 --‡ 
Parasite genotyping  HSPH 5 0.25 mL 
Hemoglobin 8000 on-site 4 0.2 mL 
Anti-CS antibodies 8000** CEVAC 2 
1.0 mL 
Anti-HBs antibodies 8000** CEVAC 3 
    Total for Clinic Visit 22 1.45 mL† 
       
Month 21 23 
Hemoglobin 8000 on-site 3 0.2 mL 
Anti-CS antibodies 8000** CEVAC 1 
1.0 mL 
Anti-HBs antibodies 8000** CEVAC 2 
    Total for Clinic Visit 23 1.2 mL† 
       
Month 32 34 
Parasite density 8000 on-site 1 --‡ 
Parasite genotyping  HSPH  0.25 mL 
Hemoglobin 8000 on-site 4 0.2 mL 
Anti-CS antibodies 8000** CEVAC 2 
1.0 mL 
Anti-HBs antibodies 8000** CEVAC 3 
    Total for Clinic Visit 34 1.45 mL † 
       
**: a subset will be analyzed; refer to footnotes of Table 18 ;  †: Refer to Section 5.8.3.1;  
‡ A volume of 16 L is required for this test 
CEVAC: Center for Vaccinology, Ghent University, Belgium 
HSPH: Harvard School of Public Health, Cambridge, Massachusetts, USA 
Amended 19 August 2008 
Amended 24 October 2008 
Amended 23 January 2012 
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Table 26 Summary of blood sampling timepoints/immunological assays and 
volumes to be collected in children of both age categories during 
extension 
Blood sampling  
timepoint 
Test 
Estimated No. 
subjects# 
Laboratory 
Priority 
ranking 
Volume of 
whole blood 
required 
Study 
month 
Clinic 
Visit No. 
Month 44 36 
Parasite density 12000-16000 on-site 1 --‡ 
Parasite genotyping 12000-16000 HSPH 2 0.25 mL 
Hemoglobin 12000-16000 on-site 3 0.2 mL 
Anti-CS antibodies 1200** CEVAC 4 0.6 mL 
    Total for Clinic Visit 36 
0.45 mL† 
(1.05 mL§) 
       
Month 56 38 
Parasite density 12000-16000 on-site 3 --‡ 
Parasite genotyping 12000-16000 HSPH 2 0.25 mL 
Hemoglobin 12000-16000 on-site 1 0.2 mL 
Anti-CS antibodies 1200** CEVAC 4 0.6 mL 
    Total for Clinic Visit 38 
0.45 mL† 
(1.05 mL§) 
**: Anti-CS antibody samples will be collected only on the first 200 subjects in each age category of the primary trial phase of 
each of the at least 3 selected sites. 
§ In the subset for immunogenicity. 
† Not in the subset for immunogenicity. 
‡ A volume of 16 L is required for this test. 
CEVAC: Center for Vaccinology, Ghent University, Belgium 
HSPH: Harvard School of Public Health, Cambridge, Massachusetts, USA 
Amended 01 December 2010 
Amended 23 January 2012 
Amended 08 August 2012 
GSK Biologicals may use collected samples for purposes related to the quality assurance 
of the laboratory tests described in this protocol. This may include the management of the 
quality of these current tests, the maintenance or improvement of these current tests, the 
development of new test methods for the markers described in this protocol, as well as 
making sure that new tests are comparable to previous methods and work reliably. The 
GSK Biologicals’ clinical laboratories have established a Quality System supported by 
procedures. The activities of GSK Biologicals’ clinical laboratories are audited regularly 
for quality assessment by an internal (sponsor-dependent) but laboratory-independent 
Quality Department. 
In addition, GSK Biologicals may, if findings in the present or in other studies 
necessitate, conduct further investigation into the efficacy or immunogenicity of the 
RTS,S/AS01E vaccine, AS01E adjuvant, or further research in malaria. Under these 
circumstances, additional testing on the samples may be performed by GSK Biologicals 
outside the scope of this protocol. Any sample testing will be done in line with the 
consent of the individual subject. No human pharmacogenetic testing is planned for this 
study. Any human pharmacogenetic testing will require additional separate consent from 
the individual subjects and the ethics committee approval. 
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5.8.3.1. Ancillary studies 
Additional assays may be performed if: 
1. They are to further evaluate or understand vaccine effect or the immune responses 
induced by vaccine; in particular further evaluation of the cellular arm of the immune 
response. 
2. The total blood draw including the ancillary study does not exceed 5 mL. 
3. The ancillary study protocol is approved by the relevant IRBs. 
Amended 19 August 2008 
6. INVESTIGATIONAL PRODUCTS AND ADMINISTRATION 
Note: Abbreviations for vaccination groups 
The abbreviations below are used to describe the vaccination groups in the sections 
following: 
R3R: Children to receive 3 doses of RTS,S/AS01E on a 0, 1, 2 schedule with an 
RTS,S/AS01E booster. 
R3C: Children to receive 3 doses of RTS,S/AS01E on a 0, 1, 2 schedule without an 
RTS,S/AS01E booster. 
C3C: Children to receive 3 doses of a comparator vaccine on a 0, 1, 2 schedule with a 
dose of comparator vaccine at Visit 22. 
6.1. Study vaccines 
The candidate vaccine (i.e. RTS,S/AS01E) to be used has been developed and 
manufactured by GSK Biologicals. 
The Quality Control Standards and Requirements for the candidate vaccine are described 
in separate release protocols and the required approvals have been obtained.  
Commercial vaccines (i.e. Tritanrix HepB
™
/Hib, Polio Sabin™, MCC vaccines and 
rabies vaccines) are assumed to comply with the specifications given in the 
manufacturer’s Summary of Product Characteristics. 
Amended 19 August 2008 
Note: Meningococcal C conjugate vaccines 
To ensure consistent vaccine availability three brands of Meningococcal C Conjugate 
vaccine will be procured for this trial: Meningitec (Wyeth), NeisVac-C (Baxter) or 
Menjugate (Novartis). In preference Meningitec, which has product data on co-
administration with hepatitis B will be used. It will be ensured that each child randomized 
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to receive three doses of MCC will receive all three primary immunization doses of MCC 
from the same manufacturer. 
Note: Rabies vaccines 
To ensure consistent vaccine availability, three cell-culture rabies vaccines from two 
manufacturers will be sourced for this trial (Sanofi-Pasteur and Novartis). It will be 
ensured that an individual child will receive all 3 doses of cell culture rabies vaccine from 
the same product. 
Amended 24 October 2008 
6.1.1. RTS,S/AS01E 
The RTS,S/AS01E vaccine consists of two fractions: the lyophilized fraction containing 
the RTS,S antigen in one vial and the liquid fraction, consisting of the AS01E adjuvant in 
the other vial, to be used for reconstitution just prior to injection. The presentation of the 
reconstituted RTS,S/AS01E candidate malaria vaccine is an opalescent liquid. 
6.1.1.1. RTS,S antigen presentation: 
 The RTS,S antigen is presented as a lyophilized pellet in a monodose vial. One dose 
contains approximately 25 g of antigen with sucrose as cryoprotectant. 
6.1.1.2. AS01E adjuvant presentation: 
 AS01E is presented in a monodose vial. One dose contains 25 g of MPL® and 25 
g of Stimulon
®
 QS21 (a triterpene glycoside purified from the bark of Quillaja 
saponaria) with liposomes. 
6.1.2. Tritanrix HepB/Hib 
DTPwHepB/Hib (Tritanrix HepB™/Hib, GSK Biologicals) is presented as two individual 
vaccine components: DTPwHepB (Tritanrix HepB™) as a suspension in a monodose 
glass vial and Hib (Hiberix™, GSK Biologicals) as a white pellet in a glass vial. 
The vaccine contains diphtheria (D) and tetanus (T) toxoids, inactivated whole cell 
pertussis bacteria (Pw) and the purified major surface antigen of the hepatitis B virus 
(HBV), adsorbed on aluminum salts and purified polyribosyl-ribitol-phosphate capsular 
polysaccharide (PRP) of Hemophilus influenzae type b (Hib), covalently bound to tetanus 
toxoid. 
Tritanrix HepB™/Hib is prepared by reconstitution of the Hiberix™ pellet with the 
Tritanrix HepB™ suspension. Each 0.5 mL dose contains not less than 30 International 
Units (IU) of adsorbed diphtheria toxoid, not less than 60 IU of adsorbed tetanus toxoid, 
not less than 4 IU of whole cell pertussis, 10 g of recombinant HBsAg protein and 10 g 
of purified capsular polysaccharide covalently bound to approximately 30 g tetanus 
toxoid. Tritanrix HepB™ also contains 2-phenoxyethanol, polysorbate 20, sodium 
chloride, thiomersal and water for injection. Hiberix also contains lactose. 
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6.1.3. Oral Polio Vaccine 
Polio Sabin™ (GSK Biologicals) (OPV MRC5) is a stabilized suspension of types 1, 2 
and 3 live attenuated polioviruses (Sabin strains): Type 1 (strain LSc, 2ab), Type 2 (strain 
P 712 ch, 2ab), Type 3 (strain Leon 12a, 1b). The viruses are propagated in human 
diploid cells. 
The excipients of Polio Sabin™ (oral) comprise magnesium chloride, L-arginine, 
polysorbate 80, neomycin sulphate (residual), polymyxin B sulphate (residual) and 
purified water. 
6.1.4. Meningococcal C conjugate vaccines 
6.1.4.1. Meningitec 
Meningitec is (after shaking) a homogenous white suspension presented in a vial. 
One dose (0.5 mL) of Wyeth’s Meningitec contains: 
10 g Neisseria meningitidis (strain C11) Group C oligosaccharide conjugated to 15 g 
(approx) Corynebacterium diptheriae CRM197 protein adsorbed on aluminium phosphate 
(0.125 mg Al
3+
). 
The excipients include sodium chloride and water for injections. 
6.1.4.2. NeisVac-C 
NeisVac-C is (after shaking) a semi-opaque white to off-white suspension presented in a 
pre-filled syringe (PFS). 
One dose (0.5 mL) of Baxter’s NeisVac-C contains: 
10 g Neisseria meningitidis (strain C11) Group C polysaccharide (de-O-acetylated) 
conjugated to 10-20 g tetanus toxoid adsorbed on aluminium hydroxide (0.5 mg Al
3+
). 
The excipients include sodium chloride and water for injections. 
6.1.4.3. Menjugate 
Menjugate is supplied in a single-dose (0.5 mL) presentation consisting of one vial 
containing a lyophilized powder (vaccine component) and a syringe containing the 
diluent (containing a suspension of aluminium hydroxide as the adjuvant). 
Amended 26 November 2009 
One dose (0.5 mL) of Novartis’s Menjugate contains: 
10 g Neisseria meningitidis (strain C11) Group C oligosaccharide conjugated to 
12.5-25 g (approx) Corynebacterium diptheriae CRM197 protein adsorbed on aluminium 
hydroxide (1.0 mg). 
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The excipients include: in the MenC-CRM197 vial, mannitol, sodium phosphate 
monobasic monohydrate, sodium phosphate dibasic heptahydrate; in the adjuvant vial, 
sodium chloride, water for injections. 
6.1.5. Cell-culture rabies vaccines 
6.1.5.1. Sanofi-Pasteur’s Human Diploid Cell Rabies Vaccine  
Sanofi-Pasteur’s Human Diploid Cell Rabies Vaccine is a sterile freeze-dried suspension 
of rabies virus prepared from strain PM 1503-3M obtained from the Wistar Institute, 
Philadelphia, PA. 
The potency of one dose (1.0 mL) of Sanofi-Pasteur’s Human Diploid Cell Rabies 
Vaccine is at least 2.5 IU of rabies antigen. Sanofi-Pasteur’s Human Diploid Cell Rabies 
Vaccine is a creamy white to orange, freeze-dried vaccine for reconstitution with the 
diluent prior to use. 
Amended 26 November 2009 
A dose of 1.0 mL will be injected. The presentation of the reconstituted vaccine is as a 
pink to red liquid. One dose of Sanofi-Pasteur’s Human Diploid Cell Rabies Vaccine 
contains less than 100 mg albumin, less than 150 g neomycin sulphate and 20 g phenol 
red indicator. The vaccine contains no preservative or stabilizer. 
6.1.5.2. Rabipur/Rabavert Rabies Vaccine 
Novartis’ Rabipur/Rabavert, is a sterile freeze-dried vaccine obtained by growing the 
fixed-virus strain Flury LEP in primary cultures of chicken fibroblasts. 
The potency of one dose (1.0 mL) Rabipur/Rabavert is at least 2.5 IU of rabies antigen. 
Rabipur/Rabavert is a white, freeze-dried vaccine for reconstitution with the diluent prior 
to use; the reconstituted vaccine is a clear to slightly opaque, colorless suspension. 
A dose of 1.0 mL will be delivered. The presentation of the reconstituted vaccine is as a 
clear or slightly opaque suspension. 
6.1.5.3. Sanofi-Pasteur’s Vero-cell Rabies Vaccine 
Sanofi-Pasteur’s chromatographically purified Vero cell culture rabies vaccine Verorab is 
composed of rabies virus Wistar Rabies PM/W138 1503-3M strain (inactivated) 
(  2.5 IU/0.5 mL dose). 
Before reconstitution, the powder has a uniform white color. 
A dose of 0.5 mL will be injected. 
Amended 24 October 2008 
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6.2. Dosage and administration 
The vaccinees will be observed closely for at least 30 minutes following the 
administration of all vaccines used in the study, with appropriate medical treatment 
readily available in case of an anaphylactic reaction. 
Children and infants who received an incomplete primary vaccination schedule (not the 3 
doses within the expected timings) must not receive the booster dose of RTS,S/AS01E or 
control vaccine. 
Amended 01 December 2010 
6.2.1. RTS,S/AS01E (0.5 mL dose) 
RTS,S/AS01E will be supplied such that the reconstituted vaccine volume will provide a 
0.5 mL pediatric dose. One 0.5 mL dose will be withdrawn from each vial and used. 
Disinfect top of vaccine vial (pellet) and adjuvant vial with alcohol swabs and let dry. 
Withdraw the contents of the adjuvant vial in a syringe and inject adjuvant into the vial of 
lyophilized antigen. The pellet is then dissolved by gently shaking the vial. Wait for 1 
minute to ensure complete dissolution of vial contents before withdrawing the content of 
the vial (0.5 mL). The reconstituted vaccine should be administered by slow IM injection, 
using a fresh 25G needle with length of 1 inch (25 mm): for children 6 to 12 weeks of age 
at enrollment inject into antero lateral thigh for primary course; for children 5 to 17 
months of age at enrollment, inject into left deltoid for primary course; all children 
should be injected in the left deltoid for booster. Vaccine should be injected within 4 
hours of reconstitution (storage at +2°C to +8°C). 
6.2.2. TritanrixHepB/Hib (0.5 mL dose) 
Disinfect top of vaccine vials with alcohol swabs and let dry. Shake the vial of 
Tritanrix HepB™ in order to obtain a homogenous turbid white suspension. Using a 
syringe, add the entire contents of the Tritanrix HepB™ vial to the vial containing the 
Hiberix™ pellet. Shake the mixture until the pellet is completely dissolved. The 
reconstituted Tritanrix HepB™/Hib vaccine should be inspected visually for any foreign 
particulate matter prior to administration; if this is observed the vaccine should be 
discarded. The reconstituted vaccine should be administered by slow IM injection, using 
a fresh 25G needle with length of 1 inch (25 mm), into the right antero-lateral thigh 
within 4 hours of reconstitution (storage at +2°C to +8°C). 
6.2.3. OPV 
The OPV vaccine will be administered orally. For the monodose container (European 
Pharmacopoeia formulation), one immunizing dose of 0.135 mL is contained in 3 drops. 
For the multidose container (WHO formulation), one immunizing dose of 0.1 mL is 
contained in 2 drops. 
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After opening, monodose containers should be kept in a refrigerator and used within eight 
hours. Multidose containers which are not completely used should be stored again at +2-
8°C and should be used within eight hours. 
Amended 24 October 2008 
Amended 26 November 2009 
6.2.4. Meningococcal C conjugate vaccines 
6.2.4.1. Meningitec 
Disinfect top of vial with alcohol swabs and let dry. Shake the vial in order to obtain a 
homogenous turbid white suspension. Visually inspect for any foreign particulate matter 
and/or variation of physical aspect. If this is observed discard the vaccine. The vaccine 
should be administered by slow IM injection (into left anterolateral thigh in children < 1 
year, into left deltoid in children > 1 year), using a fresh 25G needle with length of 1 inch 
(25 mm). 
Amended 26 November 2009 
6.2.4.2. NeisVac-C 
The PFS of vaccine should be well shaken in order to obtain a homogenous suspension. 
Visually inspect for any foreign particulate matter and/or variation of physical aspect. If 
this is observed discard the vaccine. The reconstituted vaccine should be administered by 
slow IM injection (into left anterolateral thigh in children < 1 year, into left deltoid in 
children > 1 year), using a fresh 25G needle with length of 1 inch (25 mm) immediately 
after reconstitution. 
6.2.4.3. Menjugate 
Disinfect top of vials with alcohol swabs and let dry. Inject the entire contents of the 
syringe into the vaccine powder vial. The vaccine is dissolved by gently shaking the vial 
to obtain a homogeneous suspension of the vaccine. Immediately withdraw 0.5 mL of the 
suspension and inject. The reconstituted vaccine should be administered by slow IM 
injection (into left anterolateral thigh in children < 1 year, into left deltoid in children > 1 
year), using a fresh 25G needle with length of 1 inch (25 mm) immediately after 
reconstitution. 
Amended 01 December 2010 
6.2.5. Cell-culture rabies vaccines 
6.2.5.1. Sanofi-Pasteur’s Human Diploid Cell Rabies Vaccine (1.0 mL dose) 
Disinfect top of vaccine vial with alcohol swabs and let dry. Inject the entire contents of 
the diluent syringe into the vaccine vial. The freeze-dried vaccine is dissolved by gently 
shaking the vial. Wait for 1 minute to ensure complete dissolution of vial contents before 
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withdrawing a sufficient volume to provide a 1.0 mL dose. The reconstituted vaccine 
should be administered by slow IM injection, using a fresh 25G needle with length of 1 
inch (25 mm), into the left deltoid directly after reconstitution. 
6.2.5.2. Rabipur/Rabavert Rabies Vaccine (1.0 mL dose) 
Disinfect top of vaccine vial with alcohol swabs and let dry. Inject the entire contents of 
the diluent ampoule into the vaccine vial. The freeze-dried vaccine is dissolved by gently 
shaking the vial. Wait for 1 minute to ensure complete dissolution of vial contents before 
withdrawing a sufficient volume to provide a 1.0 mL dose. The original needle should 
then be replaced with a fresh needle for IM injection. The reconstituted vaccine should be 
administered by slow IM injection, using a fresh 25G needle with length of 1 inch (25 
mm), into the left deltoid directly after reconstitution. 
6.2.5.3. Sanofi-Pasteur’s Vero-cell Rabies Vaccine (0.5 mL dose) 
Disinfect top of vaccine vial with alcohol swabs and let dry. Inject the entire contents of 
the solvent syringe into the vaccine powder vial. The freeze-dried vaccine is dissolved by 
gently shaking the vial to obtain a homogeneous suspension of the vaccine. The 
reconstituted vaccine appears as a limpid liquid. Immediately withdraw 0.5 mL of the 
suspension and inject. The reconstituted vaccine should be administered by slow IM 
injection, using a fresh 25G needle with length of 1 inch (25 mm), into the left deltoid 
directly after reconstitution. 
Amended 24 October 2008 
6.3. Storage 
All study vaccines to be administered to subjects must be stored in a safe and locked 
place with no access by unauthorized personnel. 
A site assessment will be performed during the pre-study activities to ensure that the 
study vaccines will be stored in appropriate conditions during the study. 
Study vaccines will be stored at the defined temperature range (i.e. +2 to +8°C). 
The storage temperature of study vaccines will be monitored daily while using validated 
temperature monitoring devices and the temperature measurements will be recorded 
during working days, preferably at the same time of the day (e.g. at the beginning of the 
day). Freezing indication will be continuously controlled by an appropriate device placed 
close to the study vaccines. 
Any temperature deviation, meaning temperature outside the defined range (i.e. +2 to 
+8°C), must be reported within 2 working days to the Clinical Trial Supplies Unit. 
Following exposure to a temperature deviation, the study vaccines will not be used until 
written approval is given by the sponsor. In case of temperature deviations between 0 and 
+2°C, the impacted study vaccines can still be administered, but the site must take 
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adequate actions to get back to the defined range +2 to +8°C and avoid re-occurrence of 
such a temperature deviation. 
Amended 01 December 2010 
Storage conditions for transport of the study vaccines from country medical department 
or dispatch centre to study sites or between sites are described in Appendix D. 
6.4. Treatment allocation and randomization 
A randomization list will be generated at GSK Biologicals, Rixensart, using a standard 
SAS  (Statistical Analysis System) program and will be used to number the vaccines. A 
randomization blocking scheme (1: 1: 1 ratio [R3R: R3C: C3C] for each age category) 
will be used to ensure that balance between treatments is maintained: a treatment number 
will identify uniquely the vaccine doses to be administered to the same subject. 
The vaccine doses will be distributed to the study centre while respecting the 
randomization block size. At first vaccination (Day 0 [Month 0]), subjects will be 
administered the vaccine dose in accordance with the treatment numbers provided by a 
central randomization system on Internet (SBIR). 
The actual treatment number used for first vaccination of the subject must be recorded by 
the investigator in the CRF/eCRF (Randomization/Treatment Allocation Section). 
6.4.1. Randomization of supplies 
To allow GSK Biologicals to take advantage of greater rates of recruitment than 
anticipated at individual centers in this multicenter study and to thus reduce the overall 
study recruitment period, an over-randomization of supplies will be prepared. 
6.4.2. Randomization of subjects 
The treatment allocation at the investigator site will be performed using a central 
randomization system on Internet (SBIR). 
Subjects will be allocated a subject number at the screening visit (Clinic Visit 1). Subject 
numbers will be issued consecutively at each site; there will be no overlap of subject 
numbers between sites. Prior to vaccination, at Clinic Visit 2, after verification of 
eligibility criteria, subjects will be allocated a Treatment Number using SBIR. The 
correspondence between the Subject Number and the Treatment Number will be noted 
down in the source document and subsequently transferred to the CRF/eCRF. The 1: 1 
relationship between Treatment Number and Study Number established at Dose 1 of 
vaccine will be maintained for subsequent doses. 
Amended 19 August 2008 
Study subjects will receive study identification cards bearing their subject number. 
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The actual treatment number used for first vaccination of the subject must be 
recorded by the investigator in the CRF/eCRF (Randomization/Treatment 
Allocation Section). 
6.5. Method of blinding and breaking the study blind 
Data pertaining to RTS,S/AS01E or control vaccines will be collected in a double blinded 
(observer blind) manner. ‘Double blinded (observer blind)’ means that the vaccine 
recipient and their parent(s)/guardian(s) as well as those responsible for the evaluation of 
study endpoint data will all be unaware which treatment, RTS,S/AS01E or control 
vaccine, was administered to a particular subject. The vaccines in this study are of 
different appearance and volume. The contents of the syringe will be masked with an 
opaque label to ensure that parent(s)/guardian(s) are blinded. The only study staff aware 
of the vaccine assignment for RTS,S/AS01E or control vaccine will be those responsible 
for preparation and administration of vaccines; these staff will play no other role in the 
study except screening or collection of biospecimens which do not require clinical 
evaluation. 
The LSM or in the event they are unavailable, the investigator, or person designated by 
the investigator, should contact GSK Biologicals’ Central Safety physician directly or via 
the local safety contact (see below and Study Contact for Emergency Code Break in 
Sponsor Information page) to discuss the need for emergency unblinding. The GSK 
Biologicals’ Central Safety Office will be allowed to access the individual randomization 
code. 
Central Safety, GSK Biologicals, Rixensart will have access to the individual 
randomization code in electronic format. The code will be broken using the central 
randomization system (SBIR) by the GSK Biologicals’ Central Safety physician (see 
below and Study Contact for Emergency Code Break in Sponsor Information) only in the 
case of medical events that the investigator/physician in charge of the subject feels cannot 
be treated without knowing the identity of the study vaccine(s). 
Unblinding of a subject’s individual treatment code should occur only in the case of a 
medical emergency, or in the event of a serious medical condition, when knowledge of 
the study treatment is essential for the clinical management or welfare of the subject, 
as judged by the investigator. 
The emergency unblinding process consists of the automated system that allows the 
investigator to have unrestricted, immediate and direct access to the subject’s 
individual study treatment. 
The investigator has the option of contacting a GSK Biologicals’ On-call Central 
Safety Physician (or Backup) if he/she needs medical advice. The safety physician may 
also support to perform the unblinding (i.e. he/she cannot access the automated 
Internet-based system). 
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Any emergency unblinding must be fully documented by using the Emergency 
Unblinding Documentation Form, which must be appropriately completed by the 
investigator and sent within 24 hours to GSK Biologicals. 
Amended 26 November 2009 
Amended 08 August 2012 
Note that all the period of observation of the extension corresponds to the double-blind 
phase of the primary trial phase. However, cleaning of the data will be performed after 
the primary trial phase is unblinded. For that reason the extension is referred to as single-
blinded. ‘Single-blind’ means that the vaccine recipient and their parent(s)/guardians will 
be unaware, and that the persons responsible for the collection of blood samples and the 
evaluation of study endpoint data will be aware of which treatment, RTS,S/AS01E or 
control vaccine, was administered to a particular subject. 
Amended 01 December 2010 
GSK Biologicals’ policy (incorporating ICH E2A guidance, EU Clinical Trial Directive 
and Federal Regulations) is to unblind any serious adverse event (SAE) report associated 
with the use of the investigational product, which is unexpected and 
attributable/suspected, prior to regulatory reporting. The Clinical Safety physician is 
responsible for unblinding the treatment assignment in accordance with specified time 
frames for expedited reporting of SAEs (Refer to Section 8.7.2). 
GSK Biologicals Clinical Safety Physician  
(Study Contact for Emergency Code Break) 
Phones for 7/7 day availability: 
 (GSK Biologicals Central Safety 
Physician on-call) 
 (GSK Biologicals Central Safety 
Physician on-call) 
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GSK Biologicals’ Contact information for Emergency Unblinding 
24/24 hour and 7/7 day availability 
GSK Biologicals’ Central Safety Physician: 
  (GSK Biologicals Central Safety Physician on-call) 
GSK Biologicals’ Central Safety Physician Back-up: 
 
Emergency Unblinding Documentation Form transmission: 
Fax:   or   
Amended 01 December 2010 
Amended 08 August 2012 
6.6. Replacement of unusable vaccine doses 
Additional vaccine doses will be provided to replace those that are unusable (see 
Appendix D for details of supplies). 
In addition to the vaccine doses provided for the planned number of subjects (including 
over-randomization when applicable), at least 3% additional doses will be supplied. In 
case a vaccine dose is broken or unusable, the investigator should replace it with a 
replacement vaccine dose. Although the sponsor need not be notified immediately in 
these cases (except in the case of cold-chain failure), documentation of the use of the 
replacement vaccine must be recorded by the investigator on the vaccine administration 
page of the CRF/eCRF and on the vaccine accountability form. 
6.6.1. Replacement of unusable doses 
The investigator will use the central randomization system (SBIR) to obtain the 
replacement vial number for any randomized treatment. The system will ensure, in a 
blinded manner, that the replacement vial is of the same formulation as the randomized 
vaccine. 
Amended 24 October 2008 
6.7. Packaging 
See Appendix D. 
6.8. Vaccine accountability 
See Appendix D. 
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6.9. Concomitant medication/treatment 
6.9.1. Concomitant medication/treatment during the primary trial phase 
Immune modifying drugs and blood transfusions will be captured through the hospital 
surveillance system for severe disease for the duration of the trial. 
Malaria treatments will be captured through the surveillance system for clinical malaria 
for the duration of the trial. 
Antipyretics, analgesics, systemic antibiotics will be collected from children who are 
assessed for reactogenicity in the 6-day period following each vaccine dose (i.e. the first 
200 children vaccinated in each age category at each study center). The indication for 
administration (‘prophylaxis’ or ‘treatment’) will be recorded. The reporting period will 
be from the day of vaccination and the 6 subsequent days. 
Some EPI interventions will be recorded from birth to study end (Visit 34, Month 32). In 
some cases, specific CRF sections will be supplied for the recording of Vitamin A, IPTi, 
Hepatitis B, pneumococcal vaccines (all subjects), BCG, OPV (6 to12 weeks of age 
category), Hemophilus vaccines (5 to 17 months of age category). 
Other vaccines administered concomitantly with study vaccine, not specified per protocol 
(i.e. within 30 days of a vaccine dose), will be recorded e.g. measles, polio mass 
vaccination. General concomitant vaccination pages are supplied for the recording of any 
other vaccines. 
Amended 19 August 2008 
Amended 23 January 2012 
6.9.2. Concomitant medication/treatment during the extension 
During the extension, immune modifying drugs and blood transfusions will be recorded 
through the hospital surveillance system for severe disease from study end of the primary 
trial phase (Visit 34, Month 32) until the last visit of the extension. Specific CRF sections 
will be supplied for the recording of Vitamin A and pneumococcal vaccines (all subjects). 
Amended 01 December 2010 
7. HEALTH ECONOMICS 
Measures of vaccine efficacy on clinical disease endpoints as specified in this protocol 
may be utilized in an assessment of health economics. 
Additional data to support the full health economic evaluation will be collected in an 
ancillary protocol to this protocol. This may include factors such as assessment of quality 
of life, subject preferences, the measurement of resource utilization and direct and 
indirect costs. The ancillary protocol and a subject informed consent will be submitted for 
IRB review. 
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8. ADVERSE EVENTS AND SERIOUS ADVERSE EVENTS 
The investigators are responsible for the detection and documentation of events meeting 
the criteria and definition of an adverse event (AE) or serious adverse event (SAE) as 
provided in this protocol. During the study, when there is a safety evaluation, the 
investigator or site staff will be responsible for detecting AEs and SAEs, as detailed in 
this section of the protocol. 
Each subject’s parents/guardians will be instructed to contact the investigator 
immediately should the subject manifest any signs or symptoms they perceive as serious. 
8.1. Definition of an adverse event 
An AE is any untoward medical occurrence in a clinical investigation subject, temporally 
associated with the use of a medicinal product, whether or not considered related to the 
medicinal product. 
An AE can therefore be any unfavorable and unintended sign (including an abnormal 
laboratory finding), symptom, or disease (new or exacerbated) temporally associated with 
the use of a medicinal product. 
 Exacerbation of a chronic or intermittent pre-existing condition including either an 
increase in frequency and/or intensity of the condition. 
 New conditions detected or diagnosed after investigational product administration 
even though it may have been present prior to the start of the study. 
 Signs, symptoms, or the clinical sequelae of a suspected interaction. 
 Signs, symptoms, or the clinical sequelae of a suspected overdose of either 
investigational product or a concurrent medication (overdose per se should not be 
reported as an AE/SAE). 
Examples of an AE DO NOT include: 
 Medical or surgical procedure (e.g. endoscopy, appendectomy); the condition that 
leads to the procedure is an AE. 
 Situations where an untoward medical occurrence did not occur (social and/or 
convenience admission to a hospital). 
 Anticipated day-to-day fluctuations of pre-existing disease(s) or condition(s) present 
or detected at the start of the study that do not worsen. 
 For therapeutic studies, the disease/disorder being studied, or expected progression, 
signs, or symptoms of the disease/disorder being studied, unless more severe than 
expected for the subject’s condition. 
AEs may include pre- or post-treatment events that occur as a result of protocol-
mandated procedures (i.e. invasive procedures, modification of subject’s previous 
therapeutic regimen). 
110021 (Malaria-055 PRI) 
Amendment 6 
08-AUG-2012 
- 137 - 
N.B. AEs to be recorded as endpoints (solicited events) are described in Section 8.4.1. 
All other AEs will be recorded as UNSOLICITED AES (defined as those AEs judged to be 
related to vaccination, or leading to drop-out). 
Example of events to be recorded in the medical history section of the CRF/eCRF: 
 Pre-existing conditions or signs and/or symptoms present in a subject prior to the 
start of the study (i.e. prior to the first study vaccination). 
8.2. Definition of a serious adverse event  
A serious adverse event (SAE) is any untoward medical occurrence that: 
a. results in death 
b. is life-threatening 
NOTE: The term ‘life-threatening’ in the definition of ‘serious’ refers to an event in 
which the subject was at risk of death at the time of the event. It does not refer to an 
event, which hypothetically might have caused death, if it were more severe. 
c. requires hospitalization or prolongation of existing hospitalization, 
NOTE: In general, hospitalization signifies that the subject has been detained (usually 
involving at least an overnight stay) at the hospital or emergency ward for observation 
and/or treatment that would not have been appropriate in the physician’s office or out-
patient setting. Complications that occur during hospitalization are AEs. If a 
complication prolongs hospitalization or fulfills any other serious criteria, the event is 
serious. When in doubt as to whether “hospitalization” occurred or was necessary, the 
AE should be considered serious. 
Hospitalization for elective treatment of a pre-existing condition that did not worsen from 
baseline is not considered an AE. 
d. results in disability/incapacity, or 
NOTE: The term disability means a substantial disruption of a person’s ability to conduct 
normal life functions. This definition is not intended to include experiences of relatively 
minor medical significance such as uncomplicated headache, nausea, vomiting, diarrhea, 
influenza, and accidental trauma (e.g. sprained ankle) which may interfere or prevent 
everyday life functions but do not constitute a substantial disruption. 
e. a seizure within 30 days of vaccination. 
NOTE: In this study all seizures occurring within a 30-day period of vaccination will be 
notified as SAEs. Key information pertaining to seizures occurring within 7 days of 
vaccination will be documented in the CRF/eCRF [refer to Bonhoeffer, 2004]. 
f. Medical or scientific judgment should be exercised in deciding whether reporting is 
appropriate in other situations, such as important medical events that may not be 
immediately life-threatening or result in death or hospitalization but may jeopardize 
the subject or may require medical or surgical intervention to prevent one of the 
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other outcomes listed in the above definition. These should also be considered 
serious. Examples of such events are invasive or malignant cancers, intensive 
treatment in an emergency room or at home for allergic bronchospasm and blood 
dyscrasias. 
Amended 01 December 2010 
8.3. Clinical laboratory parameters and other abnormal 
assessments qualifying as adverse events and serious 
adverse events 
Abnormal laboratory findings (e.g. hematology) that are judged by the investigator to be 
clinically significant will be recorded as AEs or SAEs if they meet the definition of an 
AE, as defined in Section 8.1 or SAE, as defined in Section 8.2. Clinically significant 
abnormal laboratory findings or other abnormal assessments that are detected during the 
study or are present at baseline and significantly worsen following the start of the study 
will be reported as AEs or SAEs. 
The investigator will exercise his or her medical and scientific judgment in deciding 
whether an abnormal laboratory finding or other abnormal assessment is clinically 
significant. 
8.4. Time period, frequency, and method of detecting adverse 
events and serious adverse events 
All unsolicited AEs will be reported for 30 days following each vaccine dose for the first 
200 subjects in each age category enrolled at each center and reported in the CRF/eCRF. 
For all the subjects whose AEs judged to be related to vaccination or leading to drop out 
occurring within 30 days following administration of each dose of vaccine must be 
recorded on the Adverse Event form of the subject’s CRF/eCRF. 
Amended 26 November 2009 
The standard time period for collecting and recording SAEs will begin at first receipt of 
vaccine and end at the last study visit. See Section 8.7 for instructions for reporting and 
recording SAEs. 
In addition to the above-mentioned reporting requirements and in order to fulfill 
international reporting obligations, SAEs that are related to study participation (e.g. 
protocol-mandated procedures, invasive tests, a change from existing therapy) or are 
related to a concurrent GSK medication will be collected and recorded from the time the 
subject consents to participate in the study until she/he is discharged. 
An overview of the protocol-required reporting periods for adverse events and serious 
adverse events is given in Table 27. 
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Table 27 Reporting periods for adverse events and serious adverse events 
Study activity 
Pre-vacc 
(consent 
obtained) 
V1 
30 d  
post-V1 
V2 
30 d  
post-V2 
V3 
30 d 
post-V3 
 B 30 d 
post B 
 
D0 D30 M1 M1+30d M2 M2+30d M3-M19 M20 M20+30d M21-M32 
Reporting of AEs 
           
           
           
Reporting of SAEs 
           
           
           
Reporting of SAEs 
related to study  
participation and 
AEs of specific 
interest 
           
           
       
    
Pre-vacc: pre-vaccination; V: vaccination; M: study month d: days 
* Refer to Section 8.4.1 for the details on reporting requirements for each AE of specific interest. 
Table 28 Reporting periods for adverse events and serious adverse events, 
during the extension 
Study activity 
Visit 35-38 
M32 to M56* 
Reporting of SAEs 
 
 
 
Reporting of SAEs related 
to study participation 
 
 
 
Reporting of IMDs** 
 
 
 
*Or end 2013 [Nov 2013-Jan 2014] whichever occur earlier. 
** Refer to Section 8.4.1 for the details on reporting 
requirements for each AE of specific interest. 
Amended 01 December 2010 
Amended 08 August 2012 
The investigator will inquire about the occurrence of AEs/SAEs at every visit/contact 
during the study and throughout the follow-up phase as appropriate. 
SAEs will be identified by surveillance at the health facilities in the health centers in the 
study area and through monthly contacts with the study subjects. 
The investigator or study clinician will fully document any such events in the CRF/eCRF 
including, where applicable, information from relevant hospital case records, autopsy 
reports and verbal autopsies. 
All AEs either observed by the investigator or one of his clinical collaborators or 
identified through surveillance at health facilities in the study area or reported by the 
subject’s parent/guardian spontaneously or in response to a direct question will be 
evaluated by the investigator. AEs judged by the investigator to be related or leading to 
drop out that have not been previously documented in the study will be recorded in the 
Adverse Event form within the subject’s CRF/eCRF. The nature of each event, date and 
time (where appropriate) of onset, outcome, intensity and relationship to vaccination 
should be established. 
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As a consistent method of soliciting AEs, the subject or the subject’s parent/guardian 
should be asked a non-leading question such as: 
“Has your child acted differently or felt different in any way since receiving the vaccine 
or since the last visit?” 
N.B. The investigator should record only those AEs having occurred within the time 
 frame defined above. 
AEs already documented in the CRF/eCRF, i.e. at a previous assessment, and designated 
as “not recovered/not resolved” or “recovering/resolving” should be reviewed at 
subsequent visits, as necessary. If these have resolved, the documentation in the 
CRF/eCRF should be completed. 
When an AE/SAE occurs, it is the responsibility of the investigator to review all 
documentation (e.g. hospital progress notes, laboratory, and diagnostics reports) relative 
to the event. The investigator will then record all relevant information regarding an 
AE/SAE on the CRF/eCRF or SAE Report Form as applicable. It is not acceptable for 
the investigator to send photocopies of the subject’s medical records to GSK 
Biologicals in lieu of the appropriate completed AE/SAE pages. However, there may 
be instances when copies of medical records for certain cases are requested by GSK 
Biologicals. In this instance, all subject identifiers will be blinded on the copies of 
the medical records prior to submission to GSK Biologicals. 
The investigator will attempt to establish a diagnosis of the event based on signs, 
symptoms, and/or other clinical information. In such cases, the diagnosis should be 
documented as the AE/SAE and not the individual signs/symptoms. 
For centers using RDE with eCRF, the electronic system using SAE screens in the eCRF 
will be the primary mode for reporting SAEs to GSK Biologicals during the study period. 
In case this electronic system for reporting SAEs does not work or after freezing of the 
subject’s eCRF, paper SAE Report Forms and the facsimile (Fax) system should be used 
to report SAEs. Refer to Section 8.7.2 for details of the back-up reporting system. 
8.4.1. Adverse events of specific interest 
Adverse events of specific interest for safety monitoring include seizures within 30 days 
of vaccination, immune-mediated disorders (IMD), rashes and mucocutaneous lesions. In 
study centers where support for specific laboratory testing and histopathology is not 
available routinely, support can be provided at a reference laboratory. 
8.4.1.1. Seizures within 30 days of vaccination 
All seizures occurring within a 30-day period of vaccination will be reported as SAEs and 
medical documentation of the events will be reported in appropriate targeted follow-up 
forms included in the CRF/eCRF. Key information pertaining to seizures occurring 
within 7 days of vaccination will be documented in the CRF/eCRF [refer to Bonhoeffer, 
2004]. 
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8.4.1.2. Immune-mediated disorders (IMD) 
Occurrence of IMDs such as those listed below will be reported for all subjects over the 
entire study period. Medical documentation of the events will be reported in appropriate 
targeted follow-up forms included in the CRF/eCRF. The specific interest in the detailed 
description of occurrence of IMDs results from the theoretical concern that vaccination 
may interfere with immunological self-tolerance. These AEs of specific interest will be 
reported as SAEs in the CRF/eCRF. 
 Neuroinflammatory disorders: Optic neuritis, multiple sclerosis, demyelinating 
disease, transverse myelitis, Guillain-Barré syndrome, myasthenia gravis, 
encephalitis, neuritis, Bell’s palsy. 
 Musculoskeletal disorders: Systemic lupus erythematosus, cutaneous lupus, 
Sjogren’s syndrome, scleroderma, dermatomyositis, polymyositis, rheumatoid 
arthritis, juvenile arthritis, polymyalgia rheumatica, reactive arthritis, psoriatic 
arthropathy, ankylosing spondylitis, undifferentiated spondyloarthropathy. 
 Gastrointestinal disorders: Crohn’s disease, ulcerative colitis, ulcerative proctitis, 
celiac disease. 
 Metabolic diseases: Autoimmune thyroiditis, Grave's or Basedow’s disease, 
Hashimoto thyroiditis, Diabetes Mellitus Type 1, Addison’s disease. 
 Skin disorders: Psoriasis, vitiligo, Raynaud’s phenomenon, erythema nodosum, 
autoimmune bullous skin diseases. 
 Others: Auto-immune hemolytic anemia, idiopathic thrombocytopenic purpura, 
antiphospholipid syndrome, vasculitis, pernicious anemia, autoimmune hepatitis, 
primary biliary cirrhosis, primary sclerosing cholangitis, autoimmune 
glomerulonephritis, autoimmune uveitis, autoimmune myocarditis, sarcoidosis, 
Stevens-Johnson syndrome. 
8.4.1.3. Rashes and mucocutaneous lesions 
Occurrence of rashes and mucocutaneous lesions that occur within 30 days of vaccination 
in the first 200 subjects enrolled at each site in the 6 to 12 weeks age category will be 
reported as AEs/SAEs. Medical documentation of the events will be reported in the 
CRF/eCRF. Rashes and mucocutaneous lesions that meet the criteria for an SAE are 
reported in all subjects throughout the study period as usual. 
Amended 26 November 2009 
8.4.2. Solicited adverse events 
Solicited adverse events for the primary immunization course and boost will be collected 
on the first 200 subjects enrolled in each age category at each site. 
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Solicited local (injection site) AEs 
 Pain at injection site 
 Swelling at injection site 
 Redness at injection site 
Solicited general AEs 
 Drowsiness 
 Fever 
 Irritability/Fussiness 
 Loss of appetite 
N.B. Temperature will be recorded daily. Should additional temperature measurements 
be performed at other times of day, the highest temperature will be recorded. 
Amended 26 November 2009 
8.5. Evaluating adverse events and serious adverse events 
8.5.1. Assessment of intensity 
Intensity of the following AEs will be assessed as described: 
Table 29 Intensity scales for solicited symptoms in infants/toddlers and 
children less than 6 years of age 
Adverse Event Intensity grade Parameter 
Pain at injection site 0 Absent 
 1 Minor reaction to touch 
 2 Cries/protests on touch 
 3 Cries when limb is moved/spontaneously painful 
Swelling at injection site Record greatest surface diameter in mm 
Redness at injection site Record greatest surface diameter in mm 
Fever*  Record temperature in °C 
Irritability/Fussiness 0 Behavior as usual 
 1 Crying more than usual/ no effect on normal activity 
 2 Crying more than usual/ interferes with normal activity 
 3 Crying that cannot be comforted/ prevents normal activity 
Drowsiness 0 Behavior as usual 
 1 Drowsiness easily tolerated 
 2 Drowsiness that interferes with normal activity 
 3 Drowsiness that prevents normal activity 
Loss of appetite 0 Appetite as usual 
 1 Eating less than usual/ no effect on normal activity 
 2 Eating less than usual/ interferes with normal activity 
 3 Not eating at all 
*Fever is defined as axillary temperature 37.5°C  
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The maximum intensity of local injection site redness/swelling will be scored at GSK 
Biologicals as follows: 
0 : None  
1 : < 5 mm  
2 : 5 to 20 mm 
3 : > 20 mm 
The investigator will make an assessment of the maximum intensity that occurred over 
the duration of the event for all other AEs, i.e. unsolicited symptoms, including SAEs 
reported during the study. The assessment will be based on the investigator’s clinical 
judgment. 
The intensity of each AE and SAE recorded in the CRF/eCRF or SAE Report Form, as 
applicable, should be assigned to one of the following categories: 
1 (mild) = An AE which is easily tolerated by the subject, causing 
minimal discomfort and not interfering with everyday 
activities. 
2 (moderate) = An AE which is sufficiently discomforting to interfere with 
normal everyday activities. 
3 (severe) = An AE which prevents normal, everyday activities. (In a 
young child, such an AE would, for example, prevent 
attendance at school/ kindergarten/ a day-care centre and 
would cause the parents/ guardians to seek medical advice. 
In adults/ adolescents, such an AE would, for example, 
prevent attendance at work/ school and would necessitate 
the administration of corrective therapy.) 
An AE that is assessed as Grade 3 (severe) should not be confused with a SAE. 
Grade 3 is a category utilized for rating the intensity of an event; and both AEs 
and SAEs can be assessed as Grade 3. An event is defined as ‘serious’ when it 
meets one of the pre-defined outcomes as described in Section 8.2. 
8.5.2. Assessment of causality 
The investigator is obligated to assess the relationship between investigational product 
and the occurrence of each AE/SAE. The investigator will use clinical judgment to 
determine the relationship. Alternative causes, such as natural history of the underlying 
diseases, concomitant therapy, other risk factors and the temporal relationship of the 
event to the investigational product will be considered and investigated. The investigator 
will also consult the Investigator Brochure and/or Product Information, for marketed 
products, in the determination of his/her assessment. 
There may be situations when a SAE has occurred and the investigator has minimal 
information to include in the initial report to GSK Biologicals. However, it is very 
important that the investigator always makes an assessment of causality for every event 
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prior to submission of the SAE to GSK Biologicals. The investigator may change his/her 
opinion of causality in light of follow-up information, amending the SAE information 
accordingly. The causality assessment is one of the criteria used when determining 
regulatory reporting requirements. 
In case of concomitant administration of multiple vaccines, it may not be possible to 
determine the causal relationship of general AEs to the individual vaccines administered. 
The investigator should, therefore, assess whether the AE could be causally related to 
vaccination rather than to the individual vaccines. 
All solicited local (injection site) reactions will be considered causally related to 
vaccination. Causality of all other AEs should be assessed by the investigator using the 
following question: 
Is there a reasonable possibility that the AE may have been caused by the 
investigational product? 
NO : The AE is not causally related to administration of the study 
vaccine(s). There are other, more likely causes and administration 
of the study vaccine(s) is not suspected to have contributed to the 
AE. 
YES : There is a reasonable possibility that the vaccine(s) contributed to 
the AE.  
Non-serious and serious AEs will be evaluated as two distinct events. If an event meets 
the criteria to be determined “serious” (see Section 8.2 for definition of serious adverse 
event), it will be examined by the investigator to the extent to be able to determine ALL 
contributing factors applicable to each serious adverse event. 
Other possible contributors include: 
 Medical history 
 Other medication 
 Protocol required procedure 
 Other procedure not required by the protocol 
 Lack of efficacy of the vaccine(s), if applicable 
 Erroneous administration 
 Other cause (specify). 
8.6. Follow-up of adverse events and serious adverse events 
and assessment of outcome 
After the initial AE/SAE report, the investigator is required to proactively follow each 
subject and provide further information to GSK Biologicals on the subject’s condition. 
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All AEs and SAEs documented at a previous visit/contact and designated as not 
recovered/not resolved or recovering/resolving will be reviewed at subsequent 
visits/contacts. 
Investigators will follow-up subjects: 
 with SAEs or subjects withdrawn from the study as a result of an AE, until the event 
has resolved, subsided, stabilized, disappeared, the event is otherwise explained, or 
the subject is lost to follow-up; 
 or, in the case of other non-serious AEs, until they complete the study or they are lost 
to follow-up. 
Clinically significant laboratory abnormalities will be followed up until they have 
returned to normal, or a satisfactory explanation has been provided. Additional 
information (including but not limited to laboratory results) relative to the subsequent 
course of such an abnormality noted for any subject must be made available. 
GSK Biologicals may request that the investigator perform or arrange for the conduct of 
supplemental measurements and/or evaluations to elucidate as fully as possible the nature 
and/or causality of the AE or SAE. The investigator is obliged to assist. If a subject dies 
during participation in the study or during a recognized follow-up period, GSK 
Biologicals will be provided with a copy of any available post-mortem findings, 
including histopathology, and any verbal autopsy assessment. 
New or updated information will be recorded on the originally completed SAE Report 
Form. All changes on the SAE Report Form should be signed and dated by the 
investigator. The updated SAE Report Form should be resent to GSK Biologicals within 
24 hours of receipt of the follow-up information as outlined in Section 8.7.1. 
Outcome of any non-serious AE occurring within 30 days post-vaccination (i.e. 
unsolicited AE) or any SAE reported during the entire study will be assessed as: 
 Recovered/resolved 
 Not recovered/not resolved 
 Recovering/resolving 
 Recovered with sequelae/resolved with sequelae 
 Fatal (SAEs only). 
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8.7. Prompt reporting of serious adverse events to GSK 
Biologicals 
8.7.1. Time frames for submitting serious adverse event reports to GSK 
Biologicals 
8.7.1.1. For centers using paper CRF 
SAEs will be reported promptly to GSK once the investigator determines that the event 
meets the protocol definition of an SAE. The investigator or designate will fax or email 
the SAE reports to GSK Biologicals’ Study Contact for Serious Adverse Event Reporting 
WITHIN 24 HOURS OF HIS/HER BECOMING AWARE OF THESE EVENTS. Additional or 
follow-up information relating to the initial SAE report is also to be reported to the GSK 
Biologicals’ Study Contact for Serious Adverse Event Reporting within 24 hours of 
receipt of such information. This is intended to refer to events that are, in the opinion of 
the principal investigator, clinically important updates in the deterioration of a child’s 
clinical status, or to more precisely define a diagnosis. 
8.7.1.2. For centers using RDE with eCRF 
SAEs will be reported promptly to GSK once the investigator determines that the event 
meets the protocol definition of an SAE. The investigator will complete and submit 
relevant information on the SAEs in the SAE screens in eCRF WITHIN 24 HOURS OF 
HIS/HER BECOMING AWARE OF THESE EVENTS. Additional or follow-up 
information relating to the initial SAE report is also to be completed and submitted in the 
SAE screens in eCRF within 24 hours of receipt of such information. 
When paper SAE Report Form is used as back-up system (if electronic SAE reporting 
system does not work or after freezing of the subject’s eCRF), the investigator will fax or 
email the SAE reports to GSK Biologicals’ Central Safety for Serious Adverse Event 
Reporting. During the study, the investigator should update the SAE screens in eCRF 
once the electronic system is working again (and not later than 24 hours) and before 
using it to report additional information. 
8.7.2. Completion and transmission of serious adverse event reports to 
GSK Biologicals 
8.7.2.1. For centers using paper CRF 
Once an investigator becomes aware that a SAE has occurred in a study subject, she/he 
will report the information to GSK within 24 hours as outlined in Section 8.7.1. The SAE 
Report Form will always be completed as thoroughly as possible with all available details 
of the event, signed by the investigator (or designee), and forwarded to GSK within the 
designated time frames. If the investigator does not have all information regarding an 
SAE, he/she will not wait to receive additional information before notifying GSK of the 
event and completing the form. The form will be updated when additional information is 
received and forwarded to GSK WITHIN 24 HOURS as outlined in Section 8.7.1. 
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The investigator will always provide an assessment of causality at the time of the initial 
report as described in Section 8.5.2. 
Facsimile (Fax) or electronic transmission of the SAE Report Form are the preferred 
methods to transmit this information to the Study Contact for Reporting SAEs. In rare 
circumstances and in the absence of facsimile equipment or electronic connection, 
notification by telephone is acceptable, with a copy of the SAE Report Form to follow. 
Initial notification via the telephone does not replace the need for the investigator to 
complete and sign the SAE Report Form within 24 hours as outlined in Section 8.7.1. 
In the event of a death determined by the investigator to be related to vaccination, 
sending of the fax/electronic transmission must be accompanied by telephone call to the 
Study Contact for Reporting SAEs. 
Please see Sponsor Information Sheet for contact details of who to contact in the event of 
an SAE. 
GSK Biologicals Clinical Safety Physician  
(Back-up Study contact for reporting SAEs) 
GSK Biologicals Clinical Safety & Pharmacovigilance 
Fax:  or  
24/24 hour and 7/7 day availability 
Amended 26 November 2009 
Amended 01 December 2010 
8.7.2.2. For centers using RDE with eCRF 
Once an investigator becomes aware that a SAE has occurred in a study subject, the 
investigator will complete and submit the information in the SAE screens in eCRF within 
24 hours as outlined in Section 8.7.1. The SAE screens in eCRF will always be 
completed as thoroughly as possible with all available details of the event and will be 
submitted by the investigator. If the investigator does not have all information regarding 
an SAE, he/she will not wait to receive additional information before notifying GSK of 
the event and completing the SAE screens in eCRF. The SAE screens in eCRF should be 
updated when additional information is received WITHIN 24 HOURS as outlined in 
Section 8.7.1. 
The investigator will always provide an assessment of causality at the time of the initial 
report as described in Section 8.5.2. 
When paper SAE Report Form is used as back-up system (if electronic SAE reporting 
system does not work or after freezing of the subject’s eCRF), the investigator will report 
relevant information on SAEs to GSK within the 24 hours as outlined in Section 8.7.1. 
The SAE Report Form will always be completed as thoroughly as possible with all 
available details of the event, signed by the investigator, and forwarded to GSK within 
the designated time frames. If the investigator does not have all information regarding an 
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SAE, he/she will not wait to receive additional information before notifying GSK of the 
event and completing the form. When occurring during the study period, the investigator 
should update the SAE screens in eCRF once the electronic system is working again (and 
not later than 24 hours). When additional information is received on a SAE reported to 
GSK using the back-up paper SAE Report Form during the study period, the electronic 
system should be used to report the additional information WITHIN 24 HOURS if the 
electronic system is working again and only after updating the SAE screens in eCRF once 
the electronic system was working again. 
When additional information is received on a SAE after freezing of the subject's eCRF, 
new or updated information is to be recorded on the paper SAE Report Form, with all 
changes signed and dated by the investigator. The updated SAE Report Form should be 
resent to GSK Biologicals WITHIN 24 HOURS of receipt of the follow-up information 
as outlined in Section 8.7.1. 
In rare circumstances, if the electronic system for reporting SAEs does not work and in 
the absence of facsimile equipment, notification by telephone is acceptable, with a copy 
of the SAE Report Form to follow by email or by mail. Initial notification via the 
telephone does not replace the need for the investigator to complete and submit SAE 
screens in the eCRF (or complete and sign the SAE Report Form if back-up system need 
to be used) as outlined in Section 8.7.1. 
In the event of a death determined by the investigator to be related to vaccination, 
completion of SAE screens in the eCRF / sending of the fax (if electronic SAE reporting 
system does not work or after freezing of the subject’s eCRF) must be accompanied by 
telephone call to the Study Contact for Reporting SAEs. 
Please see Sponsor Information Sheet for contact details of who to contact in the event of 
an SAE. 
GSK Biologicals Clinical Safety Physician  
(Back-up Study contact for reporting SAEs) 
GSK Biologicals Clinical Safety & Pharmacovigilance 
Fax:  or  
24/24 hour and 7/7 day availability 
Amended 26 November 2009 
Amended 01 December 2010 
8.8. Regulatory reporting requirements for serious adverse 
events 
The investigator will promptly report all SAEs to GSK in accordance with the procedures 
detailed in Section 8.7. GSK Biologicals has a legal responsibility to promptly notify, as 
appropriate, both the local regulatory authority and other regulatory agencies about the 
safety of a product under clinical investigation. Prompt notification of SAEs by the 
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investigator to the Study Contact for Reporting SAEs is essential so that legal obligations 
and ethical responsibilities towards the safety of other subjects are met. 
The investigator, or responsible person according to local requirements, will comply with 
the applicable local regulatory requirements related to the reporting of SAEs to the 
IRB/IEC and, if required, to the applicable government authority. 
Investigator safety reports are prepared according to the current GSK policy and are 
forwarded to investigators as necessary. An investigator safety report is prepared for an 
SAE(s) that is both attributable to investigational product and unexpected. The purpose of 
the report is to fulfill specific regulatory and Good Clinical Practice (GCP) requirements, 
regarding the product under investigation. 
An investigator who receives an investigator safety report describing an SAE(s) or other 
specific safety information (e.g. summary or listing of SAEs) from GSK Biologicals will 
file it with the Investigator Brochure or other appropriate study documentation and will 
notify the IRB or IEC, if appropriate according to local requirements. 
8.9. Post-study adverse events and serious adverse events 
A post-study AE/SAE is defined as any event that occurs outside of the AE/SAE 
detection period defined in Section 8.4. Investigators are not obligated to actively seek 
AEs or SAEs in former study participants. 
However, if the investigator learns of any SAE, including a death, at any time after a 
subject has been discharged from the study, and he/she considers the event reasonably 
related to the investigational product, the investigator will promptly notify the Study 
Contact for Reporting SAEs. 
At centers using RDE with eCRF, after freezing of the subject’s eCRF, if SAE follow-ups 
or new SAEs have to be reported, the investigators or designate should use paper SAE 
Report Forms and the fax/email system. 
8.10. Pregnancy 
Not applicable. 
8.11. Treatment of adverse events 
Treatment of any adverse event is at the sole discretion of the investigator and according 
to current good medical practice. Any medication meeting the criteria listed in Section 
6.9 administered for the treatment of an AE should be recorded in the subject’s 
CRF/eCRF. 
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9. SUBJECT COMPLETION AND WITHDRAWAL 
9.1. Subject completion 
A subject who returns for the concluding visit/is available for the concluding contact 
foreseen in the protocol is considered to have completed the study. 
9.2. Subject withdrawal 
Subjects who are withdrawn because of AEs must be clearly distinguished from subjects 
who are withdrawn for other reasons. Investigators will follow subjects who are 
withdrawn as result of a SAE/AE until resolution of the event (see Section 8.6). Further 
obligations for withdrawn subjects are given in Section 5.1.4.6. 
Withdrawals will not be replaced. 
9.2.1. Subject withdrawal from the study 
From an analysis perspective, a ‘withdrawal’ from the study is any subject who did not 
come back for the concluding visit/was not available for the concluding contact foreseen 
in the protocol. 
A subject qualifies as a ‘withdrawal’ from the study when no study procedure has 
occurred, no follow-up has been performed and no further information has been collected 
for this subject from the date of withdrawal/last contact. 
Investigators will make an attempt to contact those subjects who do not return for 
scheduled visits or follow-up. 
Information relative to the withdrawal will be documented on the Study Conclusion page 
of the CRF/eCRF. The investigator will document whether the decision to withdraw from 
the study was made by the subject/ the subject’s parent or guardian or the investigator 
and which of the following possible reasons was responsible for withdrawal: 
 death 
 serious adverse event 
 non-serious adverse event 
 protocol violation (specify) 
 consent withdrawal, not due to an adverse event 
 moved from the study area 
 lost to follow-up 
 other (specify). 
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9.2.2. Subject withdrawal from investigational product 
A ‘withdrawal’ from the investigational product is any subject who does not receive the 
complete treatment, i.e. when no further planned dose is administered from the date of 
withdrawal. A subject withdrawn from the investigational product may not necessarily be 
withdrawn from the study as further study procedures or follow-up may be performed 
(safety or immunogenicity) if planned in the study protocol. 
Information relative to premature discontinuation of the investigational product will be 
documented on the Vaccine Administration page of the CRF/eCRF. The investigator will 
document whether the decision to discontinue further vaccination/treatment was made by 
the subject/ the subject’s parent or guardian or the investigator and which of the 
following possible reasons was responsible for withdrawal: 
 serious adverse event, 
 non-serious adverse event, 
 other (specify). 
9.3. Screen and Baseline Failures 
In all subjects who sign a consent form and subsequently are found to be ineligible for the 
trial or who withdraw prior to study start the reason the reason for exclusion will be 
captured in the screening booklet of the CRF/eCRF. 
10. DATA EVALUATION: CRITERIA FOR EVALUATION OF 
OBJECTIVES 
10.1. Primary endpoints 
10.1.1. Efficacy against clinical malaria disease when primary 
immunization starts at 6-12 weeks, or 5-17 months of age 
 For a primary schedule, the occurrence of cases of malaria meeting the primary case 
definition for clinical malaria disease over a period starting 14 days post Dose 3 
(Visit 4 +14 days) for 12 months in children aged 6-12 weeks at the time of Dose 1, 
or until the time at which 450 subjects experience a case, whichever occurs later. If 
450 are not accumulated by the time of boost (Visit 22), the analysis will proceed. 
 For a primary schedule, the occurrence of cases of malaria meeting the primary case 
definition for clinical malaria disease over a period starting 14 days post Dose 3 
(Visit 4 +14 days) for 12 months in children aged 5-17 months at the time of Dose 1, 
or until the time at which 450 subjects experience a case, whichever occurs later. If 
450 are not accumulated by the time of boost (Visit 22), the analysis will proceed. 
Amended 19 August 2008 
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10.2. Secondary endpoints 
10.2.1. Efficacy secondary endpoints 
10.2.1.1. Efficacy against severe malaria disease 
 For a primary schedule (pooled with and without a boost), the occurrence of severe 
malaria disease meeting the primary and secondary case definitions up to the time at 
which 250 subjects are diagnosed with severe malaria meeting the primary case 
definition. 
 For a primary schedule with and without a boost, the occurrence of severe malaria 
disease meeting the primary and secondary case definitions analyzed over the time 
periods starting 14 days post Dose 3 (Visit 4 +14 days) until boost (Visit 22), boost 
(Visit 22) until study end (Visit 34) and 14 days post Dose 3 (Visit 4 +14 days) until 
study end (Visit 34). 
10.2.1.2. Efficacy against incident severe anemia and malaria hospitalization 
 For a primary schedule with and without a boost, the occurrence of incident severe 
anemia and malaria hospitalization meeting the primary and secondary case 
definitions analyzed over the time periods starting 14 days post Dose 3 (Visit 4 +14 
days) until boost (Visit 22), boost (Visit 22) until study end (Visit 34) and 14 days 
post Dose 3 (Visit 4 +14 days) until study end (Visit 34). 
10.2.1.3. Efficacy; duration of efficacy of a primary course 
 For a primary schedule without a boost, the occurrence of clinical malaria disease 
meeting the primary case definition analyzed over the time periods starting 14 days 
post Dose 3 (Visit 4 +14 days) until boost (Visit 22), boost (Visit 22) until study end 
(Visit 34) and 14 days post Dose 3 (Visit 4 +14 days) until study end (Visit 34). 
10.2.1.4. Efficacy; role of a booster 
 For a primary schedule with and without a boost, the occurrence of clinical malaria 
disease meeting the primary case definition analyzed over the time period starting at 
boost (Visit 22) until study end (Visit 34). 
10.2.1.5. Efficacy under different transmission settings 
 For each site, for a primary schedule with and without a boost, the occurrence of 
clinical malaria disease meeting the primary case definition analyzed over the time 
periods starting 14 days post Dose 3 (Visit 4 +14 days) until boost (Visit 22), boost 
(Visit 22) until study end (Visit 34) and 14 days post Dose 3 (Visit 4 +14 days) until 
study end (Visit 34). 
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10.2.1.6. Efficacy against secondary case definitions of clinical malaria disease 
 For a primary schedule with and without a boost, the occurrence of clinical malaria 
disease meeting the secondary case definitions analyzed over the time periods 
starting 14 days post Dose 3 (Visit 4 +14 days) until boost (Visit 22), boost (Visit 22) 
until study end (Visit 34) and 14 days post Dose 3 (Visit 4 +14 days) until study end 
(Visit 34). 
10.2.1.7. Efficacy against prevalence of parasitemia 
 For a primary schedule without a boost, the presence of parasitemia at 18 months 
(Visit 22) and 30 months (Visit 34) after a primary schedule. 
 For a booster schedule, the presence of parasitemia 12 months after a boost (Visit 
34). 
10.2.1.8. Efficacy against prevalence of moderate and severe anemia 
 For a primary schedule without a boost, the presence of moderate and severe anemia 
at 18 months (Visit 22) and 30 months (Visit 34) after a primary schedule. 
 For a booster schedule, the presence of moderate and severe anemia 12 months after 
a boost (Visit 34). 
10.2.2. Safety secondary endpoints 
10.2.2.1. Safety of a primary course 
 For each age category, for a primary schedule, the occurrence of SAEs from Dose 1 
(Visit 2) until 14 months post Dose 1 (Visit 16). 
 For each age category, for a primary schedule, the occurrence of SAEs over a 30-day 
follow-up period (day of vaccination and 29 subsequent days) after each vaccination. 
Amended 26 November 2009 
 For each age category, for a primary schedule without boost, the occurrence of SAEs 
analyzed over the time periods starting at Dose 1 (Visit 2) until boost (Visit 22), 
boost (Visit 22) until study end (Visit 34) and Dose 1 (Visit 2) until study end (Visit 
34). 
 For each age category, for a primary schedule, the occurrence of solicited symptoms 
over a 7-day follow-up period (day of vaccination and 6 subsequent days) after each 
vaccination. 
 For each age category, for a primary schedule, the occurrence of all unsolicited 
symptoms over a 30-day follow-up period (day of vaccination and 29 subsequent 
days) after each vaccination. 
Amended 26 November 2009 
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 For each age category, for a primary schedule, the occurrence of unsolicited 
symptoms related to vaccination or leading to withdrawal over a 30-day follow-up 
period (day of vaccination and 29 subsequent days) after each vaccination. 
10.2.2.2. Safety of a booster dose 
 For each age category, for a booster dose, the occurrence of SAEs analyzed over the 
time period starting at boost (Visit 22) until study end (Visit 34). 
 For each age category, for a booster dose, the occurrence of SAEs over a 30-day 
follow-up period (day of vaccination and 29 subsequent days) after boost. 
Amended 26 November 2009 
 For each age category, for a booster dose, the occurrence of solicited symptoms over 
a 7-day follow-up period (day of vaccination and 6 subsequent days) after the boost. 
 For each age category, for a booster dose, the occurrence of all unsolicited symptoms 
over a 30-day follow-up period (day of vaccination and 29 subsequent days) after 
each vaccination. 
Amended 26 November 2009 
 For each age category, for a booster dose, the occurrence of unsolicited symptoms 
over a 30-day follow-up period (day of vaccination and 29 subsequent days) after the 
boost. 
10.2.3. Immunogenicity secondary endpoints 
10.2.3.1. Immunogenicity of a primary course 
 For each age category, for a primary schedule without a boost, the anti-CS antibody 
titers at screening, 1 month post Dose 3 (Visit 5), 18 months post Dose 3 (Visit 22) 
and 30 months post Dose 3 (Visit 34). 
 For each age category, for a primary schedule without a boost, the anti-HBs antibody 
titers at screening, 1 month post Dose 3 (Visit 5), 18 months post Dose 3 (Visit 22) 
and 30 months post Dose 3 (Visit 34). 
10.2.3.2. Immunogenicity of a booster dose 
 For each age category, for a booster schedule, the anti-CS antibody titers at boost 
(Visit 22), 1 month post boost (Visit 23), 12 months post boost (Visit 34). 
 For each age category, for a booster schedule, the anti-HBs antibody titers at boost 
(Visit 22), 1 month post boost (Visit 23), 12 months post boost (Visit 34). 
Amended 26 November 2009 
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10.2.3.3. Immunogenicity of polio serotypes 1, 2 and 3 
 To analyze in a subset of African children whose age at first dose will be 6-12 weeks 
the percentage of subjects with seroprotective levels of anti-polio 1, 2, 3 antibodies 
when OPV is given on a primary schedule co-administered with DTPwHepB/Hib 
(Tritanrix HepB/Hib) with or without RTS,S/AS01E at one month post dose 3 
(Visit 5). 
 To analyze in a subset of African children whose age at first dose will be 6-12 weeks 
the percentage of subjects with seroprotective levels of anti-polio 1, 2, 3 antibodies 
when OPV is given on a primary schedule (co-administered with DTPwHepB/Hib 
with or without RTS,S/AS01E) and a booster dose at 18 months post primary (with 
or without RTS,S/AS01E) at one month post boost (Visit 23). 
Amended 19 August 2008 
Amended 24 October 2008 
 
10.3. Additional Secondary endpoints 
Amended 19 August 2008 
10.3.1. Additional efficacy secondary endpoints 
Amended 19 August 2008 
10.3.1.1. Efficacy against other serious illness 
 For a primary schedule with and without a boost, the occurrence of other serious 
illness meeting the primary and secondary case definitions analyzed over the time 
periods starting 14 days post Dose 3 (Visit 4 + 14 days) until boost (Visit 22), boost 
(Visit 22) until study end (Visit 34) and 14 days post Dose 3 (Visit 4 + 14 days) until 
study end (Visit 34). Other serious illness is all medical hospitalization, sepsis and 
pneumonia. 
10.3.1.2. Efficacy against fatal malaria and all-cause mortality 
 For a primary schedule with and without a boost, the occurrence of fatal malaria 
(meeting the case definitions) and all-cause mortality analyzed over the time periods 
starting 14 days post Dose 3 (Visit 4 +14 days) until study end (Visit 34). 
10.3.1.3. Effect on growth 
 For a primary schedule with and without a boost, to compare the height/length for 
age z-score at study end (Visit 34). 
 For a primary schedule with and without a boost, to compare the weight for age z-
score at study end (Visit 34). 
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 For a primary schedule with and without a boost, to compare the mid upper arm 
circumference for age z-score at study end (Visit 34). 
 For children 6-12 weeks at first vaccination, for a primary schedule with and without 
boost, to compare the absolute height at study end (Visit 34). 
Amended 26 November 2009 
10.3.1.4. Gender-specific efficacy 
 In male and female children, for a primary schedule with and without a boost the 
occurrence of clinical malaria disease meeting the primary case definition analyzed 
over the time periods starting 14 days post Dose 3 (Visit 4 +14 days) until boost 
(Visit 22), boost (Visit 22) until study end (Visit 34) and 14 days post Dose 3 (Visit 
4 +14 days) until study end (Visit 34). 
If important differences in efficacy are observed between male and female children, then 
all primary and secondary immunological and efficacy endpoints will be presented for 
male and female children. 
10.3.2. Additional immunogenicity secondary endpoint 
Amended 19 August 2008 
10.3.2.1. Immunological correlates of protection 
 In cases and non-cases of malaria disease, CS-antibody titers. 
10.3.3. Additional safety and immunogenicity secondary endpoints 
Amended 19 August 2008 
10.3.3.1. Safety and immunogenicity in ‘special’ subgroups 
Note: HIV testing is not a trial procedure. This analysis will include all children known 
to be HIV-infected at enrollment or subsequently diagnosed 
 In HIV-infected children, for each age category, for a primary schedule with and 
without a boost, the occurrence of SAEs analyzed over the time periods starting at 
Dose 1 (Visit 2) until boost (Visit 22), boost (Visit 22) until study end (Visit 34) and 
Dose 1 (Visit 2) until study end (Visit 34). 
 In HIV-infected children, for each age category, for a primary schedule and a booster 
dose, the occurrence of unsolicited symptoms related to vaccination or leading to 
withdrawal over a 30-day follow-up period (day of vaccination and 29 subsequent 
days) after each vaccination. 
 In HIV-infected children, for each age category, for a primary schedule with and 
without a boost, the anti-CS antibody titers at screening, 1 month post Dose 3 (Visit 
5), 18 months post Dose 3 (Visit 22) and 30 months post Dose 3 (Visit 34). 
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 In HIV-infected children for each age category, for a primary schedule with and 
without a boost, the anti-HBs antibody titers at screening, 1 month post Dose 3 (Visit 
5), 18 months post Dose 3 (Visit 22) and 30 months post Dose 3 (Visit 34). 
 In low weight for age children (weight for age z-score -2) and in very low weight 
for age children (weight for age z-score -3), for each age category, for a primary 
schedule with and without a boost, the occurrence of SAEs analyzed over the time 
periods starting at Dose 1 (Visit 2) until boost (Visit 22), boost (Visit 22) until study 
end (Visit 34) and Dose 1 (Visit 2) until study end (Visit 34). 
 In low weight for age children (weight for age z-score -2) and in very low weight 
for age children (weight for age z-score -3), for each age category, for a primary 
schedule and a boost, the occurrence of unsolicited symptoms related to vaccination 
or leading to withdrawal over a 30-day follow-up period (day of vaccination and 29 
subsequent days) after each vaccination. 
 In low weight for age children (weight for age z-score -2) and in very low weight 
for age children (weight for age z-score -3), for each age category, for a primary 
schedule with and without a boost, the anti-CS antibody titers at screening, 1 month 
post Dose 3 (Visit 5), 18 months post Dose 3 (Visit 22) and 30 months post Dose 3 
(Visit 34). 
 In low weight for age children (weight for age z-score -2) and in very low weight 
for age children (weight for age z-score -3), for each age category, for a primary 
schedule with and without a boost, the anti-HBs antibody titers at screening, 1 month 
post Dose 3 (Visit 5), 18 months post Dose 3 (Visit 22) and 30 months post Dose 3 
(Visit 34). 
10.4. Additional secondary endpoints for the extension 
Efficacy 
 In each of at least three study centers, the occurence of clinical malaria disease 
meeting the primary and secondary case definitions for clinical malaria over a period 
starting 14 days post Dose 3 until the last visit of the extension. 
 Pooled across at least three study centers, the occurrence of severe malaria disease 
meeting the primary and secondary case definitions for severe malaria over annual 
time periods. 
 Pooled across all participating study centers, the occurrence of severe malaria 
disease meeting the primary and secondary case definitions for severe malaria over a 
period starting 14 days post Dose 3 until the last visit of the extension. 
 Pooled across all participating study centers, the occurrence of malaria 
hospitalization meeting the primary and secondary case definitions for malaria 
hospitalization over a period starting 14 days post Dose 3 until the last visit of the 
extension. 
 Pooled across all participating study centers, the presence of parasitemia at annual 
timepoints during the extension. 
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 Pooled across all participating study centers, the presence of moderate and severe 
anemia at annual timepoints during the extension. 
 Pooled across all participating study centers, the occurrence of all-cause mortality 
and fatal malaria meeting the primary and secondary case definitions over a period 
starting 14 days post Dose 3 until the last visit of the extension. 
 Pooled across all participating study centers, the occurrence of all-medical 
hospitalization meeting the primary case definition over a period starting 14 days 
post Dose 3 until the last visit of the extension. 
 Pooled across all participating study centers, the occurrence of pneumonia meeting 
the primary and secondary case definitions over a period starting 14 days post 
Dose 3 until the last visit of the extension. 
 Pooled across all participating study centers, the occurrence of sepsis meeting the 
primary case definition over a period starting 14 days post Dose 3 until the last visit 
of the extension. 
Safety 
 In all participating study centers, the occurrence of SAEs from Dose 1 (Day 0) until 
the end of extension. 
Immunogenicity 
 In a subset of subjects, the anti-CS antibody titers at annual timepoints during the 
extension. 
Effect on growth 
 In all subjects at all participating study centers, to compare the height for age z-score 
at the end of extension. 
Relevant efficacy and immunogenicity endpoints will also be analyzed by annual time 
periods, age category and by site. 
Amended 01 December 2010 
Note: Abbreviations for vaccination groups 
The following abbreviations are used to describe the vaccination groups in the next 
sections: 
R3R: Children to receive 3 doses of RTS,S/AS01E on a 0, 1, 2 schedule with an 
RTS,S/AS01E booster. 
R3C: Children to receive 3 doses of RTS,S/AS01E on a 0, 1, 2 schedule without an 
RTS,S/AS01E booster. 
C3C: Children to receive 3 doses of a comparator vaccine on a 0, 1, 2 schedule with a 
dose of comparator vaccine at Visit 22. 
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10.5. Estimated sample size 
10.5.1. Sample size and power: primary analysis 
10.5.1.1. Co-primary endpoint - Efficacy clinical malaria 
The analysis of efficacy of a primary schedule of RTS,S/AS01E will be carried out after 
at least 6000 subjects have been enrolled in the age category under evaluation and 
followed for 14½ months. 
It is anticipated that enrolment of the 5-17 months age category will be faster than in the 
infant age category and thus analysis of the two co-primary efficacy endpoints may take 
place at different times. In order to control the overall alpha-level (5%) of the trial both 
evaluations will be performed at a 2.5% alpha level (Bonferroni correction) thus, for the 
evaluation of the co-primary endpoint leading to 97.5% Confidence Intervals (CI). 
Assuming at least 5400 evaluable subjects (randomized 2:1), an attack rate in controls of 
10/100 cyr (children years at risk) over the follow-up period from 2 weeks post Dose 3 to 
1 year post Dose 3 and a true vaccine efficacy of 30%, the study has 90% power to detect 
a lower limit of the 97.5% CI around estimated VE above 0%. 
In the event that the attack rate is lower than anticipated and there have not been 450 
accumulated cases in the observation period 14 days to 12 months post dose 3, then the 
period of observation contributing to the primary analysis will be extended. The analysis 
will be conducted when 450 cases have accumulated, or until boost (visit 22) 
(approximately 18 months post dose 3) whichever occurs earlier. 
Amended 19 August 2008 
10.5.1.2. Secondary endpoint - Safety 
All available safety data to Month 14½ will be presented at each of the primary analyses. 
For a primary course, safety will be evaluated by examining SAEs, unsolicited adverse 
events related to vaccination or leading to drop out, and on a subset of subjects in each 
study center, reactogenicity and all unsolicited adverse events. 
Amended 26 November 2009 
Table 30 gives an overview of the power of the trial to detect statistically significant 
differences between study groups on the incidence of reported adverse events (2-sided 
Fisher’s exact test, alpha 5%). 
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Table 30 Power to detect fold-differences in SAE increases at primary 
analysis at Month 14.5 
Evaluable child years at risk in controls 2272 
Evaluable child years at risk in vaccines 4543 
 increase by factor of power 
Frequency of preferred 
term per year in controls 
1/100 1.5 35% 
2.0 87% 
1/500 3.5 67% 
4.5 90% 
1/1000 5.0 67% 
7.0 92% 
10.5.2. Sample size and power: secondary analysis 
A secondary analysis of severe malaria will be performed when 250 episodes of severe 
malaria meeting the primary case definition, pooled over the study centers and age 
categories, have occurred, or at the end of the follow-up period (Month 32), whichever 
occurs first. 
250 episodes give 80% power to detect 30% VE with a lower limit of the 95% CI above 
0%. Assuming 50% VE 250 episodes give 90% power to detect a lower limit of the 95% 
CI above 25%. 
10.5.3. Sample size and power: final analyses 
10.5.3.1. Efficacy: Evaluation of clinical malaria 
Recipients of a primary course of RTS,S/AS01E plus booster will be compared to 
controls (R3R vs C3C) over the time period starting 14 days post Dose 3 (Visit 4 + 14 
days) until study end (Visit 34). Analysis will be performed separately for the 2 age 
categories (6-12 weeks and 5-17 months). 
Assuming 2300 evaluable subjects in each age category per group, 30% VE and an attack 
rate in controls of 10/100 cyr, at the final analysis at Month 32, the trial has 90% power 
to detect a lower limit of the 95% CI of the VE estimate above 15%. Attack rate in 
controls of 20/100 cyr and 30/100 cyr lead to lower limits of 22% and 24% respectively. 
10.5.3.2. Efficacy: Evaluation of booster 
Recipients of a primary course of RTS,S/AS01E plus booster (R3R vs R3C) will be 
compared over the time period starting from booster at 18 months post primary schedule 
until study end at Month 32, pooled over the age categories. 
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Assuming 4500 evaluable subjects per group and 30% VE for the RTS,S/AS01E booster 
and 10% VE for the control booster and an attack rate in controls of 10/100 cyr, at the 
final analysis at Month 32, the trial has 88% power to detect a lower limit of the 95% CI 
above 0%. Attack rate in controls of 20/100 cyr and 30/100 cyr lead to 99% power to 
detect a lower limit of the 95% CI above 0%. If VE for controls is 15% the trial has 62%, 
91% and 99% power to detect a lower limit of the 95%CI above 0% for attack rates in 
control of 10/100 cyr, 20/100 cyr and 30/100 cyr respectively. 
VE will be estimated in recipients of a primary course of RTS,S/AS01E plus booster 
compared to recipients of control vaccines over the time period starting from booster 
(R3R vs C3C), 18 month post primary schedule until study end at Month 32, pooled over 
the age categories. Assuming 4500 evaluable subjects per group, 30% VE and an attack 
rate in controls of 10/100 cyr, at the final analysis at Month 32, the trial has 90% power 
to detect a lower limit of the 95% CI of 12%. Attack rate in controls of 20/100 cyr and 
30/100 cyr lead to lower limits of 18% and 21% respectively, and 21% respectively. 
10.5.3.3. Evaluation of safety 
Safety will be evaluated by examining SAEs, unsolicited adverse events related to 
vaccination or leading to drop out, and on a subset of subjects in each study center, 
reactogenicity and all unsolicited adverse events. This will be evaluated after a primary 
course and after a booster dose, separately for both age categories. 
Amended 26 November 2009 
Table 31 gives an overview of the power of the trial to detect statistically significant 
differences between study groups on the incidence of reported adverse events (2-sided 
Fisher’s exact test, alpha 5%). 
Safety will also be evaluated over the time period starting from Dose 1 (Visit 2) until 
boost (Visit 22) (R3R + R3C vs C3C) and from boost (Visit 22) until study end (Visit 34) 
(R3R vs C3C and R3C vs C3C). 
Table 31 gives an overview of the power of the trial to detect statistically significant 
differences between study groups on the incidence of reported adverse events (2-sided 
Fisher’s exact test, alpha 5%). 
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Table 31 Power to detect fold-differences in SAE increases at final analysis at 
Month 32 
Evaluable child years at risk in controls 5902 
Evaluable child years at risk in vaccines 11 805 
 increase by factor of power 
Frequency of preferred 
term per year in controls 
1/100 1.5 77% 
2.0 99% 
1/500 2.0 53% 
3.0 97% 
1/1000 3.0 71% 
4.0 95% 
10.5.4. Sample size and power: extension analysis 
10.5.4.1. Efficacy: evaluation of clinical malaria disease 
The power of the extension phase to demonstrate an overall benefit of all clinical malaria 
episodes over the total follow up time for each of the vaccine regimens R3C and R3R 
compared to control is presented below. 
The assumptions were an initial enrolment of at least 1200 subjects at each of the at least 
three centers, 15% drop out in primary trial phase and 10% drop out in extension phase. 
Results are presented for varying attack rates (0.2, 0.5 and 1.5 episodes per child per year 
at risk). 
0.2 episodes per child per year at risk: 
- 96% power to detect 30% benefit 
- 80% power to detect 23% benefit and -25% negative impact 
0.5 episodes per child per year at risk: 
- 99% power to detect 30% benefit 
- 80% power to detect 15% benefit and -16% negative impact 
1.5 episodes per child per year at risk: 
- 99% power to detect 30% benefit  
- 80% power to detect 10% benefit and -9% negative impact 
For the endpoint evaluating vaccine efficacy by yearly time periods pooled across the at 
least 3 participating centers, the study has at least 83 % power to detect 30 % VE in the 
subsequent year of follow up, assuming an attack rate of 0.7 episodes per child per year at 
risk. 
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10.5.4.2. Efficacy: evaluation of severe malaria disease 
The power of the study to establish an overall benefit on the total number of severe 
malaria episodes over the total follow up time is calculated. Data are pooled across 
vaccination regimens (R3C and R3R), age categories and sites and compared to control. 
Due to the uncertainty in the attack rate some scenarios are presented. 
Assumptions: 16000 enrolled in primary trial phase, 15% drop out in primary trial phase 
and 10% drop out in extension. 
Table 32 Power to detect VE against severe malaria disease 
Rate (pyr) 
power to detect 
30% benefit 
80% power to 
detect benefit of: 
80% power to 
detect negative 
impact of 
0.01 97% 22% -25% 
0.005 80% 30% -38% 
10.5.4.3. Safety: evaluation of uncommon safety events 
Extending the trial in all study sites for safety monitoring (SAEs) from Month 32 to end 
of December 2013 corresponds to a total follow up of approximately 73100 person years 
(20300 in controls and 40700 in RTS,S recipients) from study start to end of December 
2013. The power of the study to detect SAEs with the frequency is shown in the table 
below. 
Table 33 Power to detect SAEs 
Evaluable child years at risk in controls 20350 
Evaluable child years at risk in vaccines 40700 
 increase by factor of Power 
Frequency of preferred term per 
year in controls 
1/100 1.2 60% 
1.3 90% 
1/500 1.7 85% 
1.8 92% 
1/1000 2.0 81% 
2.2 91% 
Amended 01 December 2010 
10.6. Study cohorts to be evaluated 
10.6.1. Intention to Treat (ITT) cohort 
The ITT cohort will include all subjects that received at least 1 dose of study vaccine. 
The analyses on the ITT cohort will be performed per treatment assignment. 
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10.6.2. According-To-Protocol (ATP) cohort for analysis of 
immunogenicity 
The ATP cohort for immunogenicity will include all subjects included in the ITT that 
received all vaccinations according to protocol procedures within specified intervals and 
did not take any immune modifying medication or have blood transfusions. 
10.6.3. According To Protocol (ATP) cohort for analysis of efficacy 
The ATP cohort for efficacy will include all subjects included in the ITT who received all 
vaccinations according to protocol procedures within specified intervals. 
10.7. Analyses 
10.7.1. Covariates 
Potential covariates will include bednet usage (refer to Appendix J for methodology for 
collecting bednet data), distance from nearest inpatient health facility, distance from 
nearest outpatient health facility, pneumococcal/Hemophilus vaccination status, ethnicity, 
anthropometric measurements and feeding history. 
10.7.2. Primary analyses at 14.5 months post Dose 1 (for the first 6000 
children in each age category) 
Two primary analyses will be performed evaluating the efficacy and safety of 
RTS,S/AS01E over the first 14½ months of follow-up in the two age categories. In order 
to maintain blinding of the study, the analysis will be carried out by a statistician external 
to GSK and the investigator teams. 
Amended 01 December 2010 
10.7.2.1. Efficacy 
The analysis of efficacy of the primary schedule will be carried out when approximately 
6000 children in an age category have been enrolled and followed to Month 14½. The 
primary analysis will be performed on the ATP cohort for efficacy however, an ITT 
analysis will also be performed. 
As a primary analysis, VE will be evaluated taking into account first or only episodes 
using Cox regression, modeling the time to first or only episode as a function of group 
assignment (R3R+R3C vs C3C), stratified by study site. VE will be defined as 1 minus 
Hazard Rate (HR). 95% CI and p-values (Likelihood Ratio test) on VE estimates will be 
calculated from the Cox model. Primary analysis will be unadjusted for covariates, 
however both adjusted and unadjusted estimates will be presented. 
As there are two co-primary endpoints, for decision making, 97.5% CIs on VE will be 
calculated using the same methodology, ensuring an overall 2-sided 5% alpha-level. 
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Secondary analysis on the total number of episodes will also be performed. VE will be 
estimated from the incidence rate ratio using a negative binomial regression model 
allowing for interdependence between episodes within the same subject. 95% CI and p-
values on VE estimates (R3R+R3C vs C3C), defined as 1 minus Rate Ratio will be 
calculated from this model. To avoid counting the same malaria episode more than once, 
total time at risk will be adjusted by subtracting 14 days following a malaria episode 
meeting the malaria case definition under evaluation. Both unadjusted and adjusted 
estimates of VE will be presented. 
Amended 19 August 2008 
10.7.2.2. Safety 
Safety will be evaluated by examining SAEs, unsolicited adverse events related to 
vaccination or leading to drop out, and, on a subset of subjects in each study center 
reactogenicity and all unsolicited adverse events. The analysis of safety will be 
performed on the ITT cohort. 
Amended 26 November 2009 
Recipients of a primary course of RTS,S/AS01E will be compared to recipients of control 
(R3R + R3C vs C3C) over the time period starting from Dose 1 (Visit 2) until 14½ 
months post Dose 1. 
The proportion of subjects with an SAE, classified by the MedDRA preferred term level, 
will be tabulated with exact 95% CI. 
The proportion of subjects with fatal SAEs, classified by the MedDRA preferred term 
level, will be tabulated with exact 95% CI. 
The proportion of subjects reporting SAEs within 30 days following each vaccination 
will be tabulated with exact 95% CI. 
Amended 26 November 2009 
The proportion of subjects with at least one report of unsolicited AEs related to 
vaccination or leading to drop out classified by MedDRA preferred term, reported up to 
30 days after each vaccination will be tabulated with exact 95% CI. The same tabulation 
will be performed for Grade 3 unsolicited AEs. 
For seizures occurring within 7 days of vaccination, an analysis will be performed based 
on the Brighton Collaborations guidelines [Bonhoeffer, 2004]. This includes descriptive 
tables of the time relationship of seizures to vaccination, the duration of seizures, the 
level of diagnostic certainty and the relationship to episodes of fever. 
For rashes and mucocutaneous diseases within 30 days of vaccination, an analysis will be 
performed based on the Brighton Collaboration Guidelines [Beigel, 2007]. 
Amended 26 November 2009 
For a subset of subjects in each study site, the percentage of subjects with at least one 
local AE (solicited and unsolicited), with at least one general AE (solicited and 
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unsolicited) and with any AE during the solicited follow-up period (7 days) will be 
tabulated with exact 95% CI after each vaccine dose and overall. The percentage of doses 
followed by at least one local AE (solicited and unsolicited), by at least one general AE 
(solicited and unsolicited) and by any AE will be tabulated, overall vaccination course, 
with exact 95% CI. 
For a subset of subjects in each study site, the percentage of subjects reporting each 
individual solicited local and general AE during the solicited follow-up period (7 days) 
will be tabulated with exact 95% CI. The percentage of doses followed by each 
individual solicited local and general AE will be tabulated, overall and by vaccination 
course, with exact 95% CI. 
For all solicited symptoms, the same tabulation will be performed for Grade 3 AEs and 
for AEs with relationship to vaccination. 
10.7.2.3. Immunogenicity 
Immunogenicity will be evaluated on a subset of subjects in each study site. Analyses of 
immunogenicity will be performed separately for both age categories. The primary 
analysis will be based on the ATP cohort for immunogenicity, however, ITT analyses 
will also be performed. 
The percentage of subjects with seropositive levels of anti-CS (proportion of subjects 
with anti-CS antibody titers greater than or equal to 0.5 EU/mL) with 95% CI will be 
determined at each blood sampling timepoint. Antibody titers will be summarized by 
GMT with 95% CI at all timepoints at which serological samples are taken. Antibody 
titers after the third dose will also be investigated using reverse cumulative curves. 
The seroprotective level for anti-HBs is  10 mIU/mL. The percentage of subjects with 
protective levels of anti-HBs (  10 mIU/mL) with 95% CI will be determined at each 
blood sampling timepoint. Antibody titers will be summarized by GMT with 95% CI at 
all timepoints at which serological samples are taken. Antibody titers after the third dose 
will also be investigated using reverse cumulative curves. 
10.7.3. Secondary analyses at the time 250 cases of severe malaria have 
accumulated 
In order to maintain blinding of the study, the secondary analysis will be carried out by a 
statistician external to GSK and the investigator teams. 
Amended 01 December 2010 
10.7.3.1. Efficacy 
VE against severe malaria disease will be evaluated when 250 subjects (both age 
categories together) have reported an episode of severe malaria meeting the primary case 
definition. The primary analysis of interest is comparing the pooled RTS,S/AS01E 
groups (with or without RTS,S/AS01E booster dose) versus controls (R3R+R3C vs 
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C3C). VE against severe malaria disease will be estimated as 1-RR where RR is the risk 
ratio (proportion of subjects reporting severe malaria disease in the RTS,S/AS01E group 
over the proportion in controls) together with 95% CIs. 
Multiple episodes of severe malaria are considered secondary and will be analyzed the 
same way as multiple episodes of clinical malaria, by negative binomial regression 
allowing for interdependence between episodes within the same subject. 95% CI and p-
values on VE estimates will be calculated from this model. 14 days following a malaria 
episode meeting the severe malaria case definition under evaluation will be subtracted 
from follow-up time. Both unadjusted and adjusted estimates of VE will be presented. 
Amended 19 August 2008 
10.7.3.2. Safety 
Safety will be evaluated by examining SAEs from study start (Dose 1) up to the time 
when 250 accumulated episodes have occurred. All available safety data for both age 
categories will be presented for the ITT cohort. All safety analyses will be performed 
separately for both age categories. 
Recipients of a primary course of RTS,S/AS01E with or without booster will be 
compared to recipients of control (R3R + R3C vs C3C) over the time period starting from 
Dose 1 (Visit 2) until 250 accumulated episodes have occurred. 
The proportion of subjects with an SAE, classified by the MedDRA preferred term level, 
will be tabulated with exact 95% CI. 
The proportion of subjects with fatal SAEs, classified by the MedDRA preferred term 
level, will be tabulated with exact 95% CI. 
10.7.4. Secondary analysis at Month 20 (Visit 22) 
An analysis of safety, efficacy and immunogenicity will be performed when all children 
have completed 18 months follow-up post Dose 3 (Visit 22). The endpoints including an 
assessment at Visit 22 are: 
 Efficacy against severe malaria disease (Refer to 10.2.1.1) 
 Efficacy against incident severe anemia and malaria hospitalization (Refer to 
10.2.1.2) 
 Efficacy; duration of efficacy of a primary course (Refer to 10.2.1.3) 
 Efficacy under different transmission settings (Refer to 10.2.1.5) 
 Efficacy against secondary case definitions of clinical malaria disease (Refer to 
10.2.1.6) 
 Efficacy against prevalence of parasitemia (Refer to 10.2.1.7) 
 Efficacy against prevalence of moderate and severe anemia (Refer to 10.2.1.8) 
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 Efficacy against other serious illness (Refer to 10.3.1.1) 
 Safety of a primary course (Refer to 10.2.2.1) 
 Immunogenicity of a primary course (Refer to 10.2.3.1) 
 Safety and immunogenicity in ‘special’ subgroups (Refer to 10.3.3.1) 
The detailed analysis of gender-specific vaccine efficacy (as described in 10.3.1.4) will 
be reported in full at the end of the study (Visit 34). 
Amended 23 January 2012 
10.7.5. Secondary analysis at one month post booster (Month 21) 
10.7.5.1. Polio serotypes 1, 2 and 3 antibody responses 
A secondary analysis of the immune response for polio serotypes 1, 2 and 3 when OPV is 
given on a primary schedule co-administered with DTPwHepB/Hib (Tritanrix HepB/Hib) 
with or without RTS,S/AS01E at screening, at one month post primary course (Visit 5) 
and following a booster dose at 18 months post primary (with or without RTS,S/AS01E) 
at one month post boost will be performed in a subset of children in the 6 to 12 weeks age 
category. The seroprotective level for anti-polio 1, 2, 3 is  8 EU/mL. The percentage of 
subjects with protective levels of anti-polio 1, 2, 3 antibodies with 95% CI will be 
determined at one month post primary series (Visit 5) and at one month post booster dose 
(at Visit 23). Antibody titers will be summarized by GMT with 95% CI. Antibody titers 
will also be investigated using reverse cumulative curves. 
Amended 19 August 2008 
Amended 24 October 2008 
10.7.6. Final analyses 
10.7.6.1. Final analyses - Efficacy 
Efficacy; role of a Booster 
As a secondary endpoint, the benefit of a booster dose of RTS,S/AS01E given 18 months 
post primary schedule will be evaluated. These evaluations will be performed pooled 
across age categories. The first analysis of interest will compare the group that received a 
primary schedule of RTS,S/AS01E and a booster of RTS,S/AS01E to the group receiving 
a primary schedule of RTS,S/AS01E and a control booster (R3R vs R3C) over a 
timeframe starting from the booster dose until study end (at Month 32). First or only 
episodes will be modeled through a Cox regression model stratified by study site to 
estimate the HR and its 95% CI as well as the likelihood ratio p-value. 
Another analysis, using the methodology outlined above will be performed to estimate 
VE of the group that received a primary schedule of RTS,S/AS01E and a booster of 
RTS,S/AS01E (R3R vs C3C) and VE of the group receiving a primary schedule of 
RTS,S/AS01E and a control booster (R3C vs C3C) over a timeframe starting from the 
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booster dose until study end (at Month 32). These analyses will be performed for both 
age categories separately. VE estimates, both adjusted and unadjusted, for first or only 
episodes as well as for multiple episodes will be presented. 
Efficacy; duration of efficacy of a primary course 
At final analysis at Month 32, evaluations of VE over the entire follow-up period will be 
performed using the same methodology as outlined above for first or only episodes and 
multiple episodes (R3C vs C3C). 
Efficacy under different transmission settings 
Evaluating the entire follow-up period also allows estimating VE in different 
transmission settings. The study sites being a proxy for transmission setting, VE 
estimates by study site will be presented. 
10.7.6.2. Final analyses - Safety 
Safety will be evaluated by examining SAEs from study start (Dose 1) until study end at 
Month 32. All safety analyses will be performed separately for both age categories on the 
ITT cohort. 
Recipients of a primary course of RTS,S/AS01E with or without a boost will be 
compared to recipients of control (R3R + R3C vs C3C) over the time period starting from 
Dose 1 (Visit 2) until study end (Visit 34). This analysis will be repeated for R3R vs C3C 
and R3C vs C3C. 
Safety will also be evaluated over the time period starting from Dose 1 (Visit 2) until 
boost (Visit 22) (R3R + R3C vs C3C) and from boost (Visit 22) until study end (Visit 34) 
(R3R vs C3C and R3C vs C3C). 
The proportion of subjects with an SAE, classified by the MedDRA preferred term level, 
will be tabulated with exact 95% CI. 
The proportion of subjects with fatal SAEs, classified by the MedDRA preferred term 
level, will be tabulated with exact 95% CI. 
The proportion of subjects reporting SAEs within 30 days following boost will be 
tabulated with exact 95% CI. 
Amended 26 November 2009 
10.7.6.3. Final analyses - Immunogenicity 
Immunogenicity will be evaluated on a subset of subjects in each study site. Analyses of 
immunogenicity will be performed separately for both age categories. The primary 
analysis will be based on the ATP cohort for immunogenicity, however, ITT analyses 
will also be performed. 
The percentage of subjects with seropositive levels of anti-CS (proportion of subjects 
with anti-CS antibody titers greater than or equal to 0.5 EU/mL) with 95% CI will be 
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determined at each blood sampling timepoint. Antibody titers will be summarized by 
GMT with 95% CI at all timepoints at which serological samples are taken. Antibody 
titers after the third dose will also be investigated using reverse cumulative curves. 
The seroprotective level for anti-HBs is  10 mIU/mL. The percentage of subjects with 
protective levels of anti-HBs (  10 mIU/mL) with 95% CI will be determined at each 
blood sampling timepoint. Antibody titers will be summarized by GMT with 95% CI at 
all timepoints at which serological samples are taken. Antibody titers after the third dose 
will also be investigated using reverse cumulative curves. 
As a secondary analysis, associations between immune responses and VE will be 
investigated. Full details will be provided in the statistical analysis plan (SAP). 
Amended 19 August 2008 
Amended 23 January 2012 
10.7.7. Extension analyses 
10.7.7.1. Extension analysis – Risk benefits over time 
A number of statistical analyses will be performed to assess the risk benefit ratio of the 
RTS,S/AS01E vaccine over time: safety, all episodes, cases averted and vaccine efficacy 
against prevalent parasitemia. 
 Safety will be evaluated by examining all SAEs and fatal SAEs from study start 
(Dose 1) until study end of extension (Visit 38). SAEs will be classified by the 
MedDRA preferred term level and tabulated with exact 95% CI. All safety analyses 
will be performed on the ITT cohort pooled for age categories. Recipients of a 
primary course of RTS,S/AS01E with or without a boost will be compared to 
recipients of control (R3R + R3C vs C3C). This analysis will be repeated for R3R vs 
C3C and R3C vs C3C. 
 All severe disease episodes over time will be presented in all sites. It will be 
analysed by determining vaccine efficacy (VE) by comparison of multiple episodes 
over the total follow up time post Dose 3. A negative binomial regression model 
allowing for interdependence between episodes within the same subject will be used. 
95% CI and p-values on VE estimates, defined as 1 minus Rate Ratio will be 
calculated from this model. 
 Cases of severe disease averted over time will be calculated in all sites. The 
calculation will use observed rates in controls and the estimated VE from the model 
described above and results will be expressed as the number of severe episodes 
averted per 1000 children at risk per year (cyr) with 95% CIs. Cumulative cases 
averted over time will be calculated and expressed as per 1000 cyr with 95% CIs and 
presented graphically. 
 Vaccine efficacy against prevalent parasitemia will be calculated in all sites as 
relative reduction calculated as 1- (prevalence in RTS,S / prevalence in controls). 
 All clinical malaria disease episodes over time will be presented in at least three 
transmission settings. It will be analysed by determining vaccine efficacy (VE) by 
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comparison of multiple episodes over the total follow up time post Dose 3. A 
negative binomial regression model allowing for interdependence between episodes 
within the same subject will be used. 95% CI and p-values on VE estimates, defined 
as 1 minus Rate Ratio will be calculated from this model. 
 Cases of clinical malaria disease averted over time will be calculated in at least three 
transmission settings. The calculation will use observed rates in controls and the 
estimated VE from the model described above and results will be expressed as the 
number of clinical episodes averted per 1000 children at risk per year (cyr) with 95% 
CIs. Cumulative cases averted over time will be calculated and expressed as per 
1000 cyr with 95% CIs and presented graphically. 
10.7.7.2. Additional analyses 
For consistency with the analyses presented for the primary trial phase the following 
analysis will also be conducted. 
 Vaccine efficacy against first or only episodes of clinical malaria disease will be 
assessed using Cox regression models. VE is defined as 1 minus R where R was the 
hazard ratio of the RTS,S/AS01E group versus control. 95% CI and p-values 
(Likelihood Ratio test) on VE estimates will be calculated from the Cox model. Cox 
regression assumes proportional hazards throughout the follow-up period. This 
assumption will be checked by plotting, per group, the log of the cumulative hazard 
against the log of time. Under the assumption of proportionality of the hazard, both 
curves should be parallel. A test based on the Schoenfeld residuals will be 
performed. 
 Vaccine efficacy against at least one episode of severe malaria disease will be 
estimated as 1-RR where RR is the risk ratio (proportion of subjects reporting severe 
malaria disease in the RTS,S/AS01E group over the proportion in controls) together 
with 95% CIs. 
 Vaccine efficacy against all clinical episodes will be assessed by breaking down the 
time at risk in annual periods. 
 Prevalent Parasitemia and anemia will be analyzed by 2x2 tables and Fisher exact 
tests. Mean parasite density and mean Hb values will also be tabulated. 
Amended 01 December 2010 
11. ADMINISTRATIVE MATTERS 
To comply with Good Clinical Practice important administrative obligations relating to 
investigator responsibilities, monitoring, archiving data, audits, confidentiality and 
publications must be fulfilled. See Appendix A for details. 
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primary sporozoite challenge and rechallenge, of GSK Biologicals’ candidate malaria 
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administered intramuscularly at months 0, 1, 2 in healthy malaria-naive volunteers aged 
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Appendix A Administrative Matters 
I. Responsibilities of the Investigator 
 To ensure that he/she has sufficient time to conduct and complete the study and has 
adequate staff and appropriate facilities and equipment which are available for the 
duration of the study and to ensure that other studies do not divert essential subjects 
or facilities away from the study at hand. 
 To submit an up-to-date curriculum vitae or Investigator Biography and other 
credentials (e.g. medical license number in the United States) to GSK and—where 
required—to relevant authorities. It is recommended that this documentation 
indicates any previous clinical research experience and history of training in GCP. 
 To acquire the reference ranges for laboratory tests performed locally and, if required 
by local regulations, obtain the laboratory’s current certification or Quality 
Assurance procedure manual. 
 To ensure that no clinical samples (including serum samples) are retained onsite or 
elsewhere without the approval of GSK Biologicals and the express written informed 
consent of the subject and/or the subject’s legally authorized representative.  
 To perform no other biological assays on the clinical samples except those described 
in the protocol, its amendment(s) or ancillary protocols connected with this study.  
 To prepare and maintain adequate subject source data or raw data designed to record 
observations, and other data pertinent to the study. 
 To conduct the study in compliance with the protocol any amendment and “Good 
Clinical Practice” (GCP) and all applicable regulatory requirements. 
 To co-operate with a representative of GSK Biologicals in the monitoring process of 
the study and in resolution of queries about the data. 
 To permit drug regulatory agencies and GSK audits. 
II. Protocol Amendments and Administrative changes 
 No changes to the study protocol will be allowed unless discussed in detail with the 
GSK Biologicals' Clinical Development Manager/Medical Monitor and filed as an 
amendment/administrative change to this protocol. 
 Any amendment/administrative change to the protocol will be adhered to by the 
participating centre(s) and will apply to all subjects. Written IRB/IEC approval of 
protocol amendments is required prior to implementation, except where permitted by 
all applicable regulatory requirements; administrative changes and amendments not 
submitted for approval are submitted to IRBs/IECs for information only. 
 Submission of protocol amendments to regulatory agencies will occur in accordance 
with local regulatory requirements. For some countries, submission to the local 
regulatory authority may not be required. When submission to the local regulatory 
authority is required, the timing of the submission relative to IEC/IRB submission or 
approval and whether or not the authority will provide their approval of or favorable 
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opinion on the amendment before it can be implemented will depend on local 
regulatory requirements. 
III. Sponsor’s Termination of Study 
GSK Biologicals reserves the right to temporarily suspend or prematurely discontinue 
this study either at a single site or at all sites at any time for reasons including, but not 
limited to, safety or ethical issues or severe non-compliance. Reasons for suspension or 
early termination will be documented in the study file at GSK Biologicals.  
If GSK Biologicals determines that suspension or early termination is needed, GSK 
Biologicals will discuss this with the Investigator (including the reasons for taking such 
action). When feasible, GSK Biologicals will provide advance notification to the 
investigator of the impending action prior to it taking effect. 
GSK Biologicals will promptly inform, via written communication, all investigators 
and/or institutions conducting the study, if the study is suspended or terminated for safety 
reasons, and will also inform the regulatory authorities of the suspension or termination 
of the study and the reason(s) for the action. If required by applicable regulations, the 
investigator must inform the IEC/IRB promptly and provide the reason for the suspension 
or termination. 
If the study is prematurely discontinued, all study data must be returned to GSK. In 
addition, arrangements will be made for all unused investigational product(s) in 
accordance with the applicable GSK procedures for the study. Financial compensation to 
investigators and/or institutions will be in accordance with the agreement established 
between the investigator and/or institutions and GSK. 
IV. Case Report Form Instructions / Remote Data Entry Instructions 
In this study, where technically possible, study centers will use remote data entry (RDE) 
with electronic case report form (eCRF) in preference to conventional paper case report 
form (CRF) 
Remote Data Entry 
Where technically possible, remote data entry (RDE) will be used as the method for data 
collection, which means that subject information will be entered into a computer at the 
investigational site preferably within 5 working days of becoming available. The site will 
be capable of modifying the data to assure accuracy with source documentation. All 
new/updated information will be reviewed and verified by a GSK Biologicals’ 
representative. This information will finally be stored in a central database maintained by 
GSK Biologicals. At the conclusion of the study, GSK Biologicals will archive the study 
data in accordance with internal procedures. In addition, the investigator will be provided 
with a CD-ROM of the final version of the data generated at the investigational site. 
Specific instructions for use of RDE will be included in the training material provided to 
the investigational site. 
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Case Report Forms 
Prior to screening the first potential participant, the investigator will provide the Site 
Monitor with a list (Site Staff Signature Sheet) showing the name and title, signature and 
initials of all site staff who have a critical effect on the conduct of the study and to whom 
the investigator has delegated significant study related duties such as entering data on the 
CRFs or changing entries on CRFs. If the authorized individuals should change during 
the study, the investigator is to inform GSK Biologicals GSK Biologicals’ representative 
of the specific change(s). 
CRFs (and subject diary cards, if applicable), will be supplied by GSK Biologicals for 
recording all data. It is the responsibility of the investigator or co-investigator to ensure 
that study data are legible, accurate, adequately recorded and, when entered on paper 
copy, completely filled in with a black ink fountain or ballpoint pen. 
Errors must be corrected by drawing a single line through the incorrect entry and writing 
in the new value/data positioned as close to the original as possible. The correction must 
then be initialed and dated (and justified, whenever possible), where necessary, by the 
authorized individual making the change. The original entry must not be obliterated, 
overwritten or erased when a correction is made. 
When a subject completes a visit, it is anticipated that relevant sections of the CRF will 
be completed by the investigator (or designated staff as documented in the Site Staff 
Signature Sheet) as soon as possible after the last data becoming available (preferably 
within 5 working days of becoming available). Similarly, when a subject completes a 
study, it is anticipated that all relevant CRF pages will be completed promptly after the 
last data becoming available. This also applies to forms for potential study participants 
who were screened but not randomized to a study group. 
As soon as the subject has completed/withdrawn from the study and the CRF is 
completed, the investigator or medically qualified sub-investigator to whom this task has 
been delegated will sign the study conclusion pages of the CRF to confirm that they have 
reviewed the data and that the data are complete and accurate. In all cases the investigator 
remains accountable for the study data collected. 
An original (top copy) CRF or log sheets must be submitted for all subjects who have 
undergone protocol specific procedures, whether or not the subject completed the study. 
While completed CRFs are reviewed by a GSK Biologicals’ professional monitor at the 
study site, errors detected by subsequent in-house CRF review may necessitate 
clarification or correction of errors with documentation and approval by the investigator 
or appropriately qualified designee as documented on the Site Staff Signature Sheet. In 
all cases, the investigator remains accountable for the study data. Wherever possible the 
investigator should assist in the clarification or correction of errors detected after study 
finalization promptly after being brought to the attention of the investigator (preferably 
within 5 working days). 
Any questions or comments related to the CRF should be directed to the assigned Site 
Monitor. 
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V. Monitoring by GSK Biologicals 
To ensure compliance with the protocol, monitoring visits by a professional 
representative of the sponsor will be scheduled to take place early in the study, during the 
study at appropriate intervals and after the last subject has completed the study. It is 
anticipated that monitoring visits will occur at a frequency defined and communicated to 
the investigator before study start.  
These visits are for the purpose of confirming that GSK Biologicals’ sponsored studies 
are being conducted in accordance with the ethical principles that have their origins in the 
Declaration of Helsinki and that are consistent with Good Clinical practice (GCP) and the 
applicable regulatory requirement(s) (verifying continuing compliance with the protocol, 
amendment(s), reviewing the investigational product accountability records, verifying 
that the site staff and facilities continue to be adequate to conduct the study. Direct access 
to all study-related site and source data/ documents is mandatory for the purpose of 
monitoring review. The monitor will perform a CRF review and a Source Document 
verification (verifying CRF/ RDE entries by comparing them with the source 
data/documents that will be made available by the investigator for this purpose: any data 
item for which the CRF will serve as the source must be identified, agreed and 
documented. Data to be recorded directly into the CRF pages/RDE screens will be 
specified in writing preferably in the source documentation agreement form that is 
contained in both the monitor’s and investigator’s study file. For RDE, the monitor will 
mark completed and approved screens at each visit. The investigator must ensure 
provision of reasonable time, space and adequate qualified personnel for monitoring 
visits. Source data verification (SDV) must be conducted using a GSK standard SDV 
sampling strategy (as defined at the study start in the study specific monitoring 
guidelines) in which monitors will perform partial SDV for all subjects and full SDV for 
selected subjects. 
VI. Archiving of Data 
Following closure of the study, the investigator must maintain all site study records in a 
safe and secure location. The records must be maintained to allow easy and timely 
retrieval, when needed (e.g. audit or inspection), and, whenever feasible, to allow any 
subsequent review of data in conjunction with assessment of the facility, supporting 
systems, and staff. Where permitted by applicable laws/regulations or institutional policy, 
some or all of these records can be maintained in a validated format other than hard copy 
(e.g. microfiche, scanned); however, caution needs to be exercised before such action is 
taken. The investigator must assure that all reproductions are legible and are a true and 
accurate copy of the original, and meet accessibility and retrieval standards, including re-
generating a hard copy, if required. Furthermore, the investigator must ensure there is an 
acceptable back-up of these reproductions and that an acceptable quality control process 
exists for making these reproductions. 
GSK will inform the investigator/ institution of the time period for retaining these records 
to comply with all applicable regulatory requirements. However, the investigator/ 
institution should seek the written approval of the sponsor before proceeding with the 
disposal of these records. The minimum retention time will meet the strictest standard 
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applicable to that site for the study, as dictated by ICH GCP E6 Section 4.9, any 
institutional requirements or applicable laws or regulations, or GSK 
standards/procedures; otherwise, the minimum retention period will default to 15 years.  
The investigator/ institution must notify GSK of any changes in the archival 
arrangements, including, but not limited to, the following: archival at an off-site facility, 
transfer of ownership of the records in the event the investigator leaves the site.  
VII. Audits 
For the purpose of compliance with Good Clinical Practice and Regulatory Agency 
Guidelines it may be necessary for GSK or a Drug Regulatory Agency to conduct a site 
audit. This may occur at any time from start to after conclusion of the study. 
When an investigator signs the protocol, he agrees to permit drug regulatory agencies and 
GSK audits, providing direct access to source data/ documents. Furthermore, if an 
investigator refuses an inspection, his data will not be accepted in support of a New Drug 
Registration and/or Application, Biologics Licensing Application. 
Having the highest quality data and studies are essential aspects of vaccine development. 
GSK has a Regulatory Compliance staff who audit investigational sites. Regulatory 
Compliance assesses the quality of data with regard to accuracy, adequacy and 
consistency. In addition, Regulatory Compliance assures that GSK Biologicals’ 
sponsored studies are in accordance with GCP and that relevant regulations/guidelines 
are being followed. 
To accomplish these functions, Regulatory Compliance selects investigational sites to 
audit. These audits usually take 1 to 2 days. GSK’s audits entail review of source 
documents supporting the adequacy and accuracy of CRFs, review of documentation 
required to be maintained, and checks on vaccine accountability. GSK’s audit therefore 
helps prepare an investigator for a possible regulatory agency inspection as well as 
assuring GSK Biologicals of the validity of the database across investigational sites. 
The Inspector will be especially interested in the following items: 
 Log of visits from the sponsor’s representatives 
 Study personnel 
 Study file 
 Safety reporting 
 IRB/IEC and regulatory authority approvals 
 Facilities 
 monitoring 
 Vaccine accountability 
 Approved study protocol and amendments and investigator brochure 
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 Informed consent of the subjects (written consent or witnessed oral if applicable ) 
 Medical records and other source documents supportive of CRF data 
 Reports to the IRB/IEC and the sponsor 
 Record retention. 
GSK Biologicals will gladly help investigators prepare for an inspection. 
VIII. Ownership, Confidentiality and Publication 
Ownership: 
All information provided by GSK and all data and information generated by the site as 
part of the study (other than a subject’s medical records) are the sole property of GSK. 
All rights, title, and interests in any inventions, know-how or other intellectual or 
industrial property rights which are conceived or reduced to practice by site staff during 
the course of or as a result of the study are the sole property of GSK, and are hereby 
assigned to GSK. 
If a written contract for the conduct of the study which includes ownership provisions 
inconsistent with this statement is executed between GSK and the study site, that 
contract’s ownership provisions shall apply rather than this statement. 
Tripartite agreements are in place for the conduct of the study the signatories to which are 
the investigator groups, MVI and GSK. The operation of the investigator network is 
guided by Clinical Trials Partnership Committee (CTPC) charter. 
Confidentiality: 
Documented evidence that a potential investigator is aware and agrees to the confidential 
nature of the information related to the study must be obtained by means of a 
confidentiality agreement. 
All information provided by GSK and all data and information generated by the site as 
part of the study (other than a subject’s medical records) will be kept confidential by the 
investigator and other site staff. This information and data will not be used by the 
investigator or other site personnel for any purpose other than conducting the study. 
These restrictions do not apply to: (1) information which becomes publicly available 
through no fault of the investigator or site staff; (2) information which it is necessary to 
disclose in confidence to an IEC or IRB solely for the evaluation of the study; (3) 
information which it is necessary to disclose in order to provide appropriate medical care 
to a study subject; or (4) study results which may be published as described in the next 
paragraph. If a written contract for the conduct of the study which includes 
confidentiality provisions inconsistent with this statement is executed, that contract’s 
confidentiality provisions shall apply rather than this statement. 
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Publication: 
For multicenter studies, the first publication or disclosure of study results shall be a 
complete, joint multicenter publication or disclosure coordinated by GSK. Thereafter, 
any secondary publications will reference the original publication(s). 
All publications will be based on a pre-agreed Statistical analysis plan (SAP). In the 
event that GSK and MVI make or coordinate a publication of results from a study in the 
CDP, then authorship shall be determined in accordance with GSK and MVI’s respective 
policies and generally accepted standards for authorship. Principles of authorship for 
publications on multi-site studies shall be determined by the CTPC prior to the 
commencement of each trial. 
Prior to submitting for publication, presentation, use for instructional purposes, or 
otherwise disclosing the study results generated by the site (collectively, a “Publication”), 
the investigator shall provide GSK with a copy of the proposed Publication and allow 
GSK a period to review the proposed Publication (at least 21 [twenty-one] days, or at 
least 15 [fifteen] working days for abstracts/posters/presentations). Proposed Publications 
shall not include either GSK, MVI or another investigator group’s confidential 
information other than the study results or personal data on any subject, such as name or 
initials and according to the terms of the clinical trial agreement. 
At GSK’s request, the submission or other disclosure of a proposed Publication will be 
delayed a sufficient time to allow GSK to seek patent or similar protection of any 
inventions, know-how or other intellectual or industrial property rights disclosed in the 
proposed Publication. 
If a written contract for the conduct of the study, which includes publication provisions 
inconsistent with this statement is executed, that contract’s publication provisions shall 
apply rather than this statement. 
Amended 23 January 2012 
110021 (Malaria-055 PRI) 
Amendment 6 
08-AUG-2012 
- 186 - 
Appendix B Handling of Biological Samples Collected by the Investigator 
Instructions for Handling of Serum Samples 
When materials are provided by GSK Biologicals, it is MANDATORY that all clinical 
samples (including serum samples) will be collected and stored using exclusively those 
materials in the appropriate manner. The use of other materials could result in the 
exclusion of the subject from the ATP analysis. The investigator must ensure that his/her 
personnel and the laboratory(ies) under his/her supervision comply with this requirement. 
However, when GSK Biologicals does not provide material for collecting and storing 
clinical samples, then appropriate materials from the investigator’s site are to be used. 
1. Collection 
The whole blood (by capillary or venous route) should be collected observing appropriate 
aseptic conditions. It is recommended that Vacutainer  tubes WITH integrated serum 
separator (e.g. Becton-Dickinson Vacutainer  SST or Corvac  Sherwood Medical) be 
used to minimize the risk of hemolysis and to avoid blood cell contamination of the 
serum when transferring to standard serum tubes. 
2. Serum separation 
These guidelines aim to ensure high quality serum by minimizing the risk of hemolysis, 
blood cell contamination of the serum or serum adverse cell toxicity at testing. 
 For separation of serum using Vacutainer® tubes, the instructions provided by the 
manufacturer should be followed. Often the manufacturer’s instruction states that the 
relative centrifugal acceleration known also as “G” must be “between 1000 and 1300 
G” with tubes spinning for ten minutes. Error in calculation of centrifuge speed can 
occur when laboratory personnel confuse “G” acceleration with “RPM” (revolutions 
per minute). The speed of centrifugation must be calculated using the “G” rate 
provided in the manufacturer’s instructions and the radius of the centrifuge head. 
After measuring the radius of the centrifuge machine, a speed/acceleration 
nomograph must be employed to determine the centrifuge speed in “RPM”. 
 Following separation, the serum should be aseptically transferred to the appropriate 
standard tubes using a sterile disposable pipette. The serum should be transferred as 
gently as possible to avoid blood cell contamination. 
 The tube should not be overfilled (max. 3/4 of the total volume) to allow room for 
expansion upon freezing. 
 The tube should be identified by the appropriate label provided by GSK Biologicals 
(see point 3). 
3. Labeling 
 The standard labels provided by GSK Biologicals should be used to label each serum 
sample. 
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 If necessary, any hand-written additions to the labels should be made using indelible 
ink. 
 The label should be attached to the tube as follows (see diagram): 
- first attach the paper part of the label to the tube 
- then wrap the label around the tube so that the transparent, plastic part of the 
label overlaps with the label text and bar code and shields them. 
This will ensure optimal label attachment. 
Plastic, transparent part
Paper, text part
Bar code
    Study N°.........
 Subject N° ......
  POST VACC. I
 STUDY MTH 1
For GlaxoSmithKline
 Biologicals
 
 Labels should not be attached to caps. 
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4. Sorting and storage 
 Tubes should be placed in the GSK Biologicals’ cardboard boxes in numerical order 
from left to right, starting from the lower left hand corner, beginning with the pre-
vaccination samples series, then with the post-vaccination sample series. 
 The tubes of serum should be stored in a vertical position at approximately -20°C 
(alternatively at approximately -70°/80°C is also acceptable) until shipment to GSK 
Biologicals. The storage temperature should be checked regularly and documented. 
Wherever possible, a backup facility for storage of serum samples should be 
available. 
 A standard Biological Specimen Listing Form, specifying the samples being shipped 
for individual subjects at each timepoint, should be prepared for each shipment. A 
copy of this list should be retained at the study site, while the original should be 
sealed in a plastic envelope and shipped with the serum samples.  
 Once shipment details are known, a standard Specimen Transfer Form must be 
completed and faxed to GSK Biologicals to the number provided below. A copy of 
the Specimen Transfer Form must be in the parcel.
1
 
GLAXOSMITHKLINE BIOLOGICALS 
PII - blinded 
 
                                                 
1 The Biological Specimen Listing Form and the Specimen Transfer Form are standard documents used in 
GSK Biologicals’ clinical trials. These documents are provided by GSK Biologicals’ Clinical Trials’ 
monitor at study initiation. 
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Appendix C Shipment of Biological Samples 
Instructions for Shipment of Serum Samples 
Serum samples should be sent to GSK Biologicals at regular intervals. The frequency of 
shipment of samples should be decided upon by the Site Monitor, Central Study 
Coordinator and the investigator prior to the study start. 
Serum samples must be placed with dry ice (maximum -20°C) in a container complying 
with International Air Transport Association (IATA) requirements if shipment by air or 
complying with ADR or local regulations if transport by road. The completed standard 
Biological Specimen Listing Form should always accompany the shipment. 
The container must be clearly identified with the labels provided by GSK Biologicals 
specifying the shipment address and the storage temperature (-20°C). 
The airway bill should contain the instruction for storage of samples at maximum -20°C. 
A “proforma” invoice, stating a value for customs purposes only, should be prepared and 
attached to the container. This document should contain the instruction for storage of 
samples at maximum -20°C. 
Details of the shipment, including: * number of samples 
* airway bill 
* flight number 
* flight departure and arrival times 
should be sent by fax or by e-mail, two days before shipment, to: 
PII - blinded 
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Appendix D Vaccine supplies, packaging and accountability 
1. Vaccine and/or other supplies 
GSK Biologicals will supply the following study vaccines, sufficient number of doses to 
administer to all subjects as described in the present protocol. 
Sufficient doses for: 
 up to 11 000 recipients of RTS,S/AS01E (5500 to receive 3 doses plus boost, 5500 to 
receive 3 doses without boost) 
 up to 3500 recipients of Rabies vaccine (all to receive 3 doses) 
 up to 11 000 recipients of meningococcal C vaccine (3500 to receive a primary 
course, 11 000 to receive boost) 
 up to 10 000 recipients of Tritanrix HepB/Hib (all to receive 3 doses) 
 up to 10 000 recipients of Polio Sabin (all to receive 4 doses) 
Amended 24 October 2008 
At least an additional 3% of each vaccine will be supplied for replacement in case of 
breakage, bad storage conditions or any other reason that would make the vaccine 
unusable (i.e. given by mistake to another subject). 
All containers must be accounted for on the form provided. 
2. Labels for sample identification: 
The investigator will receive labels from GSK Biologicals to identify samples taken from 
each subject at each timepoint. Each label will contain the following information: study 
number, subject number, sampling timepoint (e.g., post vaccination 3), timing (e.g., study 
Month 7). 
Amended 26 November 2009 
In addition to the vaccines, the study documentation and the sample labels, the 
investigator will receive the following supplies: 
 tubes with screw caps for serum samples, 
 racks for the tubes of serum. 
The investigator or pharmacist must sign a statement that he/she has received the clinical 
supplies for the study.  
It is NOT permitted to use any of the supplies provided by GSK Biologicals for purposes 
other than those specified in the protocol.  
3. Vaccine packaging 
The vaccines will be packed in labelled boxes. The box label will contain, as a minimum, 
the following information: study number, treatment number, lot number (or numbers, 
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when double-blind), instructions for vaccine administration and any other relevant 
regulatory requirements. 
Vaccine shipment from GSK Biologicals Rixensart to local country medical department, 
dispatching centre or investigational site from local country medical department to 
investigational site 
Upon reception of the shipment, its content, quality and maintenance of the cold-chain 
must be checked. 
The supplies receipt documents must then be returned to the sender, as appropriate:  
PII - blinded 
 
PII - blinded 
 
Amended 26 November 2009 
In case of any temperature deviation, the official written approval for the use of vaccine 
must be obtained from GSK.  
4. Vaccine accountability 
At all times the figures on supplied, used and remaining vaccine doses should match. At 
the end of the study, it must be possible to reconcile delivery records with those of used 
and unused stocks. An explanation must be given of any discrepancies. 
After approval from GSK Biologicals and in accordance with GSK SOP WWD-1102, 
used and unused vaccine containers should be destroyed at the study site using locally 
approved biosafety procedures and documentation unless otherwise described in the 
protocol. If no adequate biosafety procedures are available at the study site, the used and 
unused vaccine containers are to be returned to an appropriate GSK Biologicals site for 
destruction, also in accordance with current GSK SOP WWD-1102.  
5. Transfers of clinical vaccines or products from country medical department or 
dispatch centre to study sites or between sites 
Storage temperatures must be maintained during transport and deviations must be 
reported to GSK for guidance. All transfers of clinical vaccines or products must be 
documented. 
All packaging and shipment procedures for transfer of clinical vaccines or products must 
follow procedures approved by the sponsor. 
Clinical vaccines or products should always be sent by contract courier designated by the 
sponsor, unless otherwise requested by the sponsor. 
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Appendix E Assessment of a potential case of severe malaria disease 
Algorithm for the evaluation of a hospital admission as a potential case of 
severe malaria 
For all acute hospital admissions (i.e. except planned admissions for medical 
investigation/care or elective surgery and trauma admissions), a CRF/eCRF module will 
be filled in and a blood sample taken for evaluation of  
 malaria parasite density 
 blood culture 
 hemoglobin 
 blood glucose, lactate and base excess determination 
Amended 24 October 2008 
Amended 26 November 2009 
Lumbar Puncture (LP) is indicated by:  
 Seizure except simple febrile seizure (simple febrile seizure is defined as associated 
with fever, lasts for 5 minutes or less, generalized as opposed to focal, not followed 
by transient or persistent neurological abnormalities, occurring in a child  6 months 
of age, with full recovery within 1 hour) 
 Level of consciousness < 5 (children ≤ 9 months of age < 4 [in association with best 
motor response of 1]) 
 Prostration in child < 3 year of age 
 Meningism stiff neck/bulging fontanelle 
 Clinician’s judgment: note that this list is not an exhaustive list of indications for 
lumbar puncture in clinical practice  
NB can be delayed until child is stable 
Chest X-ray (CXR) is indicated by: 
 Tachypnea ( 50 breaths per minute < 1 year and  40 breaths per minute  1year) 
[Berkley, 2003] 
 Lower chest wall indrawing 
 Abnormally deep breathing 
 Clinician’s judgment: note that this list is not an exhaustive list of indications for 
CXR in clinical practice  
Amended 24 October 2008 
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Methodologies for the assessment of clinical signs 
Level of consciousness (Blantyre Score) 
Conscious level will be scored using the Blantyre coma scale (Appendix E Table 1) 
[Molyneux, 1989].  
Appendix E Table 1 Coma scale for young children 
 Score 
Best motor response  
Localizes painful stimulus* 2 
Withdraws limb from painful stimulus† 1 
No response or inappropriate response 0 
Best verbal response  
Cries appropriately with painful stimulus* or, if verbal, speaks 2 
Moan or abnormal cry with painful stimulus 1 
No vocal response to painful stimulus 0 
Eye movement  
Watches or follows (e.g. mother’s face) 1 
Fails to watch or follow 0 
To obtain ‘coma score’, add the scores for each section; maximum = 5, minimum = 0 
* Pressure with blunt end of pencil on sternum or supraorbital ridge 
† Pressure with horizontal pencil on nailbed of finger or toe 
 
Guidance on the application of the scale is given by WHO [WHO, 2000a]. ‘Testing 
should begin with a minimal stimulus which should be increased only to a point where a 
clear response is obtained. A localizing response must be distinguished from a brisk 
flexion response which brings the hand into coincidental proximity to the stimulus. The 
interpretation of ‘verbal cry’ is difficult, some children are stoical and the appropriateness 
of verbal response needs to be considered in the light of other responses and the age of 
the child. It is best to test orientation by asking the mother to move her face across the 
child’s field of vision as the child may be less interested in looking at a strangers face.’  
The coma score will be assessed at presentation. If it is depressed, it will be re-assessed 
after initial resuscitation; approximately one hour after correction of hypoglycemia and 
control of fits. This value will be recorded in the CRF/eCRF (if anticonvulsants were 
given prior to the assessment this will be documented in the CRF/eCRF). The intention is 
to avoid diagnosing cerebral malaria in a child with post-ictal coma [WHO, 2000a]. A 
child with persistent seizure activity despite optimal therapy, should have the coma scale 
recorded 1 hour after treatment is optimized. 
A normal coma score in a child of > 9 months of age is 5. In children  9 months of age, 
because localization of pain is difficult to assess, a normal coma score is 4 (in association 
with a best motor response of 1).  
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Skin Turgor 
Dehydration will be assessed by skin pinch test. The standard procedures are: 
 Locate the area on the child’s abdomen halfway between the umbilicus and the side 
of the abdomen. The hand should be placed so that when the skin is pinched, the fold 
of skin will be in a line up and down the child’s body and not across the child’s body 
 Pinch the skin using the thumb and first finger. It is important to firmly pick up all of 
the layers of skin and the tissue under them for one second and then release it.  
 When released, the skin pinch goes back either very slowly (longer than 2 seconds), 
or slowly (skin stays up even for a brief instant), or immediately. In a child with 
marasmus (severe malnutrition), the skin may go back slowly even if the child is not 
dehydrated. In an overweight child, or a child with edema, the skin may go back 
immediately even if the child is dehydrated. [WHO, 2000b; WHO, 2001; WHO, 
2005] 
Appendix E Figure 1 Diagnosis of dehydration: Left: pinching the child’s abdomen 
to test for decreased skin turgor Right: Slow return of skin pinch in severe 
dehydration [WHO, 2005] 
 
Prostration 
Prostration will be defined as, in an acutely sick child, the inability to perform 
previously-acquired motor function: in a child previously able to stand, inability to stand; 
in a child previously able to sit, inability to sit and in a very young child, inability to 
suck. 
Guidance on the assessment of prostration is given by the WHO [WHO, 2000a]. 
‘Prostration must always be recorded directly and not based on history. Many children 
who are pyrexial and feel unwell prefer to lie or be carried but are capable of sitting if 
gently encouraged to do so.’  
Respiratory signs 
Respiratory signs will be assessed in line with the guidance on the assessment of 
respiratory signs by WHO [WHO, 2005]. ‘Respiratory signs should be looked for while 
the child is calm; (usually before the child is disturbed by hands on clinical examination). 
Ask the mother or caretaker to cautiously reveal part of the chest to look for lower chest 
wall indrawing or to count the respiratory rate. If a child is distressed or crying, it might 
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need to be left for a brief time with its mother in order to settle, or the mother could be 
ask to breastfeed, before key signs such as respiratory rate can be measured. Then 
proceed to signs which require touching the child but are little disturbing.’ 
Rate 
The respiratory rate will be counted over one full minute while the child is calm [WHO, 
2005]. 
Lower chest wall indrawing 
Lower chest wall indrawing will be defined as the inward movement of the bony 
structure of the chest wall with inspiration [WHO, 2001]. 
Appendix E Figure 2  Lower chest wall indrawing: with inspiration, the lower chest 
wall moves in [WHO, 2005] 
 
 
Note: chest indrawing should only be considered present if it is consistently present in a 
calm child. Agitation, a blocked nose or breastfeeding can all cause temporary chest 
indrawing [WHO, 2001]. 
Note: lower chest wall indrawing occurs when the lower chest wall goes in when the 
child breathes in; if only the soft tissue between the ribs or above the clavicle goes in 
when the child breathes, this is not lower chest wall indrawing [WHO, 2005]. 
Acidotic or Kussmaul respiration 
Abnormally deep breathing will be defined as breathing that is deep and labored while 
the chest is clear [WHO, 2005]. The key component is increased inspiratory and 
expiratory excursion of the chest [WHO, 2000a]. 
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Appendix F Determination of Plasmodium falciparum asexual parasite density 
Slide reading methodology 
Two blood slide reading methods will be used in the study. Comparability of results will 
be assured through an external Quality Assessment Program ongoing through the trial. 
All slide readers, by both methods will be required to demonstrate proficiency at 
“Competent” level or above. The external quality assurance program is based on current 
WHO recommendations [World Health Organization, 2006].  
Method 1: Counting against known blood cell concentration  
Refer to the method described in Greenwood and Armstrong 1991 [Greenwood, 1991].  
A contemporaneous measured white and red blood cell count will be determined and 
used in parasite density calculation.  
6 L of blood for the thick smear and 2 L of blood for the thin smear are put on the 
same slide with a standard template. All slides are prepared in duplicates. 
Negative result: 100 fields on the thick blood smear free of parasites are to be read 
before a slide is declared negative 
Positive result: 
 High parasitemia: If 100 parasites or more are seen on the first field of the thick 
smear, the parasites are counted on the thin film. RBC and parasitized red blood cells 
are counted on the thin film until a minimum of 20 parasitized RBC are reached. If 
20 parasitized RBCs are counted before all the parasitized RBCs in a field are 
counted, finish counting all parasitized RBCs and non-parasitized RBCs in that field.  
 Medium parasitemia: If less than 100 parasites are seen on the first field of the thick 
smear, parasites are counted up to when 200 white blood cells (WBC) are counted, 
on the thick smear. If 200 WBC are counted before finishing a field, finish counting 
all parasites and WBC in that field. 
 Low parasitemia: If less than 10 parasites are counted per 200 WBC on the thick 
smear, the parasite counting is extended up to when 500 WBC have been counted. If 
500 WBC are counted before finishing a field, finish counting all parasites and WBC 
in that field. 
Method 2. Counting against known blood volume 
Refer to the method described in Planche et al, 2001 [Planche, 2001].  
10 L blood are spread with a pipette on an area of 1x1.8 cm, using a template on which 
the slide is set. 
Negative result: 100 fields free of parasites are read before a slide is declared negative 
Positive result: if there are 1-9 parasites per field, 100 fields are counted. If there are 10-
99 parasites per field, 10 fields are counted. If there are 100-999 parasites per field, 1 
field is counted. 
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The parasitemia count will be calculated on the basis of the following formula: 
 Parasites/ L = parasites/field x Microscope Factor (MF, assumed blood 
volume/microscope high power field). 
To calculate the MF: 
 Make a thick blood film with 10 L of blood 
 Calculate the mean number of leucocytes per high power field, after counting 
leucocytes across 10 fields 
 Count the number of leucocytes in 10 L of blood using a computerized blood 
analyzer. 
X = Mean leucocytes number per high power field (microscopy) 
Y = Leucocytes in 10 L of blood (automated analyzer) 
MF = Y / X 
For each microscope this predetermination of MF is done once. 
Criteria for concordance for double reading of slides 
All slides will be read twice, by two independent readers to quantify the P. falciparum 
parasite density. Slides are judged to be discordant and a third independent read will be 
organized in the following cases: 
a. The result from one reader is negative and the one of the other is positive  
b. For high and medium positive parasitemia results (blood parasitemia > 400/ L), the 
higher count divided by the lower count is > 2 
c. For low parasitemia (blood parasitemia  400/ L), the highest reading density is 
more than one log10 higher than the lowest reading. 
If parasitemia result is high or medium and one is low, i.e. one is > 400/ L and the other 
is  400/ L, parasitemia, criteria (C) will be applied. 
Amended 24 October 2008 
Determination of final result 
If there are two concordant results the final result is the geometric mean of the two 
readings. 
If the first two readings are discordant then the final result will follow the following 
principles:  
 For cases of positive/negative discrepancy (A), the majority decision will be adopted. 
If the decision is positive, the final result will be the geometrical mean of the two 
positives. 
 For cases of three positive reads (B and C), the final result will be the geometric 
mean of the two geometrically closest readings 
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Identification of Plasmodium species 
Positive parasitemia identified on any thick blood film must always be identified to 
species. This will be done on thin blood film except in case of low parasitemia. Only 
Plasmodium falciparum results will be accounted for in the efficacy analyses.  
 
Amended 24 October 2008 
Archiving of blood slides 
Two blood slides are taken, one for reading and archiving at the sites; the second one will 
be archived centrally. 
Amended 19 August 2008 
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Appendix G Radiography 
PERFORMANCE OF CHEST X-RAY 
Chest anterior-posterior erect basic: technique 
1. Position the patient. Support the child by holding him/her by the arms (If possible, 
his/her feet can rest on a stool or the floor or by another person holding his/her 
thighs) with its back resting against the front of the cassette holder.  
Amended 19 August 2008 
2. USE A PROTECTIVE LEAD STRIP OVER THE INFANT’S PELVIC AREA. 
3. THE PERSON HOLDI NG THE CHILD, preferably one of the parents, MUST 
WEAR A LEAD APRON and whenever possible LEAD GLOVES. 
4. Center between the nipples. COLLIMATE FURTHER, if possible. 
5. Expose when the infant is not moving, preferably in INSPIRATION. 
Chest anterior-posterior supine: technique 
Required for infant weighing up to 10 kg and for older children as judged appropriate by 
the radiologist 
Amended 24 October 2008 
1. Lie the infant on its back on the cassette. THE INFANTS’ HEAD AND LEGS 
MUST BE SUPPORTED.  
2. USE A PROTECTIVE LEAD STRIP OVER THE INFANT’S PELVIC AREA.  
3. THOSE SUPPORTING, preferably the infants’ parents, MUST WEAR LEAD 
APRONS, and, whenever possible, LEAD GLOVES. 
4. Center between the nipples. COLLIMATE FURTHER, if possible. 
5. Expose when the infant is not moving, preferably in INSPIRATION. 
Quality X-ray parameters 
 ID on the right side 
 Position: clavicles and ribs symmetric on each side of the spine 
 Boundaries: Rib cage and costophrenics angles 
 Inspiration: dome of the diaphragm is below the anterior tip of the 6th right rib 
Amended 24 October 2008 
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 Movement: heart, diaphragm, central vessels and ribs sharply defined, without 
blurring 
 Exposure: vascular shadows can be seen in lung periphery, thoracic vertebrae and 
large lower lobe vessels visible through cardiac silhouette 
 Contrast: background outside patient’s silhouette is black. Bones and airway easily 
distinguished from soft tissue. 
Digital X-ray quality parameters 
It is recommended to follow the guidelines listed in the manual ‘Standardization of 
interpretation of chest radiographs for the diagnosis of pneumonia in children’ (WHO 
Pneumonia Vaccine Trial Investigators’ Group). 
The objectives are: 
 To establish standard definitions for the interpretation of chest radiographs in children 
with suspected pneumonia for use as an epidemiological tool. 
 To establish a mechanism for ensuring the quality of radiographic images stored in 
digital format. 
Optimal interpretation of a chest radiograph will depend on the quality of the image and 
the methods used to interpret the image.  
Computed Radiography (CR) digital system 
Most CR systems are easy to configure and order, easy to install and to operate and are 
virtually maintenance free. Good CR systems provide excellent image quality. Systems 
use an Imaging Plate (“electronic” film) which is placed in a reader that can provide the 
image using standard computers. 
The inherent sensitivity of CR systems is comparable to Speed 200 in Film screen 
systems. Depending on image quality requirements sensitivity in the range of 200 to 400 
can be selected. Dose levels should be kept within the limits recommended for pediatric 
chest x-rays. 
INTERPRETATION OF CHEST X-RAYS 
All x-rays will be classified for quality and findings according to the scales in Appendix 
G Table 1 and Appendix G Table 2. For more details about these definitions, please refer 
to [WHO, 2001]. Note that for ‘uninterpretable’ chest x-rays, no further reading will be 
made.  
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Appendix G Table 1: Classification of quality of chest x-rays 
Uninterpretable an image is classified as “uninterpretable” if the features of the image are not interpretable 
without additional images. No further reading should be made for such images. 
Suboptimal an image is classified as “suboptimal” if the features allow interpretation of primary end-
point but not of other infiltrates or findings. No entries should be made for other infiltrates 
for such images 
Adequate an image is classified as “adequate” if the features allow confident interpretation of end-
point as well as other infiltrates 
  
Appendix G Table 2: Classification of findings of chest x-rays 
Consolidation or 
pleural effusion 
where consolidation is defined as a dense opacity that may be a fluffy consolidation of a 
portion or whole of a lobe or of the entire lung, often containing air bronchograms* and 
where pleural effusion is defined if it occurs in the lateral pleural space (and not just in the 
minor or oblique fissure) and is spatially associated with a pulmonary parenchymal 
infiltrate (including other infiltrate) or if the effusion obliterates enough of the hemithorax 
to obscure an opacity 
* atelectasis of an entire lobe that produces a dense opacity and a positive silhouette sign with the 
mediastinal border will be considered to be an endpoint consolidation 
Amended 24 October 2008 
Other infiltrate linear and patchy densities (interstitial infiltrate) in a lacy pattern involving both lungs, 
featuring peribronchial thickening and multiple areas of atelectasis. Lung inflation is 
normal to increased. It also includes minor patchy infiltrates that are not of sufficient 
magnitude to constitute primary end-point consolidation, and small areas of atelectasis 
which in children can be difficult to distinguish from consolidation. 
No consolidation, 
infiltrate or effusion 
 
Definitions of terms: for the purposes of this study. (See Appendix G Figure 1, below) 
1) Infiltrate: any pathologic density in the lung. 
2) Alveoli: tiny air-filled spaces where oxygen and C02 are exchanged (see diagram B) 
3) Bronchi: tubes leading from the trachea to the alveoli 
4) Interstitium: lung tissue outside the air-containing spaces: includes support tissues, blood vessels, bronchial 
walls, lymphatics 
5) Alveolar infiltrate: alveoli filled with fluid (pus, edema, etc.) 
6) Heart and diaphragm borders: (see diagram A). 
7) Air bronchogram: branching linear lucent structure representing air still present in bronchi after the alveoli 
around them have consolidated; not to be confused with peribronchial thickening (an interstitial infiltrate) 
8) Consolidation: especially dense, often homogeneous, confluent alveolar infiltrate sometimes may encompass 
an entire lobe or large segment, fluffy, mass-like, cloud-like density, erases heart and diaphragm borders 
(silhouette sign); often contains air bronchograms 
9) Atelectasis: volume loss as air is absorbed from lung tissue, usually distal to an airway obstruction (e.g. a 
mucous plug). The lung tissue collapses like a Japanese fan, leaving a dense streak on the film that radiates 
outward from the hilum (see diagram D). 
10) Interstitial infiltrate: includes peribronchial thickening and tiny areas of atelectasis (thought to be typical of 
viral infection). 
11) Pleural effusion: fluid collecting in the pleural space around the lung, seen as a dense rim (the same density 
as the chest-wall muscles) interposed between the lung and the ribs (see diagram C) 
12) Peribronchial thickening or cuffing: increased density of the walls of the smaller bronchi (away from the 
immediate hilar area) so that they become visible as circles or parallel lines (see diagram E) 
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Appendix G Figure 1: Diagrams to support classification of findings of 
chest x-rays 
 
1) Right diaphragm: erased by a right lower lobe infiltrate.  
2) Right heart (right atrium): erased by a right middle lobe infiltrate.  
3) Minor fissure: divides the right upper lobe from the right middle lobe; seen as a line when there is fluid in it; seen as 
a border when there is infiltrate in the lobe adjacent to it.  
4) Left heart (left ventricle): erased by an infiltrate in the lingula (homolog of the right middle lobe; actually a part of 
the left upper lobe).  
5) Left diaphragm: erased by an infiltrate in the left lower lobe, often behind the heart shadow.  
6) & 7) Right hilum and left hilum: contain large blood vessels, lymph nodes, and main bronchi; bronchial walls may 
be normally visible here, but should disappear quickly just outside the immediate hilar area.  
8) Thymus: bi-lobed semi-lucent structure in the upper mid chest with defined borders, may resemble an upper lobe 
infiltrate but often shrinks when the child is sick.  
9) Heart: from the spine to the left heart border should be the same density. 
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QUALITY ASSURANCE PROCESS FOR THE STANDARDIZED 
INTERPRETATION OF CHEST X-RAYS 
Appendix G Figure 2: quality assurance process  
 Independent reading by clinician and radiologist 1  
     
 Concordant 2  Discordant 2  
     
 Final reading    
     
 
10% sample of positive plus equal 
number of negative 
   
     
 Panel of two radiologists 3  
     
 Readings fed back to investigators  Final reading  
     
1. The first read of each CXR will be done by: 
a clinician trained in per-protocol CXR interpretation attached to the site where the CXR is taken AND 
a radiologist trained in per-protocol CXR interpretation 
The CXRs will be classified according to quality (Appendix G Table 1) and findings (Appendix G Table 2). Note that for 
‘uninterpretable’ chest x-rays, no further reading will be made. 
2. Concordance will be defined as agreement on the presence or absence of consolidation or pleural effusion as 
defined in Appendix G Table 2.  
3. A reference panel of two radiologists will be established. They will review all CXRs that are not concordant and, of 
those that are concordant. In addition, they will review a 10% sample of all concordant CXRs with presence of 
consolidation or pleural effusion and an equal number of absences of consolidation or pleural effusion as defined 
in Appendix G Table 2.  
 
References for Appendix G 
WHO. Standardization of interpretation of chest radiographs for the diagnosis of 
pneumonia in children. World Health Organization, Geneva, 2001. 
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Appendix H Microbiology methodology and interpretation of results 
Blood culture methodology 
Bactec bottles and automated Bactec incubators will be used.  
The blood culture bottles will be inspected for damage or defect before use, and it will be 
ensured that the expiry date is not exceeded. It will be ensured that the blood culture 
bottles are stored according to the manufacturers specifications. 
Blood will be withdrawn by peripheral venipuncture. To avoid contamination, the use of 
disposable plastic gloves will be encouraged. It is required to disinfect adequately the site 
of venipuncture. The skin will be cleaned with water and soap if necessary and 
disinfected with iodine or alcohol-based solution. 
Samples will not be taken through an intravenous catheter or other access device unless 
no other access is available. Blood culture bottles will be inoculated immediately after 
blood collection. If blood samples for other tests are to be taken at the same venipuncture, 
the blood culture bottles should be inoculated first to avoid contamination. 
Single pediatric bottles will be used. The recommended ideal volume for this purpose is 
3 mL. The minimal volume inoculated will be 0.5 mL. The maximum recommended 
volume per bottle will not be exceeded.  
Blood culturing should be started as soon as possible after sampling, using a licensed 
fully automated continuously monitoring blood culture system, detecting positive cultures 
based on CO2 production. In the meanwhile, blood should not be stored in a refrigerator 
but at room temperature with air conditioning (15-25 C) out of direct sunlight. 
Amended 26 November 2009 
Once the incubator detects a positive sample, the sample will be processed as soon as 
possible and certainly less than 10 hours after detection of positivity. Positive cultures (or 
other types of cultures) will be sub-cultured by plating onto chocolate, sheep or horse 
blood agar and MacConkey agar plates and incubated aerobically with 5-10% CO2 at 
35°C for 48 hours. A sample of each positive blood culture bottle will be stored for 
possible further analysis in case the bacterial subculture was negative. Bacterial isolates 
will be kept in 20% skim milk medium or other cryo-conservation medium at -70 °C.  
Amended 19 August 2008 
Amended 26 November 2009 
Blood culture result interpretation 
The principles of interpretation will be according to previously described methodologies 
[WHO, 1999]. 
Blood culture will be considered to be positive if: 
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 a definite pathogen is isolated; examples are Streptococcus pneumoniae, S. 
agalactiae, S. pyogenes, Haemophilus influenzae, Salmonella spp., (this list is not 
exhaustive)  
 a bacteria that could be either a pathogen or a contaminant is isolated within 48 hours 
of incubation; examples are Escherichia coli, Klebsiella pneumoniae, 
Staphylococcus aureus, Enterococcus faecalis (group D), (this list is not exhaustive) 
Blood culture will be considered to be contaminated if: 
 a known contaminant is isolated; examples are coagulase-negative staphylococci, 
Micrococcus spp., and Bacillus spp. (i.e., aerobic spore-bearing bacilli), (this list is 
not exhaustive) 
 a bacteria that could be either a pathogen or a contaminant is isolated after more than 
48 hours of incubation  
Blood culture will be considered to be negative if: 
 there is no bacteria isolated 
Other body fluids 
Cerebrospinal fluid will be collected by lumbar puncture following the same sterility 
precautions as described above. Cerebrospinal fluid will be collected in a sterile plastic 
collector tube and brought to the laboratory without delay after collection.  
Cerebrospinal fluid and other normally sterile body fluids, such as pleural effusion, 
synovial fluid, peritoneal fluid or pericardial fluid, will be examined by direct smears and 
cultured in parallel on appropriate chocolate and blood agar plates. Samples may also be 
inoculated in automated culture bottles as are used for blood culture. Positive automated 
cultures will be sub-cultured by plating onto chocolate and blood agar plates and 
incubating aerobically with 5-10% CO2 at 35 C for 48 hours.  
Gram staining, white cell count and differential, latex antigen (Streptococcus 
pneumoniae, Haemophilus influenzae, Neisseria meningitidis) agglutination tests, glucose 
and protein concentration determination will be performed on cerebrospinal fluid by 
standard methods. 
In case of macroscopic blood contamination of the cerebrospinal fluid, only culture 
results will be taken into account. 
More details of microbiology procedures including bacterial isolates identification and 
the set up of laboratory internal and external Quality Assurance programs will be 
described in internal laboratory standard operating procedures.  
Excess CSF may be frozen for future testing for infectious agents if applicable.  
Amended 19 August 2008 
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References for Appendix H 
WHO Young Infants Study Group. Bacterial etiology of serious infections in young 
infants in developing countries: results of a multicenter study. Pediatr Infect Dis J. 
1999;18 (Suppl): S17-22) 
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Appendix I The WHO pediatric clinical staging system (for HIV disease) 
The text below is an extract from the ‘Pocket book of hospital care for children: 
guidelines for the management of common illnesses with limited resources’ [WHO, 
2005]. The document can currently be downloaded from 
http://whqlibdoc.who.int/publications/2005/9241546700.pdf (accessed 07 March 2008). 
Please refer to the current version of the guidelines for updated procedures.  
For use in those <13 years with confirmed laboratory evidence of HIV infection (HIV AB 
where age >18 months, DNA or RNA virological testing for those age <18 months) 
STAGE 3 
Unexplained moderate malnutrition not responding to standard therapy 
Unexplained persistent diarrhea (>14 days) 
Unexplained persistent fever (intermittent or constant, for longer than 1 month) 
Oral candidiasis (outside neonatal period) 
Oral hairy leukoplakia 
Pulmonary tuberculosis
1
 
Severe recurrent presumed bacterial pneumonia (2 or more episodes in 6 months) 
Acute necrotizing ulcerative gingivitis/periodontitis 
LIP (lymphoid interstitial pneumonia) 
Unexplained anemia (<8 g/dL), neutropenia (<500/mm
3
) or thrombocytopenia 
(<30,000/mm
3
) for >1 month 
STAGE 4 
Unexplained severe wasting or severe malnutrition not responding to standard therapy 
Pneumocystis pneumonia 
Recurrent severe presumed bacterial infections (2 or more episodes within one year, e.g. 
empyema, pyomyositis, bone or joint infection, meningitis, but excluding pneumonia) 
Chronic orolabial or cutaneous herpes simplex infection (of >1 month duration) 
Disseminated or extrapulmonary tuberculosis 
Kaposi sarcoma 
Oesophageal candida 
110021 (Malaria-055 PRI) 
Amendment 6 
08-AUG-2012 
- 209 - 
Symptomatic HIV seropositive infant <18 months with 2 or more of the following; oral 
thrush, +/– severe pneumonia, +/– failure to thrive, +/– severe sepsis2 
CMV retinitis 
CNS toxoplasmosis 
Any disseminated endemic mycosis including cryptococcal meningitis (e.g. extra-
pulmonary cryptococcosis, histoplasmosis, coccidiomycosis, penicilliosis) 
Cryptosporidiosis or isosporiasis (with diarrhea >1 month) 
Cytomegalovirus infection (onset at age >1 month in an organ other than liver, spleen, or 
lymph nodes) 
Disseminated mycobacterial disease other than tuberculous  
Candida of trachea, bronchi or lungs 
Acquired HIV-related recto-vesico fistula 
Cerebral or B cell non-Hodgkin’s lymphoma 
Progressive multifocal leukoencephalopathy (PML) 
HIV encephalopathy 
HIV-related cardiomyopathy 
HIV-related nephropathy 
 
Footnotes:  
1 TB may occur at any CD4 count and CD4 % should be considered where available 
2 Presumptive diagnosis of stage 4 disease in seropositive children <18 month 
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Appendix J Documentation of bednet usage and indoor residual spraying 
Bednet usage and indoor residual spraying will be assessed at two home visits at the 
timepoints 14 months from study start (Visit 16) (corresponding to the primary analysis) 
and at the last home visit, 11 months after the boost dose (Visit 31) prior to study 
conclusion. 
During the extension, bednet usage and indoor residual spraying will be assessed at the 
field worker visit (Visit 37), within one month prior to the last extension visit (Visit 38). 
Amended 01 December 2010 
Bednets 
The parent/guardian will be asked if the child sleeps under a bednet and whether or not 
the net is impregnated with insecticide. The child’s bednet will be inspected and the 
integrity of the net (i.e. whether or not the net has holes) documented. 
Net usage will be classified in the CRF/eCRF according to the following choices:  
1. No bednet 
2. Impregnated bed net with no hole large enough to admit three fingers 
3. Impregnated bed net with at least one hole large enough to admit three fingers 
4. Untreated bed net with no hole large enough to admit three fingers 
5. Untreated bed net with at least one hole large enough to admit three fingers 
Amended 26 November 2009 
Indoor residual spraying 
The parent/guardian will be asked if the house has been sprayed with a residual 
insecticide and if so when.  
The question asked at Visit 16 will be 
‘Has indoor residual spraying been performed since vaccination 1?’. 
The question at Visit 33 will be  
‘Has indoor residual spraying been performed since vaccination 4?’. 
The response to these questions (yes/no) will be documented in the CRF/eCRF.  
The investigator will endeavor to find out what chemical was used from the malaria 
control programs in the study area. 
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Appendix K Anthropometry methods 
The methodologies used for anthropometry have been adapted from Cogill, 2003. 
MEASURING WEIGHT IN INFANTS AND CHILDREN 
Scales should be digital and for medical purposes (precision class III or IIII according to 
the European directive 90/384/CEE) . The scale should not be over-heated in the sun.  
Children to the age of 2 years should be weighed nude using digital baby scales.  
Children of 2 years and above should be weighed in light clothing without shoes using 
digital standing scales. 
1. Measurer or assistant: Put the scale on an even surface enabling the reading to be 
clear. Ask the mother to undress the child as required above.  
2. Measurer: Adjust the scale to zero. 
3. Assistant: Stand behind and to one side of the measurer ready to record the 
measurement. Have the questionnaire ready.  
4. Measurer and assistant: Check the child’s position. Make sure the child is lying or 
standing on the scale completely and not touching anything. Repeat any steps as 
necessary. 
5. Measurer: Read the weight. Call out the measurement when the child is still and the 
scale is stationary. 
6. Assistant: Immediately record the measurement and show it to the measurer. 
7. Measurer: Check the recorded measurement for accuracy and legibility.  
 
MEASURING LENGTH/HEIGHT FOR INFANTS AND CHILDREN 
Measuring height for children 2 years and above 
1. Measurer or assistant: Place the measuring board on a hard flat surface against a 
wall, table, tree, staircase, etc. Make sure the board is not moving. 
2. Measurer or assistant: Ask the mother to remove the child’s shoes and unbraid any 
hair that would interfere with the height measurement. Ask her to walk the child to 
the board and to kneel in front of the child. If a Microtoise measure is used, stand the 
child vertically in the middle of the platform. 
3. Assistant: Place the questionnaire and pencil on the ground (Arrow 1). Kneel with 
both knees on the right side of the child (Arrow 2).  
4. Measurer: Kneel on your right knee on the child’s left side (Arrow 3). This will give 
you maximum mobility. 
5. Assistant: Place the child’s feet flat and together in the center of and against the back 
and base of the board/wall. Place your right hand just above the child’s ankles on the 
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shins (Arrow 4), your left hand on the child’s knees (Arrow 5) and push against the 
board/wall. Make sure the child’s legs are straight and the heels and calves are 
against the board/wall (Arrows 6 and 7). Tell the measurer when you have completed 
positioning the feet and legs. 
6. Measurer: Tell the child to look straight ahead at the mother who should stand in 
front of the child. Make sure the child’s line of sight is level with the ground (Arrow 
8). Place your open left hand under the child’s chin. Gradually close your hand 
(Arrow 9). Do not cover the child’s mouth or ears. Make sure the shoulders are level 
(Arrow 10), the hands are at the child’s side (Arrow 11), and the head, shoulder 
blades and buttocks are against the board/wall (Arrows 12, 13, and 14). With your 
right hand, lower the headpiece on top of the child’s head. Make sure you push 
through the child’s hair (Arrow 15). 
7. Measurer and assistant: Check the child’s position (Arrows 1-15). Repeat any steps 
as necessary. 
8. Measurer: When the child’s position is correct, read and call out the measurement to 
the nearest 0.1 cm. Remove the headpiece from the child’s head and your left hand 
from the child’s chin. 
9. Assistant: Immediately record the measurement and show it to the measurer.  
10. Measurer: Check the recorded measurement for accuracy and legibility 
110021 (Malaria-055 PRI) 
Amendment 6 
08-AUG-2012 
- 213 - 
Appendix K Figure 1 Child height measurement - height for children 2 years and 
older [United Nations, 1986] 
 
Measuring length for infants and children to the age of 2 years  
1. Measurer or assistant: Place the measuring board on a hard flat surface, i.e., ground, 
floor, or steady table.  
2. Assistant: Place the questionnaire and pencil on the ground, floor, or table (Arrow 1). 
Kneel with both knees behind the base of the board if it is on the ground or floor 
(Arrow 2). 
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3. Measurer: Kneel on the right side of the child so that you can hold the foot piece 
with your right hand (Arrow 3). 
4. Measurer and assistant: With the mother’s help, lay the child on the board by 
supporting the back of the child’s head with one hand and the trunk of the body with 
the other hand. Gradually lower the child onto the board. 
5. Measurer or assistant: Ask the mother to kneel close on the opposite side of the 
board facing the measurer as this will help to keep the child calm. 
6. Assistant: Cup your hands over the child’s ears (Arrow 4). With your arms 
comfortably straight (Arrow 5), place the child’s head against the base of the board 
so that the child is looking straight up. The child’s line of sight should be 
perpendicular to the ground (Arrow 6). Your head should be straight over the child’s 
head. Look directly into the child’s eyes. 
7. Measurer: Make sure the child is lying flat and in the center of the board (Arrows 7). 
Place your left hand on the child’s shins (above the ankles) or on the knees (Arrow 
8). Press them firmly against the board. With your right hand, place the foot piece 
firmly against the child’s heels (Arrow 9). 
8. Measurer and assistant: Check the child’s position (Arrows 1-9). Repeat any steps as 
necessary. 
9. Measurer: When the child’s position is correct, read and call out the measurement to 
the nearest 0.1 cm. Remove the foot piece and release your left hand from the child’s 
shins or knees. 
10. Assistant: Immediately release the child’s head, record the measurement, and show it 
to the measurer. 
11. Measurer: Check the recorded measurement for accuracy and legibility 
110021 (Malaria-055 PRI) 
Amendment 6 
08-AUG-2012 
- 215 - 
Appendix K Figure 2 Child length measurement - length for infants and children to 
the age of 2 years [United Nations, 1986] 
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MEASURING CHILD MID-UPPER ARM CIRCUMFERENCE (MUAC) 
1. Measurer: Keep your work at eye level. Sit down when possible. Very young 
children can be held by their mother during this procedure. Ask the mother to 
remove clothing that may cover the child’s left arm. 
2. Measurer: Calculate the midpoint of the child’s left upper arm by first locating the 
tip of the child’s shoulder (Arrows 1 and 2) with your finger tips. Bend the child’s 
elbow to make a right angle (Arrow 3). Place the tape at zero, which is indicated by 
two arrows, on the tip of the shoulder (Arrow 4) and pull the tape straight down past 
the tip of the elbow (Arrow 5). Read the number at the tip of the elbow to the nearest 
centimeter. Divide this number by two to estimate the midpoint. As an alternative, 
bend the tape up to the middle length to estimate the midpoint. A piece of string can 
also be used for this purpose. Either you or an assistant can mark the midpoint with a 
pen on the arm (Arrow 6). 
3. Measurer: Straighten the child’s arm and wrap the tape around the arm at midpoint. 
Make sure the numbers are right side up. Make sure the tape is flat around the skin 
(Arrow 7). 
4. Measurer and assistant: Inspect the tension of the tape on the child’s arm. Make sure 
the tape has the proper tension (Arrow 7) and is not too tight or too loose (Arrows 8-
9). Repeat any steps as necessary. 
5. Measurer: When the tape is in the correct position on the arm with the correct 
tension, read and call out the measurement to the nearest 0.1cm (Arrow 10). 
6. Assistant: Immediately record the measurement on the questionnaire and show it to 
the measurer. 
7. Measurer: While the assistant records the measurement, loosen the tape on the 
child’s arm. 
8. Measurer: Check the recorded measurement for accuracy and legibility 
9. Measurer: Remove the tape from the child’s arm. 
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Appendix K Figure 3 Child mid-upper arm circumference measurement [United 
Nations, 1986] 
 
References for Appendix K  
Cogill, B. Anthropometric Indicators Measurement Guide. Food and Nutrition Technical 
Assistance Project, Academy for Educational Development - Chapter 5: Taking 
Measurements. Washington, DC, 2003. 
United Nations. How to Weigh and Measure Children: Assessing the Nutritional Status 
of Young Children. 1986. 
